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ABSTRACT 
Cancer initiation and progression are multistep processes that rely on the generation and 
accumulation of non-lethal mutations, which deregulate function of tumor suppressor genes and 
activate oncogenic pathways. Evolving through a landscape of heterogeneous somatic mutations, 
mutated cells undergo subsequent selection pressures and the one endowed with the greatest fitness 
advantage survives giving rise to genetically diverse cell populations resulting in intratumor 
heterogeneity (ITH). Presence of abnormal number of centrosomes is one of the key factors 
contributing towards ITH. Clustering of amplified centrosomes allows cancer cells to avoid mitotic 
spindle multipolarity that could otherwise result in cell death either by mitotic catastrophe or a 
high-grade multipolar division yielding intolerably severe aneuploidy. Thus, centrosome 
clustering enables low-grade chromosomal missegregation and their unequal distribution to 
daughter cells resulting chromosomal instability (CIN), thus contributing to neoplastic 
transformation. Owing to the presence of genetically different cells in a tumor, monotargeted 
therapy spares clones lacking therapy-specific targets giving them the opportunity to repopulate 
the tumor with immunity toward the applied therapy and propensity to recur. Therefore, ITH poses 
major challenges to both clinicians and drug developers as it precludes detection of low-level 
clones, prediction of tumor evolution, development of drugs to target specific clones and 
evaluation of effective, yet non-toxic combinatorial regimens to combat ITH.  
I envision that a comprehensive quantitative analysis of centrosome amplification (CA), which is 
a bona-fide driver of ITH might help better understand clinical behavior and improve therapeutic 
management of tumors. To this end, my research, presented here, primarily focuses on testing i) 
the impact of centrosome amplification and centrosome clustering protein (KIFC1) on clinical 
outcomes in multiple malignancies and ii) the role of tumor hypoxia in inducing centrosome 
amplification in cancer. Collectively, my findings reveal that CA and KIFC1 are prognostic and 
predictive in multiple malignancies and that tumor hypoxia plays a crucial role in inducing CA in 
tumors. This body of work expands our knowledge in causes and clinical implications of CA to 
help guide treatment decisions and development of precision medicine for multiple malignancies.  
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1 INTRODUCTION  
1.1 Centrosome structure and centrosome cycle 
The centrosome is the main microtubule (MT)-organizing center in all mammalian cells; it plays 
important roles in various cellular processes such as cell division, mitotic spindle assembly, 
polarity, and migration. Structurally, a centrosome is composed of a pair of centrioles (each 
measure 200 by 400 nm)[1] arranged orthogonally connected through linker proteins and 
surrounded by a dynamic collection of 200 -300 centrosome-associated proteins collectively 
called as the pericentriolar matrix (PCM)[2, 3]. The mother centriole regulates PCM organization, 
stabilization, and size[4]. The PCM proteins include cell cycle regulators and proteins that help in 
organizing and nucleating microtubules thus, helping centrosomes to perform their key role as 
microtubule organizing centers. With recent advancements in the studies, it has become clear that 
role of centrosomes extends well beyond just the microtubule organizers. Multiple studies have 
shown that centrosomes function as coordination centers in eukaryotic cells and with the 
interaction of multiple cytoplasmic proteins major decisions regarding the cellular processes are 
made.  
      Similar to DNA replication, centrosome duplication also occurs only once per cycle (cell cycle 
control). Another level of regulation is the copy number control where only one centriole, i.e., 
daughter centriole is produced from the pre-existing mother centriole[4]. Any defect or disturbance 
in the regulation of these mechanisms can affect the proper execution of various processes that 
result in the centrosomal abnormalities. Alterations in centrosome number and structure lead to  
defects in the mitotic spindle organization and consequently in chromosome instability, which is 
a major source of aneuploidy in cancers. 
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1.2 How cells generate extra centrosomes? 
Centrosome amplification (CA) refers to the presence of supernumerary (numerical amplification) 
or abnormally large centrosomes (structural amplification),[5, 6] and occurs early in pre-cancerous 
and pre-invasive lesions and is linked to aggressiveness in several types of cancer. There are 
several pathways that can lead to the acquisition of extra centrosomes, which are not mutually 
exclusive.  Deregulation of the centrosome duplication cycle leads to the centriole overduplication 
and formation of supernumerary centrosomes via consecutive rounds of centrosome reproduction 
or fast concurrent formation of daughter centrioles around the existing centrioles giving rise to 
numerical amplification. Another cause of numerical amplification is the failure of cytokinesis, 
owing to which polyploid cells with supernumerary centrosomes are generated. On occasion, 
numerical amplification also arises from fragmentation of the pericentriolar matrix. Similarly, 
several factors account for structural defects which include accumulation of excessive PCM 
around the centrioles (likely due to deregulated expression of genes coding for centrosomal 
components or altered posttranslational modifications), resulting in centrosomes that appear 
altered in size.[7] PCM size is regulated by centrioles, free cytoplasmic αβ-tubulin, centrobin, 
kinases like PLK1 and CHK1, and several coiled-coil proteins like pericentrin and CPAP [8-10]. 
The mechanisms undergirding structural CA in cancer are still poorly defined, although several 
stimulators of PCM assembly are overexpressed in cancer (e.g., PLK1 [11] and CHK1 [12]), 
cancer cells often harbor supernumerary centrioles (which could then recruit excessive PCM), and 
the PCM expands following DNA damage [13]. Another possible reason for structural aberration 
can be tight clustering of centrosomes, which thus cannot be individually distinguished. Another 
possible reason for this can be structural defects in centrioles; this is a completely unexplored area 
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because the size of normal centriole is very small and requires very sophisticated microscopy 
techniques especially for tumor samples. [5]  
       In addition, deregulation of the oncogenes or tumor suppressor genes which regulates 
expression of centrosome-associated genes have been shown to lead to the formation of 
supernumerary centrosomes. For, e.g., the expression of an important protein Polo like kinase 4 
(PLK4) is regulated by various factors. A transcriptional factor KLF14 transcriptionally represses 
expression of PLK4 and thus knock out of KLF14 has been shown to result in centrosome 
amplification via an increase in expression of PLK4[14]. Similarly, p53 which is a tumor 
suppressor gene also negatively regulates expression of PLK4 and thus induces centrosome 
amplification indirectly through PLK4[15]. In addition, HPV-16 viral E6 and E7 oncoproteins 
have been shown to disrupt host cell cycle checkpoints important for oncogenic transformation 
that results in disruption of normal centriole duplication (increased PLK4 mRNA levels) induces 
centrosome amplification (CA)[16]. 
Another important factor which deregulates expression of the several centrosome-associated genes 
is the tumor microenvironment. Tumor hypoxia is one of the most critical component of tumor 
microenvironment. Although studies have reported that hypoxia increases levels of CA associated 
proteins such as Aurora-A/STK15 protein and PLK4 [17-19], the mechanism under grinding this 
phenomenon is not well understood. Thus, understanding the mechanism by which hypoxia 
induces CA is the primary goal of the first manuscript in this dissertation (Chapter 2).  
 
 Prognostic and predictive role of Centrosome amplification in human cancers 
Theodor Boveri postulated a century ago that multiple centrosomes are seen in cancer cells and 
may lead to tumorigenesis. Since then, centrosomes have been studied in growing list of human 
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cancers including bladder, blood, bone and soft tissue, brain, breast, cervix, colorectum, head and 
neck, hepatobiliary tract, kidney, ovary, prostate, and hematological malignancies. From these 
observations, the question naturally arises whether supernumerary centrosomes are simply 
innocent bystanders or whether they play a causative role in fueling tumor evolution. Studies have 
reported that CA occurs in precancerous and preinvasive lesions (including DCIS) , indicating that 
CA is an early event in tumorigenesis and is involved in the transition from early to advanced 
stages of carcinogenesis. Furthermore, one landmark study demonstrated that induction of CA 
could initiate tumor formation and metastasis in flies [5]. Multiple studies have reported that 
centrosome amplification correlates with high-grade tumors and poor prognosis [16]. In prostate, 
head and neck and breast cancers, CA is correlated with the lymph node and distant metastasis. 
Thus, it is becoming increasingly understood that rather than serving as a mere beacon of 
malignancy, supernumerary centrosomes actually drive malignant transformation. Indeed, several 
threads of evidence now suggest the association of CA with more aggressive tumors raising the 
possibility that CA could be an evolutionarily-favored trait that confers advantageous 
characteristics on the cells that harbor this feature and could promote tumor progression and 
aggressiveness. In sum, CA is associated with several indices of aggressiveness, like genomic 
instability, cell migration, and metastasis which may indicate the propensity of a tumor to 
metastasize, although further study to substantiate this paradigm is required in clinical models with 
high rates of metastasis. Thus, testing the role of CA in the underlying aggressive disease course 
in one of the highly metastasized and aggressive cancer i.e, Pancreatic adenocarcinoma is the 
primary goal of the study described in the second manuscript in this dissertation (Chapter 3). 
Furthermore, the role of CA in predicting tumor recurrence has been highlighted in multiple 
malignancies such as urothelial cancers and head and neck squamous cell carcinoma (HNSCC)  
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 highlighting its potential as a biomarker for advanced disease [26]. In HNSCC it has been 
observed that tumor margins with higher CA recur more frequently than those with less CA. These 
findings are interesting as ideally, the tumor margins should be free of malignant cells but if CA 
is observed in the tumor margins that indicates either presence of malignant or potentially 
malignant cells harboring CA in these tumor margins. This escape of the premalignant cells from 
histological detection may be a potential cause of tumor recurrence. Similarly, a high rate of 
recurrence is observed in the ductal carcinoma in situ and due to the lack of accurate recurrence 
risk prediction models patients are often under or over treated. Studies have shown that CA is 
present in the precancerous and preinvasive lesions of the breast. In addition, genes whose 
deregulation has been previously implicated in induction of CA such as Cyclin-d, Aurora-A, Nek2, 
and p53 are also deregulated in DCIS. Thus, there is tantalizing possibility that the organellar-level 
differences may exist between recurrent and nonrecurrent DCIS. To this end evaluating the role of 
CA to predict the risk of LR after lumpectomy (breast conservation surgery) is the primary goal 
of the study described in the third manuscript of this dissertation (Chapter 4).  
 
1.3  Drawbacks of current quantitation methods of Centrosome amplification 
Although the extent of CA in tumor samples can be readily quantified by using simple 
immunohistochemical methods that are clinically adaptable and cost-effective, the quantitative 
techniques currently used to measure CA suffer severe drawbacks. Most of the studies have 
considered the numerical amplification as a measure of centrosome amplification.  Although some 
recent studies have highlighted the role of structural amplification and quantitated them using 
either volume of gamma-tubulin spots or centriolar length but were not able to show all this in the 
human clinical samples. Moreover, the clustered centrosomes have often been misquantified as 
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structurally amplified centrosomes. Furthermore, none of the studies have made a clear distinction 
regarding the contribution of structural and numerical amplification towards the progression of the 
disease in cancer. A rigorous statistical analysis of correlations between clinicopathologic factors 
(such as tumor grade, stage, outcome) and CA has not been performed yet.  Thus, a true systematic 
quantitation technique which includes both structural and numerical amplification is urgently 
needed as a foundation for centrosome-based risk assessment in clinical tissue samples. In the 
study presented in the third manuscript (Chapter 4) of this dissertation, we have presented a novel 
methodology to quantitate both numerical and structural centrosomal aberrations in tumor 
samples. Our analytical pipeline allows robust interrogation of the ability of centrosomal overload 
to predict the risk of LR after lumpectomy. 
 
1.4  Centrosome clustering and chromosomal instability 
Presence of extra centrosomes leads to the formation of the multi-polar mitotic spindles and 
ultimately undergoes the mitotic catastrophe. In cancer cells, excess centrosomes cluster into two 
polar groups during mitosis, giving rise to pseudo-bipolar spindles which undergoes a transient 
multipolar stage. This multipolar intermediate favors the formation of merotelic attachment of 
individual kinetochores to more than one spindle pole. Such inappropriate attachments can cause 
missegregation of whole chromosomes and/or chromosomal breakage which gives rise to a lagging 
chromosome which may result in chromosome missegregation and aneuploidy. The quantity of 
microtubules involved in merotelic attachments dictates the behavior of the merotelically attached 
chromosome [20]. If the microtubules oriented on the wrong spindle pole are few the chromosome 
segregation proceeds without apparent impairment whereas if equal number of microtubules are 
attached to the right and wrong spindle poles, the chromosome lags during anaphase due to strong, 
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opposite poleward forces, but ultimately it tends to segregate to the right cell as a micronucleus. 
Thus, inappropriate attachments cause missegregation of whole chromosomes and/or 
chromosomal breakage which gives rise to a lagging chromosome and these chromosomes 
becomes trapped in and are either removed from the site or the cleavage furrow regresses resulting 
in the polyploidy. [21]. Furthermore, even if the lagging chromosome segregates to the right cell 
as a micronucleus, micronuclear DNA replicates aberrantly and asynchronously with primary 
nuclear DNA, resulting in rapid accrual of complex, clustered chromosome rearrangements [22-
25]. Thus, if it is, equi-merotely it results in “all-at-once,” catastrophic mutagenesis, which permits 
rapid karyotype evolution and if many microtubules are attached to the wrong pole (multi-
merotely) [20], results in aneuploidy. Furthermore, clustered supernumerary centrosomes are 
inherited by progeny cells, leading to a perpetuation of chromosomal instability (CIN) in the cell 
lineage and can promote aggressive disease features [26].  
Whether CIN promotes or inhibits tumorigenesis depends on the type of cell (some being 
inherently more tolerant of DNA damage and aneuploidy than others), its genetic background (e.g., 
pre-existing p53 mutations), the specific karyotype that is acquired (e.g., gain vs. loss of an 
oncogene), and the rate of CIN (with moderate levels tolerated better than extreme levels). It has 
been presented in multiple studies that CA induction in mice with the suppressed function of p53 
leads to tumorigenesis. Single-cell genome sequencing has revealed that major aneuploid 
rearrangements (which can be caused by CA) occur early in breast tumor evolution, followed by 
incremental clonal diversification over time [27, 28]. Furthermore, studies have shown that TNBC 
the most heterogeneous subtype of breast cancer exhibits highest CA among all subtypes and CA 
is associated with poor overall survival in these patients. Intriguingly, high grade serous ovarian 
adenocarcinoma shares similar genomic features with triple negative breast cancer (TNBC) as per 
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reports from Cancer Genome Atlas (TCGA) Network analysis; in particular, the deregulated 
pathways characterizing HGSOC are very similar to those in TNBC [29]. Specifically, the most 
common mutations present in both kinds of tumors (HGSOC and TNBC) are of p53 and BRCA1/2.  
Given that the BRCA1 and BRCA2 tumor suppressor genes directly preserve genomic stability by 
regulating DNA repair, p53-mediated cell cycle checkpoint control as well as centrosome 
duplication cycle [30-32]. Mutations in these genes predisposes a cell for the development of CA 
leading to CIN.  Furthermore, HGSOC tumors frequently overexpress cyclin E and Aurora-A, 
resulting in aberrant activation of the centrosome duplication cycle that induces centrosome 
amplification (CA), [33-35]. If CA is more extensive in HGSOC, it stands to reason that their cells 
may rely more staunchly on clustering molecules, such as KIFC1, for survival; thus, clustering 
molecules may be particularly valuable prognostic biomarkers and predictors of response to 
declustering drugs in HGSOC patients.  Evaluation of KIFC1 as a prognostic biomarker in HGSOC 
is the goal of the study described in the fourth manuscript in this dissertation (Chapter 5).  
 
1.5 KIFC1 the centrosome clustering protein is a cancer cell-specific target 
 KIFC1, also known as HSET, is a nonessential kinesin motor protein, that plays a crucial role in 
centrosome clustering in cancer cells [36, 37]. Knockdown of KIFC1 was shown to induce 
multipolar spindle defects and cell death in mitotic cancer cell lines containing extra centrosomes 
like MDA-MB 231[37] whereas it had no effect on cell division in a variety of control cell lines 
like BJ fibroblasts, which virtually exhibits no CA,  mouse NIH-3T3 fibroblast sand human breast 
MCF-7, which exhibit only low level of CA [37]. Studies have shown that KIFC1 is elevated in 
several cancer types [38-41], including, breast, ovarian and colon cancer [42]. Thus, in cancer 
cells, the role of KIFC1 becomes indispensable due to the presence of supernumerary centrosomes. 
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This differential dependence of cancer cells on KIFC1 for viability makes KIFC1 a cancer-cell 
selective therapeutic target for “centrosome-rich” cancers, including those of the breast, prostate, 
bladder, colon, and brain. In addition, it has been shown in multiple studies that KIFC1 is 
overexpressed in chemoresistant (resistance against tubulin targeted drugs like docetaxel, taxane, 
and tamoxifen) breast and prostate cancers and that inhibition of KIFC1 have been seen to increase 
the sensitivity of cancer cells to taxanes. Thus, it is reasonable to suspect that KIFC1 might act as 
a therapeutic target for the chemoresistant cancers which exhibit high levels of CA. Numerical and 
structural CA has been reported in CRCS and researchers have reported CA and chromosomal 
instability in several CRC cell lines suggesting a link between CA and CIN in CRCs. In another 
study, it was reported that inactivation of p53 in CRC cells HCT116 lead to a 3.5-fold increase in 
tetraploidization. Loss or mutation of p53 gene is the most frequent genetic lesion in CRCs and is 
the reason behind resistance to 5-fluorouracil, the first-choice chemotherapy drug for CRC. Given 
that i) the p53 mutated CRCs exhibit higher levels of CA and ii) the traditional chemotherapies are 
not effective it becomes reasonable to state that centrosome declustering drugs might serve as the 
novel therapeutic target in this cancer. Thus, studying the role of KIFC1 as a therapeutic target and 
the mechanism as in how the expression of KIFC1 is regulated in p53 null/mutant CRCs is the 
main goal of the study presented in chapter 6 (manuscript 5) of this dissertation.  
1.6  Griseofulvin, a novel KIFC1 inhibitor 
Griseofulvin (GF) is an antifungal drug that is known to induce centrosome declustering. Multiple 
studies have shown that GF inhibits proliferation of the tumor cells by inducing multipolarity. The 
mechanism of action through which GF causes centrosome declustering is not very well 
understood. Recently it has been shown that GF works with the similar mechanism of action as 
other tubulin interactive agents where they act by binding a specific site of tubulin to inhibit the 
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formations of microtubules. The consequent suppression of microtubule dynamics leads to 
centrosome declustering, multipolar mitosis, and cell death. Inhibition of centrosome clustering by 
suppressing the kinesin KIFC1 selectively kills cancer cells containing extra centrosomes [37, 43]. 
Several KIFC1 inhibitors - AZ82 [44], CW069 [45, 46], and PJ34 [47, 48]- have been developed 
that induce multipolar mitosis, preferentially in cancer cells, in vitro, and in vivo. All these drugs 
work through different mechanisms and have shown high levels of toxicity in in vitro and in vivo 
models; therefore, they have not paved their way to clinical trials yet. GF [49], has attracted 
extensive interest as a potential anticancer agent due to its low toxicity and [50-53] greater 
efficiency in inhibiting proliferation of tumor cells. Furthermore, it has been shown aneuploid 
CRC cells display higher sensitivity to GF, delay aster formation and microtubular regrowth and 
display centrosome declustering. Understanding the mechanisms by which GF acts can pave the 
way for rational design and synthesis of more effective and cancer cell specific “kinder and 
gentler” chemotherapy, the secondary goal of the study described in the fifth manuscript in this 
dissertation (Chapter 6).  
1.7 Docetaxel-induced polyploidization underlying drug resistance and disease relapse in 
cancer  
Drug resistance against tubulin targeted drugs like Docetaxel, taxane and tamoxifen is a major 
issue in cancer therapeutics. Though the use of these drugs prolongs overall and progression-free 
survival in multiple malignancies their clinical utility is strictly limited due to disease relapse. 
Several lines of thought exist to explain the disease relapse after a modest increase in overall 
survival and one of the most intriguing mechanisms illustrated in various studies is the formation 
of giant multinucleated polyploid (MP) cells after therapeutic intervention with either taxane-
based chemotherapy including docetaxel or DNA damaging agents. These polyploid cells can be 
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a result of DNA over-replication [54], abrogated mitotic checkpoint [55] or failed cytokinesis 
[56]. It was long assumed that these giant polyploid cells do not survive and die due to “mitotic 
catastrophe” subsequent to multipolar cell division. But, recent evidence indicated that while most 
polyploid cells succumb to cell death, a small percentage of them survive and produce viable 
progeny [57, 58]. The mechanism of generation of viable clones from these polyploid cells is 
poorly understood. Alos, the knowledge about the characteristics of these polyploid cells which 
protects them from chemotherapy and imparts aggressive cellular features is also not sufficient to 
design therapies which can help eliminate these giant cells following docetaxel treatment. Thus, 
understanding the mechanism of the generation of polyploid cells and their chemoresistance nature 
is the primary goal of the study presented in the sixth manuscript in the dissertation (Chapter 7).  
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2 AMPLIFIED CENTROSOMES AND MITOTIC INDEX DISPLAY POOR 
CONCORDANCE BETWEEN PATIENT TUMORS AND CULTURED CANCER 
CELLS  
Parts of this chapter have been published verbatim in Scientific Reports 2017 Mar 8;7:43984 as 
“Amplified centrosomes and mitotic index display poor concordance between patient tumors 
and cultured cancer cells.”  
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2.1 Abstract 
Centrosome amplification (CA) and aberrant mitoses are considered beacons of 
malignancy. Cancer cell doubling times in patient tumors are longer than in cultures, but 
differences in CA between tumors and cultured cells are uncharacterized. We compare mitoses 
and CA in patient tumors, xenografts, and tumor cell lines. We find that mitoses are rare in-patient 
tumors compared with xenografts and cell lines. Contrastingly, CA is more extensive in-patient 
tumors and xenografts (~35-50% cells) than cell lines (~5-15%), although CA declines in patient-
derived tumor cells over time. Intratumoral hypoxia may explain elevated CA in vivo because 
exposure of cultured cells to hypoxia or mimicking hypoxia pharmacologically or genetically 
increases CA, and that HIF-1α induces CA in tumor cells by transcriptionally regulating expression 
of centrosome associated protein PLK4. HIF1α and hypoxic gene signature expression correlate 
with CA and centrosomal gene signature expression in breast tumors. These results highlight the 
importance of utilizing low-passage-number patient-derived cell lines in studying CA to more 
faithfully recapitulate in vivo cellular phenotypes. 
2.2 Introduction 
Cancer has always been reckoned as a mass of abnormal cells growing rapidly in a 
deregulated manner. This basic rationale underlies the inception of chemotherapeutic strategies 
targeting mitosis and development of antimitotic drugs. Since cancer cells divide at a more rapid 
rate than normal cells, disruption of mitosis has been perceived as the most effective and selective 
therapeutic strategy against malignant cells. Although mitosis-targeting drugs, such as inhibitors 
of Aurora kinases, Polo-like kinases, and Kinesin-spindle protein, have been very successful in 
preclinical trials, their poor performance in the clinical setting has raised doubts about the 
relevance of this chemotherapeutic strategy.[1] Multiple studies affirm that the rationale 
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undergirding the development of mitosis-targeting drugs is flawed as, frequent mitosis is not a 
hallmark of human cancers, as previously postulated.[1, 2] In contrast with immortalized cell 
cultures and xenograft models, which are most frequently used to assess the efficacy of antimitotic 
drugs, human tumors tend to have very low mitotic rates (with the mean mitotic index in many 
tumor types being <1%).[2] Furthermore, the mean doubling time of a variety of human tumors is 
>100 days, much higher than that of tumors in pre-clinical models. Although recent cell culture 
studies have been highly informative, they bear limited conformity with events in vivo. Another 
important factor affecting the potential relevance of cell culture data is drug bioavailability. The 
drug concentration in the tumor microenvironment varies significantly in vivo, with drug 
concentrations rising, peaking, and falling as the drug circulates and then is removed from the 
body. In a study evaluating single-cell responses to the antimitotic drug paclitaxel in murine 
xenograft tumors as compared with cell culture, mitotic frequency was found to be lower in tumors 
than in cell culture.[3] Interestingly, the peak mitotic index in tumors exposed to paclitaxel was 
lower and the tumor cells survived longer after mitotic arrest, becoming multinucleated rather than 
dying directly from mitotic arrest, as opposed to cell cultures. Thus, the in vivo tumor 
microenvironment was found to be far less pro-apoptotic than the environment of cultured cells. 
Another cancer cell-specific trait, CA, which refers to the presence of supernumerary or 
abnormally large centrosomes,[4, 5] occurs early in pre-cancerous and pre-invasive lesions and is 
linked to aggressiveness in several types of cancer. CA is believed to drive tumor progression by 
promoting chromosomal instability and the generation of aggressive tumor clones that are more 
capable of rapid metastasis. However, the presence of more than two centrosomes within a cell 
may result in the formation of multipolar spindles, leading to “mitotic catastrophe”[4] and eventual 
cell death. To avoid this, cancer cells cluster supernumerary centrosomes into two polar groups to 
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allow formation of a “pseudobipolar” mitotic spindle, a phenomenon that leads to their ultimate 
survival.[4-8] Given that cancer cells rely heavily on centrosome clustering mechanisms for 
viability, putative centrosome declustering agents have emerged as promising anticancer drugs.[9-
11] [12] Most studies of these drugs rely on cancer cell lines and tumor cell line xenograft models, 
yet it is unknown how faithfully they recapitulate the profound CA often observed in patient 
tumors or whether there is a potentially superior model. 
 
Herein, we quantified the prevalence of mitoses and CA in patient tumors compared with 
tumor cell lines and tumor cell line xenografts. We report that CA, but not mitotic index, is found 
at high levels in patient tumors, suggesting that CA may be a more valuable chemotherapeutic 
target than mitosis. We also found that CA progressively declines, and mitotic index progressively 
increases in culture, suggesting differences exist between the in vivo and in vitro 
microenvironments that have important ramifications for experimental design. Most often, cells 
cultured in vitro are supplied with copious amounts of oxygen, perhaps to fulfill the metabolic 
requirement of the voraciously growing log-phase cancer cells. However, in solid tumors, the 
oxygen concentrations in many regions of the tumor may be severely inadequate resulting in a 
hypoxic tumor deprived of oxygen.[13] We report here that induction of hypoxia or mimicking 
hypoxic conditions induces CA in vitro via HIF-1α and that HIF-1α induces CA in tumor cells by 
transcriptionally regulating expression of centrosome associated protein PLK4. Moreover, HIF-1α 
expression was found to correlate with CA in breast tumors. Ultimately, our study emphasizes the 
limitations of traditional cell culture models for studying CA and highlights the importance of low-
passage patient-derived cell lines as being more representative of the true clinical scenario.  
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2.3 Materials and methods 
2.3.1  Clinical tissue samples 
Formalin-fixed paraffin-embedded slides of breast, pancreatic and bladder cancer tissue were 
procured from Northside Hospital and Emory University Hospital, in Atlanta. The Institutional 
Review Board of Northside hospital and Emory University approved all aspects of the study. Fresh 
tumor samples (samples obtained by partial mastectomy pretreatment) were procured from West 
Georgia Hospital, Lagrange under approved protocols. Methods were carried out in accordance 
with approved guidelines and informed consent was obtained from all subjects. Descriptive 
statistics for patient and clinicopathologic characteristics are provided in Tables 2.3.1-3. 
 
2.3.2 Established tumor cell lines 
 MDA-MB-231, MIA PaCa-2, T24, CFPAC, CAPAN1, HCT116-p53-/-, HCT116 p53WT, PC3 
and DU145 cell lines were obtained from American type cell culture (ATCC) and were grown in 
standard conditions. Briefly, grown in Dulbecco's Modified Eagle's medium (DMEM), RPMI or 
Hyclones 5A medium as per instructions supplemented with 10% Hyclone fetal bovine serum 
(FBS) and 1% penicillin/streptomycin. Cells were maintained in humidified 5% CO2 atmosphere 
at 37°C. Patient-derived tumor cell lines: Tumor cells were isolated from a TNBC patient tumor 
(partial mastectomy) obtained from West Georgia hospital. To isolate tumor cells for culture, the 
tumor tissue was first minced into small pieces and then was digested in a mixture of DMEM/F12 
medium containing 2 mg/ml bovine serum albumin, 2 mg/ml collagenase type IV, and 2 mg/ml 
hyalurodinase at 37°C for 30-40 min with continuous agitation. After the tumor chunks were 
completely digested, cells were filtered through a 70 µm mesh, centrifuged at 2,000 rpm for 10 
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minutes, resuspended in fresh DMEM/F12 supplemented with 10% FBS and 1% penicillin, and 
plated in 10 mm culture dishes in humidified 5% CO2 atmosphere at 37°C. 
2.3.3  Tumor cell line xenografts 
All animal experiments were performed in compliance with Institutional Animal Care and Use 
Committee guidelines. For implantation into nude mice, MBD-MB-231 cells were washed with 
PBS, digested with trypsin, resuspended in DMEM 1X containing 10% FBS, and pooled. After 
centrifugation, cells were resuspended in Matrigel (BD Biosciences Discovery Labware, Bedford, 
MA)-DMEM 1X (1:3) at a concentration of 1×106 cells/100 μL, 100 μL of which was 
subcutaneously implanted into the dorsa of 6-week-old female Bald/nu mice (Harlan Sprague-
Dawley, Indianapolis, IN). Tumor volumes were monitored constantly for 6 weeks, and after that 
tumors were excised and fixed in 10% formalin, embedded in paraffin, sectioned at 5 µm, and 
immunolabeled for centrosomes (γ-tubulin) and mitotically-active cells (Ph3). 
2.3.4  Lysate preparation and immunoblotting 
Cells were cultured to ~80% confluence and protein lysates were prepared as described 
previously.[39]  Briefly cells were scraped with 250ul of 1x lysis prepared from 10x cell lysis 
buffer (Cell Signaling). The 1x lysis buffer contained 1 mM b-glycerophosphate, 20 mM Tris–
HCl (pH 7.5), 1 mM Na2EDTA, 1 mM Na3VO4, 150 mM NaCl, 1 mM EGTA, 2.5 mM 
Na4P2O7, 1ug/ml leupeptin, and 1 % Triton. 10% Protease inhibitor was added to prevent 
degradation of proteins. Cell lysates were fractionated using 10 % SDS-PAGE gel Fresh tissue 
sections were sonicated and lysates were then prepared using the same lysis buffer. Polyacrylamide 
gel electrophoresis was used to resolve the proteins, which were transferred onto polyvinylidene 
fluoride membranes (Millipore). The Pierce ECL chemiluminescence detection kit (Thermo 
Scientific) was used to visualize the immune-reactive bands. β-actin was used as loading control.  
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2.3.5 Immunohistofluoresence staining 
Formalin-fixed paraffin-embedded tissue slides were deparaffinized followed by serial rehydration 
in ethanol baths (100%, 95%, 70% and 50%). Antigens were retrieved by heating in a pressure 
cooker in citrate buffer (pH 6.0) at psi 15 for 30 min. Blocking was performed by incubating the 
slides with the ultra-vision protein block (Life Sciences) for 30 min. Tissue samples were then 
incubated overnight with primary mouse antibody against γ-tubulin (Table X) at 1:1000 dilution) 
at 4°C, followed by washing 3X with PBS. The samples were then incubated with secondary 
antibody (Alexa-488 anti-mouse) at 1:2000 dilution for 2 h, at 37°C followed by washing 3X with 
PBS. Finally, coverslips were mounted with Prolong-Gold Antifade Reagent with DAPI 
(Invitrogen).  
2.3.6  Immunohistochemical staining and scoring 
Deparaffinization and antigen retrieval were performed as described as for 
immunohistofluoresence staining. Thereafter, the tissues were immunolabeled using antibody 
against Ph3 (dilution 1:1000) or HIF-1α (1:1000). Ph3-positive cells were counted in 10 randomly 
selected fields (~500 cells) to determine the percentage of mitotic cells. Enzymatic antibody 
detection was performed with the Universal LSAB + Kit/HRP (DAKO, CA, USA). HIF-1α 
staining intensity was scored as 0=none, 1=low, 2=moderate, or 3=high, and the percentage of 
positive cells (i.e., with 1+ staining intensity) from 10 randomly selected fields (~500 cells) was 
determined. The product of the staining intensity and the percent of positive cells (nuclei) 
constituted the WI. 
2.3.7 Immunocytofluorescence staining 
Cells were grown on glass coverslips, fixed with ice-cold methanol for 10 min, and then blocked 
with 2% bovine serum albumin/1XPBS/0.05% Triton X-100 at 37°C for 1 h. Coverslips were 
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incubated in primary antibodies against γ-tubulin and α-tubulin at 1:2000 dilution for 1 h at 37°C, 
washed with 2% bovine serum albumin/1XPBS for 10 min at room temperature, and then 
incubated in 1:2000 Alexa 488- or 555-conjugated secondary antibodies (Invitrogen; Carlsbad, 
CA). Cells were mounted with Prolong Gold Antifade Reagent with DAPI (Invitrogen). 
2.3.8 Microscopy 
Images of tissue samples were taken utilizing the Zeiss LSC 700 confocal microscope 
(Oberkochen, Germany) and were processed with Zen software (Oberkochen, Germany). 
Magnifications and more details on imaging is provided in individual sections.    
2.3.9  Quantitation of centrosome amplification 
Numbers and volumes of γ-tubulin foci were used as indicators of numerical and structural 
centrosome amplification, respectively. Since gamma-tubulin is present in both centrioles and the 
PCM, above-normal volumes of γ-tubulin foci represent the cumulative structural volume 
amplification of both PCM and centrioles. Centrosomal volumes were calculated using the 3D 
measurement module from the Zeiss imaging software. Average centrosomal volumes ranged 
between 0.22-0.76 μm3 in normal breast, 0.20-0.56 μm3 in normal pancreas, and 0.20-0.74 μm3 in 
normal bladder tissue. The percentage of cells with >2 centrosomes as quantitated from 10 
randomly selected fields (around 500 cells) in tumor areas pre-marked by a pathologist was 
determined for each tissue type as well as cell lines (Supplementary Figure. 2.7.1). CA was 
calculated as a percentage by adding the percent cells harboring more than two centrosomes and 
the percent cells harboring centrosomes with volume larger than 0.76 µm3, 0.56 µm3 and 0.74 µm3 
for breast, pancreatic and bladder tissues respectively. A more detailed description of the 
quantitation process along with a schematic is given in the supplementary materials and 
Supplementary Figure.1. 
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2.3.10 Induction of hypoxia and mimicking hypoxic conditions 
Hypoxia chamber:  Cells grown on glass coverslips were either placed in a hypoxic modulated 
incubator chamber (flushed with 1% O2 gas mixture at 20 L/min for 7-10 minutes every 3-6 hrs) 
or a normoxic incubator. After 48 h, cells were trypsinized and lysates were prepared for 
immunoblotting assays. To pharmacologically induce hypoxia cells were treated with 100µm of 
Cocl2 for 24 hrs. Further to stabilize HIF-1 α in normoxic conditions cells were treated with 1mM 
DMOG (SIGMA) for 24 hrs and 5µM MG132 for 5 hrs. Glass coverslips having cells were fixed 
with ice cold methanol and staining was performed as described in cell staining section 
2.3.11 HIF-1α overexpression 
HIF-1α was genetically overexpressed by transfecting cells with GFP-tagged degradation resistant 
HIF -1α. HA-HIF-1α P402A/P564A-pcDNA3 was a generous gift from Dr. Willian Kaelin 
(Addgene plasmid # 18955).[40] Cells at a confluency of ̴70% were transfected using 
Lipofectamine 2000 according to the manufacturer’s instructions.  
2.3.12 HIF-1α gene knock out 
The gene knockout of HIF-1α was performed using CRISPR/Cas 9 method. Where in, guide RNAs 
to target the human HIF-1α gene was designed using the (http://tools.genome-engineering.org) 
source. Two individual sgRNAs were designed to target exon 1 of HIF-1α (sgRNA1, 
5’CACCGTTTCTTGTCGTTCGCGCCGC3’; sgRNA2, 
5’AAACGCGGCGCGAACGACAAGAAAC 3’). sgRNA-encoding oligonucleotides was cloned 
into pSpCas9-2A-GFP (PX458) (a generous gift from Feng Zhang (Addgene plasmid # 48138) 
(using standard procedures www.genome-engineering.org)[41].  Transfection of the MDA-MB 
231 and MDA-MB 468 cells was performed as described under the section of HIF-1α OE. As a 
negative control for the transfection efficiency vector pSpCas9-2A-GFP was used. The 
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pSpCas9(BB)-2A-GFP plasmid was GFP tagged hence the sgRNA and Cas9 expressing cells were 
sorted using FACS. The sorted GFP positive cells were expanded and the knockout in these cells 
was verified by exposing these cells to hypoxia followed by immunoblotting for HIF-1α. 
2.3.13 ChIP assay 
Briefly, MDA-MB-231 and MDA-MB-468 cells were plated at a density of 2.5 x 106 and were 
cultured in hypoxic and normoxic conditions for 48 hrs. Following the hypoxic and normoxic 
treatment the cells were crosslinked with 1% formaldehyde; crosslinking was stopped by the 
addition of 0.125M glycine. Cells were lysed, and the nuclear fraction will be sonicated to shear 
the crosslinked DNA into an average of 500 bp of sheared DNA. Sonicated lysates were run on a 
1% agarose gel to ensure proper fragment size. The sonicated lysates were pre-cleared with 
salmon-sperm coated agarose beads for an hour at 4o C, followed by washing and lysates were 
divided equally. Half of the lysate was Immunoprecipitated (IP) with 5µg of the HIF-1α antibody 
and another half of lysates was immunoprecipitated with control (IgG) antibody (function as 
nonspecific binding control) and 1% of the lysate was used as input. IP samples were isolated by 
Protein A/salmon sperm beads and were washed in increasing salt concentration buffers (low salt, 
high salt, LiCl and 1X TE buffers) followed by elution of DNA and reversal of crosslinks 
(overnight with 5M NaCl at 65˚C followed by treatment with proteinase K at 45˚C). IP’d DNA 
were isolated using phenol: chloroform: isopropanol mix (Invitrogen). Following extraction, qRT-
PCR amplification was performed on the immunoprecipitated DNA and the total input DNA. 
Primers were designed to amplify the region of the PLK4 gene that contained the full promoter 
activity as well as the HIF-1α -responsive regions.  The values obtained in the qPCR were 
normalized to the total amount of DNA put into the reaction (percent input will be used as internal/ 
positive control).  
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2.3.14 PLK4 and VEGF reporter plasmid construction 
Genomic DNA will be isolated from the HEK293 (Human Kidney epithelial cells) to serve as 
template for the PCR amplification of 1Kb promoter of human PLK4 gene containing HREs. After 
PCR cleanup the Promoter was cloned into the pGL4.51 expression vector (which has a luciferase 
reporter, cytomegalovirus promoter, and ampicillin resistance gene) (Promega) using standard 
subcloning procedure. MAX Efficiency DH5α competent E. coli was transformed with the vector 
using heat shock followed by plating on LB agar with 50 µg/ml ampicillin for selection of 
transformed clones. The plasmid DNA from individual colonies obtained was purified using a 
commercial spin column. Sequencing was performed to confirm the clones containing PLK4 insert 
with the correct promoter sequence cloned in the proper orientation, which was then be used for 
transfections. Similarly, VEGF reporter plasmid was constructed. 
2.3.15  Dual luciferase assay 
For PLK4 reporter assays, cells were transfected with 500 ng of PLK4 reporter plasmids with 500 
ng pRL-TK plasmids. As a positive control another culture of cells was transfected with VEGF 
reporter plasmids with the pRL- TK plasmid. Lipofectamine 2000 (Invitrogen) was used as a 
transfection reagent. For each transfection, plasmids were premixed with the transfection reagent. 
Twenty-four hours after transfection, the cells were transferred to a hypoxia chamber (1% O2) or 
maintained in normoxia (20% O2). After 48 hours, the cells were harvested, and a Dual Luciferase 
reporter assay system (Promega) was used for sequential measurements of firefly and Renilla 
luciferase activities). Firefly luciferase activity was normalized to the Renilla luciferase activity. 
Each sample was analyzed in quadruplicates, and each transfection was repeated three times. 
Quantification of luciferase activities and calculation of relative ratios was carried out using a 
luminometer (TD-20/20; Turner Designs, Sunnyvale, CA, USA).  
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2.3.16 Statistical analyses 
Unless otherwise stated in the methods and results sections, statistical analyses were performed 
using two-tailed Student’s t-tests. The criterion for statistical significance for all analyses was 
p<0.05. Survival analysis (simple Cox model) was performed using SPSS Statistics version 
21(IBM). 
 
2.4 Results 
2.4.1 Mitotic index is lower in-patient tumors than tumor cell lines and xenografts 
To corroborate the view that tumor cells in patients’ bodies are not as mitotically active as 
cancer cells in vitro, we first compared the mitotic indices of patient tumors and established tumor 
cell lines from different tissue types, including breast, pancreas and bladder. To this end, we 
quantitated phosphohistone H3 (Ph3)-positive (i.e., mitotic) cells microscopically in 20 paraffin-
embedded patient tumor samples (surgical resection) for each cancer type as well as their 
representative established tumor cell lines. In addition, breast tumor cell line xenografts were 
analyzed. Descriptive statistics regarding patient and clinicopathologic characteristics for tumor 
samples utilized are given in Tables 2.4.1, 2.4.2 and 2.3.3. Mitotic indices were approximately 7-
fold, 3-fold, and 8-fold higher in MDA-MB-231 breast cancer cells, MIA PaCa-2 pancreatic cancer 
cells, and T24 bladder cancer cells compared with patient tumors of the respective cancer types. 
By contrast, mitotic indices were similar between MDA-MB-231 xenografts and cell cultures 
(Figure. 2.4.1A, B). These studies suggest that established tumor cell lines, whether in cultures or 
xenografted in nude mice, display higher mitotic indices than patient tumors. 
Table 2.4.1 Descriptive statistics for patient and clinicopathologic characteristics in the 
analysis of centrosome amplification and mitotic index in breast tumors. 
Variable Level Number Percentage 
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Race AA 4 20 
 EA 16 80 
    
Gender Male 0 0 
 Female 20 100 
    
 1 9 45 
Grade 2 5 25 
 3 6 30 
    
 I 10 50 
Stage II 7 35 
 III 1 5 
 IV 2 10 
    
 ER-/PR- 8 40 
ER/PR Expression ER-/PR+ 1 5 
 ER+/PR+ 11 55 
    
 Low (<10%) 0 0 
CA (%) 
Moderate 
(10-40%) 7 35 
 High (>40%) 13 65 
    
Mitotic Index  <1 8 40 
  1~6 12 60 
    
ER: Estrogen Receptor; PR: Progesterone Receptor; CA: Centrosome Amplification; AA: African 
American; EA: European American 
 
 
Table 2.4.2Descriptive statistics for patient and clinicopathologic characteristics in the 
analysis of centrosome amplification and mitotic index in bladder tumors. 
Variable Level Number Percentage 
Race AA 13 65 
 EA 7 35 
    
 1 7 35 
Grade 2 0 0 
 3 13 65 
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Invasive 
Status 
Non-invasive 7 35 
Invasive 13 65 
    
CA (%) 
Low (<10%) 0 0 
Moderate (10-40%) 11 55 
High (>40%) 9 45 
    
Mitotic 
Index 
<1 18 90 
1-6 2 10 
CA: Centrosome Amplification; AA: African American; EA: European American 
Table 2.4.3Descriptive statistics for patient and clinicopathologic characteristics in the 
analysis of centrosome amplification and mitotic index in pancreatic tumors. 
Variable  Level Number Percentage 
 AA 9 45 
Race EA 11 55 
    
Gender Male 11 55 
 Female 9 45     
Tumor size 
(cm) ≤2 3 15 
 >2 17 85     
Grade Low 10 50 
 High 10 50     
PNI Yes 17 85 
 No 3 15     
LVI Yes  15 75 
 No 5 25     
 1 2 10 
Stage T  2 2 10 
 3 16 80     
 1 15 75 
Stage N  0 4 20 
 Unknown 1 5     
 Yes 19 95 
Stage M No 0 0 
 Unknown 1 5     
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LN Positive ≤5 15 75 
 >5 5 25     
 Low (<10%) 0 0 
CA (%) 
Moderate 
(10-40%) 14 70 
 High (>40%) 6 30 
    
 <1 5 25 
Mitotic Index 
(MI) 1-6 9 45 
  >6 6 30 
CA: Centrosome Amplification; AA: African American; EA: European American; PNI: Peri-
Neural Invasion; LVI: Lympho-Vascular Invasion 
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Figure 2.4.1 Human tumors display lower mitotic indices than tumor cell lines and 
xenografts.  
A. Representative immunofluorescent confocal micrographs of tumor cell lines labeled for the 
mitotic marker phosphohistone H3 (Ph3). Red arrows: Ph3-positive cells. Scale bar (white), 5µm. 
Bi, Bii. Representative immunohistochemical micrographs of a patient breast tumor and an MDA-
MB-231 xenograft labeled for Ph3. Red arrows: Ph3-positive cells. Scale bar (red), 20 µm C. 
Mitotic indices in patient tumors, tumor cell lines, and MDA-MB-231 xenografts. *p<0.05, 
**p<0.01.  
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2.4.2 CA is higher in-patient tumors and xenografts than tumor cell lines 
Having established the low frequency of mitoses in various patient tumor types, we next 
compared the extent of CA between patient tumor samples and respective tumor cell lines for each 
cancer type. Breast tumor cell line xenografts were also analyzed. To accomplish this, we 
microscopically visualized centrosomes in 20 cases for each tissue type along with the specific 
cell lines. Centrosomes were immunofluorescently stained with anti-gamma tubulin antibody and 
co-stained with DAPI. Basically, CA can be of two types- numerical and structural.  Numerical 
amplification can arise from several processes but the main mechanism underlying this phenotype 
is deregulation of the centrosome duplication cycle, which leads to centriole overduplication and 
formation of supernumerary centrosomes. Another cause of numerical amplification is failure of 
cytokinesis, owing to which polyploid cells with supernumerary centrosomes are generated. On 
occasion, numerical amplification arises from fragmentation of the pericentriolar 
matrix.[14]Similarly several factors account for structural defects which includes accumulation of 
excessive PCM around the centrioles (likely due to deregulated expression of genes coding for 
centrosomal components or altered posttranslational modifications), resulting in centrosomes that 
appear altered in size[15]. Another possible reason for structural aberration can be tight clustering 
of centrosomes, which thus cannot be individually distinguished. Third possible reason for this 
can be structural defects in centrioles; this is a completely unexplored area because the size of 
normal centriole is very small and requires very sophisticated microscopy techniques especially 
for tumor samples[4]. 
In light of the numerous challenges mentioned above, we used the volumes of the gamma-
tubulin foci as indicators of structural centrosome aberration/amplification. While pancreatic, 
bladder, and breast tumors exhibited 35%, 36%, and 50% CA, respectively, their corresponding 
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cultured cell lines exhibited 15%, 10% and 23% CA, respectively (Figure. 2.4.2 A, B). Centrosome 
clustering was extensive among patient tumors with CA (see inset, Figure. 2.4.2 Ai). Next, we 
determined whether CA in the MDA-MB-231 cell lines persists following subcutaneous 
implantation into nude mice. Remarkably, CA in tumor xenografts excised at the end of six weeks 
was nearly double that of the native MDA-MB-231 cell line, similar to the level of CA found in 
patient breast tumors (Figure. 2.4.2 B). Taken together, these studies clearly demonstrate a high 
prevalence of CA in human tumors and MDA-MB-231 xenografts but not in cultured tumor cell 
lines and suggest that differences between the in vivo tumor microenvironment and culture plate 
are at least partly responsible for this observation. 
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Figure 2.4.2  Human tumors have high centrosome amplification compared to cultured 
cells.  
 
A) i. Bladder, pancreatic, and breast tumors along with normal adjacent tissue immunostained for 
centrosomes (γ-tubulin, green) and counterstained with DAPI (blue). Yellow arrows, numerical 
centrosome amplification; red arrows, structural centrosome amplification. Scale bar (red), 20 µm. 
Aii. Confocal micrographs of centrosome amplification and clustering in various tumor cell lines. 
Centrosomes and microtubules were immunolabeled for γ-tubulin (green) and α-tubulin (red), 
respectively, and DNA was counterstained with DAPI (blue).  Scale bar (white) 5 µm. Aiii. 
Confocal micrographs of centrosome amplification and clustering in MDA-MB-231 xenografts. 
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Scale bar (red), 20 µm. B. Quantitation of centrosome amplification in human tumors, tumor cell 
lines, and tumor cell line xenografts. 500 cells were counted in each case. *p<0.05, **p<0.01. 
2.4.3  CA and mitotic index in patient-derived tumor cells change differently with passaging 
Our observations of the vast disparity in the degree of CA observed in patient tumors and cultured 
tumor cell lines cast doubt on the clinical relevance of tumor cell lines that are extensively utilized 
for studying CA. We thus reasoned that patient-derived tumor cell lines at a low passage number 
may mimic the cellular traits observed in tumor tissues and can emerge as a more useful 
representative model to conduct in vitro studies. We thus examined the degree of CA in patient-
derived tumor cell lines by isolating tumor cells from a triple-negative breast cancer (TNBC) and 
quantitating CA with passaging. CA in the original tumor sample was ~45% (Figure. 2.4.3 A, Bi). 
Intriguingly, when tumor cells were dissociated from the tumor mass and cultured, CA 
progressively declined after passage 2. Passage 3 cells showed a significant 3-fold reduction in CA 
compared with passage 2 cells (Figure. 3Bi), and by passage 5 the degree of CA fell to ~10%, a 
level that and was sustained through passage 10 (Figure. 2.4.3A, B). We also observed extensive 
centrosome clustering in cells from passages 2 and 3 as well as in the original tumor tissue (Figure. 
2.4.3A, inset). Taken together, our data underscore the higher concordance of centrosomal traits 
between low passage number (passage 2-3) patient-derived tumor cells and cells found in patient 
tumor tissues and xenografts.  
In addition, we assessed the change in mitotic index in patient-derived tumor cells with 
passaging, which differed remarkably from our observations of CA with passaging. The mitotic 
index did not change significantly until passage 10, at which time it was ~3-fold higher than in the 
original tumor (Figure. 2.4.3Bii). Taken together, these experiments reveal striking differences in 
the pace and direction of changes in CA and mitotic index from intratumoral values in patient-
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derived tumor cells in culture, suggesting that centrosome homeostasis and mitosis are 
differentially impacted by differences in the in vivo and in vitro microenvironments.  
 
 
Figure 2.4.3 Centrosome amplification and mitotic index in patient tumors and patient-
derived tumor cells with passaging.  
A. Confocal micrographs of centrosome amplification and mitotic figures in the original patient 
tumor and cells isolated from the tumor and cultured through passage 10 (P10). Insets: centrosome 
amplification and clustering. Scale bar, 5 µm. Bi. Quantitation of centrosome amplification at 
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various passage numbers compared with the original tumor. * and # indicate that CA is 
significantly higher in the original tumor and P2, respectively, when compared with P3, P5, P8 
and P10 (p<0.05). Bii. Mitotic index at various passage numbers compared with the original tumor. 
 
2.4.4  Hypoxia enhances CA via HIF-1α in cultured cells 
Given that a hypoxic microenvironment is one of the major potential differences between tumor 
cells in vitro and in vivo, we rationally hypothesized that hypoxia could underlie the divergence 
in CA observed in vivo, both in patient tumors and MDA-MB-231 xenografts (which have been 
shown to be hypoxic[16]), and established tumor cell lines grown in vitro, where oxygen is 
abundant. To test this hypothesis, we exposed MDA-MB-231 and MDA-MB-468 breast cancer 
cells to hypoxia for 48 h using a hypoxic chamber flushed with a 1% O2 gas mixture. The presence 
of hypoxia was confirmed by upregulation of HIF-1α (Figure. 2.4.4B). As shown in Figure. 2.4.4, 
cells grown in hypoxic conditions for 48 h showed numerical CA, with both clustered and 
dispersed centrosomes, as well as structural CA, with enlarged γ-tubulin foci (representing 
individual centrosomes with excessive γ-tubulin accumulation named as PCM accumulation see 
representative images in Figure. 2.4.4A). Following hypoxia, upregulation of proteins whose 
overexpression drives CA (Cyclin E, Aurora A, and PLK4) and centrosome structural proteins 
(pericentrin and γ-tubulin) was observed (Figure. 4B, with additional data and description provided 
in Supplementary Figure. 2.4.4C), along with a significant ~1.5-fold increase in CA (Figure. 
2.4.4C). Moreover, the average centrosomal volume in cells grown under hypoxic conditions was 
nearly double the volume in cells grown under normoxic conditions (Figure. 2.4.4D). These results 
suggest that the presence of hypoxia in patients’ tumors could explain, at least in part, the vast 
differences in CA observed in vivo and in vitro. 
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Figure 2.4.4 Hypoxia enhances centrosome amplification. 
A. Confocal micrographs of centrosome amplification in MDA-MB-231 cells after 48 h of hypoxia 
(Hx) or normoxia (Nx). Both numerical centrosome amplification (with centrosomes dispersed or 
clustered) and structural centrosome amplification (“PCM,” indicating abnormally large individual 
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γ-tubulin foci) were observed. Scale bar, 5 µm. B. Immunoblots of the hypoxia marker HIF1-α, 
proteins whose overexpression drives centrosome amplification (PLK4, Cyclin E, and Aurora A), 
and centrosome structural proteins (pericentrin and γ-tubulin) in MDA-MB-231 cells exposed to 
24 and 48 h of hypoxia (Hx). C. Quantitation of centrosome amplification in MDA-MB-231 48 h 
after hypoxia. Scale bar, 5 µm. D. Average centrosomal volumes in normoxic (Hx) and hypoxic 
(Hx) MDA-MB-231 cells. *p<0.05, **p<0.001. 
2.4.5 Mimicking hypoxia through pharmacologic and genetic methods enhances centrosome 
amplification 
To bolster the findings of our hypoxia chamber experiments, we also mimicked hypoxic conditions 
in normoxia using pharmacologic and genetic methods in MDA-MB-231 and MDA-MB-468 cells. 
Hypoxia upregulates transcription factor hypoxia inducible factor 1 which undergoes proteasomal 
degradation in normoxic conditions. [17-19] So, to stabilize HIF-1α in normoxic conditions we 
treated the cells with CoCl2, a HIF-1α-stabilizer,[20] which resulted in a ~1.5 fold increase in the 
CA compared with untreated cells (Fig 2.3.5A, E and Supplementary Figure. 2.7.2A1), similar to 
what we found in the hypoxia chamber experiments. To further characterize the observed 
centrosomal abnormalities, we co-immunolabeled γ-tubulin and centrin-2 (a centriolar marker) 
and performed the quantitation as described in Supplementary Figure. 2.7.3A-C. We found that γ-
tubulin foci invariably overlapped with centrin-2 foci in both CoCl2-treated and untreated cells, 
suggesting that the supernumerary γ-tubulin foci observed represent bona fide centrosomes and 
not mere fragments of pericentriolar material. Moreover, we failed to observe supernumerary 
centrin-2 foci in enlarged γ-tubulin foci, suggesting that the enlarged γ-tubulin foci represent 
structurally augmented centrosomes and not supernumerary centrosomes so tightly clustered as to 
be indistinguishable. The increased CA in CoCl2-treated cells was substantiated by protein 
immunoblotting, which revealed increases in centrosome structural proteins as well as proteins 
whose overexpression drives centrosome amplification compared with untreated cells (Figure. 
                                                 
1 All supplemental data, tables, and figures appear in Appendix A for this chapter 
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2.4.5B, with additional data and original blots provided in Supplementary Figure. 2.7.4). We next 
treated the cells with dimethyloxalylglycine (DMOG), which stabilizes HIF-1α in normoxic 
conditions[21], and MG132, which inhibits 26S proteasomal degradation of HIF-1α[22]. 
Treatment with either DMOG or MG132 treatment increased CA nearly ~1.5-fold (data shown in 
Supplementary Figure. 2.7.6C), in alignment with our other observations. We confirmed the 
increase in CA by protein immunoblotting (Supplementary Figure. 2.7.6B). 
Next to confirm that the increase in CA under hypoxia was due to HIF-1α we overexpressed 
HIF-1α by transfecting cells cultured under normoxic conditions with GFP-tagged degradation-
resistant HIF-1α. Transfected cells showed higher CA (~28%) under normoxic conditions than 
vector controls (~21%) (Supplementary Figure. 6A) and increase in CA was further confirmed 
with protein immunoblotting (Figure. 2.4.5C). We also knocked-out HIF-1α gene using 
CRISPR/CAS9 method (details in methods) and exposed these transfected cells to hypoxic 
conditions and found that levels of centrosomal proteins and proteins whose overexpression drives 
CA were lower than in vector controls (Figure. 2.4.4D and original blots shown in Supplementary 
Figure.2.7.5). In addition, cells transfected with vector control showed higher CA (~21%) 
(representative images Supplementary Figure. 2.7.6A) than HIF-1α knocked out cells, indicating 
that hypoxia induces CA via HIF-1α. Collectively, these experiments substantiate the paradigm 
that hypoxic conditions in the tumor microenvironment may account for differences in CA 
observed between patient tumors/ tumor cell line xenografts and established tumor cell lines. 
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Figure 2.4.5 Mimicking hypoxia through pharmacologic and genetic methods enhances 
centrosome amplification.  
A. Confocal micrographs of centrosome amplification (numerical, including dispersed and 
clustered configurations, and structural) in MDA-MB-231 cells in control conditions (top panel) 
and after 24 h CoCl2 treatment (bottom panel). Scale bar, 5 µm. B. Immunoblots of HIF-1α and 
centrosomal proteins in control and CoCl2-treated MDA-MB-231 and MDA-MB-468 cells. C. 
Immunoblots of HIF1α and centrosomal proteins in MDA-MB-231 and MDA-MB-468 transfected 
with empty vector or degradation-resistant HIF-1α. D. Immunoblots of HIF-1α and centrosomal 
proteins in MDA-MB-231 and MDA-MB-468 transfected with Cas9-sgRNA (HIF-1α) construct 
or control vector (pSpCas9-2A-GFP). E. Quantitation of numerical (including dispersed and 
clustered configurations) and structural (“PCM”) centrosome amplification per microscopic 
examination for Cocl2 treated and untreated MDA-MB-231 and MDA-MB-468 cells. 
 
2.4.6 Hypoxia is associated with CA in breast tumors 
We next examined the relationship between HIF-1α levels and CA in breast cancer 
samples. To this end, we first immunohistochemically labeled 24 breast cancer and uninvolved 
adjacent normal tissue samples (samples obtained by partial mastectomy pretreatment) for HIF-1α 
and calculated weighted indices (WIs) for nuclear HIF-1α. Adjacent serial sections from the same 
tumors were also immunofluorescently labeled for γ-tubulin (Figure. 2.4.6A, B). CA was 
calculated as described in the Supplementary Figure. 2.7.1. Descriptive statistics of patient and 
clinicopathological characteristics, CA levels, and biomarker WIs are given in Table 2.4.4. HIF-
1α WI was higher in the tumor areas when compared with adjacent normal tissue. In addition, a 
strong positive correlation between nuclear HIF-1α WI and CA was found in breast tumor samples 
(Spearman’s rho p=0.722, p<0.001).  
 
In addition, we found that higher nuclear HIF-1α was associated with worse overall 
survival (p=0.041; HR=1.03).  We also compared the expression levels of HIF-1α and centrosome 
structural proteins (γ-tubulin and pericentrin) in fresh frozen clinical samples and uninvolved 
adjacent tissue from a pair of patients, one with TNBC and the other with non-TNBC. 
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Immunoblots showed higher expression of HIF1- α and centrosomal proteins in both tumor types 
in comparison with their normal adjacent tissues (Figure. 2.4.6).  Finally, using public microarray 
datasets, we investigated whether centrosomal gene expression is enriched in breast tumors 
characterized by a hypoxic gene expression signature. We found that breast tumors with high 
expression of hypoxia-associated genes exhibited higher expression of centrosomal genes than 
breast tumors with low expression of hypoxia-associated genes regardless of mitotic index (which 
could otherwise confound analyses given that centrosomal genes are upregulated in mitosis) 
(Supplementary Figure. 2.7.7 and Supplementary Tables 2.7.1-5). Furthermore, a score based on 
the top 10 overexpressed centrosomal genes in breast tumors characterized by high levels of 
hypoxia-associated genes predicted worse distant metastasis-free survival in 94 node-negative 
breast cancer patients in multivariable analysis adjusting for various possible confounders 
(HR=3.39, p=0.011), whereas a hypoxia score previously shown to have prognostic ability in 
multiple cancers[23, 24] was non-significant in this full model (see Supplementary text and 
Supplementary Figure. 2.7.7 for more details). Together with our in vitro findings, these clinical 
data analyses support the hypothesis that hypoxia/HIF-1α drive CA in patient breast tumors and 
contribute to poor outcomes, such as distant metastasis. 
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Figure 2.4.6 Higher HIF-1α expression is associated with higher CA.  
A. Representative immunohistochemical micrographs of human breast tumors stained for HIF-1α. 
Green arrows indicate HIF-1α-positive cells. Scale bar (red), 20 µm. B. Breast tumors along with 
normal adjacent tissue were immunostained for γ-tubulin (green), and DAPI-stained (blue) to 
visualize centrosomes, and DNA. C. Immunoblots showing the levels of hypoxia and centrosomal 
markers in patient tumor samples (T) and their adjacent normal (N) tissues. 
 
Table 2.4.4 Descriptive statistics for patient and clinicopathologic characteristics in the 
analysis of centrosome amplification and HIF-1α in breast tumors. 
   Variable Level   Number    
Percentag
e 
 
     
     Race EA 
 
1
4  
58% 
 
AA 
 
1
0  
42% 
      
     Grade 1  1  4% 
 2  3  13% 
 
3 
 
2
0  
83% 
      
     Stage I 
 
1
0  
42% 
 II  8  33% 
 III  2  8% 
 IV  1  4% 
 N/A  2  8% 
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ER/PR/HER2      
Expression 
ER-/PR-/HER2- 
 
2
4  
100% 
 
     
            CA% Low (<10%)  5  21% 
 
Moderate (10%-
40%)  
1
6  
67% 
 High (>40%)  3  13% 
2.4.7 Hypoxia induces CA via HIF-1α in multiple cancer cells  
Furthermore, we wanted to explore if the association of hypoxia with CA was true for all cancers 
(prostate, pancreatic and colorectal) or was specific for the breast cancer cells. Therefore, we 
mimicked hypoxic conditions in normoxia using pharmacologic and genetic methods in prostate 
cancer (PC3 and DU145), pancreatic cancer (CFPAC and CAPAN1) and colorectal cancer 
(HCT116 p53-/- and HCT116 p53WT) cells. We observed that the stabilization HIF-1α in 
normoxic conditions resulted in an increase in the CA in all cells compared with untreated cells 
(Fig 2.4.7) and increase in CA was further confirmed with immunoblotting.  Next, we 
overexpressed HIF-1α by transfecting cells cultured under normoxic conditions with GFP-tagged 
degradation-resistant HIF-1α. All the transfected cells showed higher CA under normoxic 
conditions than the corresponding vector controls (Figure. 2.4.7 and 2.4.8B) and increase in CA 
was further confirmed with protein immunoblotting (Figure. 2.4.8A). Collectively, these 
experiments substantiate the paradigm that hypoxic conditions in the tumor microenvironment 
may enhance the CA observed in the tumor cells.  
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Figure 2.4.7 Mimicking hypoxia through pharmacologic and genetic methods enhances 
centrosome amplification-representative confocal micrographs.  
 Confocal micrographs of centrosome amplification (numerical and structural) in CAPAN-1, 
CFPAC, DU145, PC3, HCT116 p53-/- and HCT116 WT cells in control conditions and after 24 h 
CoCl2 treatment. Scale bar, 5 µm. 
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Figure 2.4.8 Mimicking hypoxia through pharmacologic and genetic methods enhances 
centrosome amplification- Immunoblots of HIF1α and centrosomal proteins and 
quantitation of CA  
A)Immunoblots of HIF1α and centrosomal proteins in CAPAN-1, CFPAC, DU145, PC3, HCT116 
p53-/- and HCT116 WT cells transfected with empty vector or degradation-resistant HIF-1α. B) 
Immunoblots of HIF-1α and centrosomal proteins in control and CoCl2-treated CAPAN-1, 
CFPAC, DU145, PC3, HCT116 p53-/- and HCT116 WT cells. C) Bar graph representing the 
quantitation of numerical (including dispersed and clustered configurations) and structural 
(“PCM”) centrosome amplification per microscopic examination for Cocl2 treated and untreated 
CAPAN-1, CFPAC, DU145, PC3, HCT116 p53-/- and HCT116 WT cells.  
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2.4.8  HIF-1α induces CA in tumor cells via transcriptionally regulating expression of PLK4  
Given that the expression of centrosome-associated protein PLK4 increased with stabilization of 
HIF-1α and that the literature evidence support the hypoxia-mediated overexpression of PLK4, we 
suspected that HIF-1α might transcriptionally regulate expression of PLK4. To this end, first, we 
performed ChIP assay to confirm if the HIF1α binds to HIF-1α-responsive elements (HREs) that 
are present in the promoter region of PLK4 genes to regulate their transcription.  Our results from 
Chip indicated HIF-1α interaction, with the HRE motif from genomic DNA of MDA-MB 231 and 
MDA-MB-468 cells under hypoxic conditions, was significantly (p=0.04) higher when compared 
with the cells cultured under normoxic conditions (Figure 2.4.9 A-D).   
Next, we performed luciferase reporter assay to confirm the role of the HIF-1α in transcriptional 
regulation of PLK4. One representative cell line from each cancer type was co-transfected with 
Plk4 reporter plasmid and pRL- TK plasmid. As a positive control, another culture of cells was 
transfected with VEGF reporter plasmid AND pRL- TK plasmid. The transfected cells were 
exposed to hypoxia or normoxia and after 48hrs the relative firefly luciferase activity was 
measured (normalized to Renilla luciferase activity). Our results indicated that RLU activity for 
the cells cultured under hypoxia for both PLK4 and VEGF reporters was significantly higher 
(p<0.05) when compared to the cells cultured under normoxic conditions (Figure 2.4.9 E and F). 
There was  3-fold increase in relative luciferase activity of all the cell lines for both Plk4 plasmid 
and VEGF. Thus, the results clearly suggest that HIF-1α transcriptionally regulate expression of 
Plk4.  
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Figure 2.4.9 HIF-1 transcriptionally regulates expression of PLK4. 
A) Bar graphs representing the binding of HIF-1 at the PLK4 promoter in MDA-MB-468 cells. 
B) Bar graphs representing the binding of HIF-1 at the GAPDH promoter in MDA-MB-468 cells. 
C) Bar graphs representing the binding of HIF-1 at the PLK4 promoter in MDA-MB-231 cells. 
D) Bar graphs representing the binding of HIF-1 at the PLK4 promoter in MDA-MB-231 cells. 
E) Bar graph representing the relative luciferase activity at PLK4 promoter in normoxic and 
hypoxic conditions for MDA-MB-231, HCT116 p53-/-, CFPAC and PC3 cells. F) Bar graph 
representing the relative luciferase activity at VEGF promoter in normoxic and hypoxic conditions 
for MDA-MB-231, HCT116 p53-/-, CFPAC and PC3 cells. * represents p <0.05. 
 
2.5 Discussion 
While mitosis-targeting drugs have shown remarkable success in immortalized cell lines and tumor 
xenografts, they have failed to deliver their efficacy in human trials. Our current study provides a 
rigorous, systematic analysis of the relationship between a universal prognostic factor (mitotic 
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index) and a well-known cancer-cell specific trait and a potential prognosticator (CA) in a 
spectrum of model systems ranging from cultured cells, preclinical tumor xenografts, patient-
derived primary cultures and patient tumors. Our data reconfirm that rapid cell division is not as 
predominant a trait of human tumors as it is of immortalized cell lines and tumor cell line 
xenografts. Since preclinical drug development experiments with antimitotic drugs are most often 
performed using immortalized cell lines or xenograft models, a large fraction of cells in these 
systems are vulnerable to antimitotic therapy. Therefore, it is not surprising that in human tumors 
where the fraction of the mitotically active cells is very low, only a small, insignificant fraction of 
cells are vulnerable to antimitotic drugs. In addition, many studies have shown that the median 
doubling times for many human tumors are on the order of months or even years, versus only hours 
or days for immortalized cell lines and tumor xenografts.[1, 25] The rapid doubling rate of tumors 
in preclinical models also explain why antimitotic agents prove very effective in these models but 
fail to show much efficacy against patient tumors. Thus, the lack of response of patient tumors to 
antimitotic drugs is due to the relative rarity of mitoses and slow doubling rate as highlighted by 
our study.   
 
While human cancers including colon, breast, bladder, prostate, gliomas, and pancreas 
show profound CA,[26] we found immortalized cell lines are characterized by a much milder 
extent of this cell biological trait. The poor concordance between the extent of CA in tumors and 
cells in vitro can thus restrict the utility of cultured cells for studying CA mechanisms in vitro as 
well as for exploring the potential and promise of CA as a therapeutic target or prognostic 
biomarker. We reason that cancer cells seeking to adapt to and thrive in the tumor 
microenvironments encounter diverse selection pressures during tumor progression, such as 
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varying levels of oxygen. CA drives chromosomal instability[27] and thereby generates karyotypic 
diversity, a trait that is highly desirable for tumors seeking a survival advantage; beyond a certain 
point however, chromosome instability itself may become a selection pressure that jeopardizes the 
viability of cancer cells, which may not be able to maintain a chromosomal composition necessary 
for optimal cell growth. It is likely that in continuous cultures, the diminution of CA is due to cells 
having achieved a karyotypic composition wherein the persistence of amplified centrosomes could 
potentially have deleterious effects. When such a state is attained, CA may itself serve as a 
selection pressure, thus explaining the attenuation in the extent of amplification in cultured cells 
compared to human tumors.   
 
Based on our findings, it seems possible that CA could be a superior target to mitosis, an 
infrequent event in patient tumors, since a third to half of cells in patient tumors exhibit CA 
(Figure. 2). Immortalized cell lines, on the other hand, display a much lower degree of CA. This 
discordance can in part be explained by the presence of hypoxia in the microenvironment of the 
tumor, which is usually absent in vitro. In addition, cells are usually cultured in vitro with excessive 
glucose and growth factors compared with the tumor microenvironment, which helps cultured cells 
to grow rapidly and thus be more sensitive to antimitotic drugs. Cancer cells dwell within a 
complex milieu of normal cells, blood vessels, endogenous small molecules, and secreted factors, 
which together comprise the tumor microenvironment. Hypoxia is one of the hallmarks of the 
tumor microenvironment, which is critically essential for cancer initiation, progression, metastasis, 
and drug resistance.[28, 29] Indeed a major detriment of using cell lines is that the vital interaction 
of tumor cells with their microenvironment is inherently omitted. Thus, when cancer cells are 
grown in culture dishes in a two-dimensional plane, the oxygen levels between cells stay relatively 
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equal, which is an improbable setting within a growing three-dimensional tumor in a patient’s 
body. Moreover, the artificial, non-physiological environment in which cells in laboratory cultures 
are sustained fails to recapitulate the complex three-dimensional cellular interactions that exist in 
vivo. Another major inadequacy of cell culture is its inability to model the effects of physiologic 
responses to a tumor, such as the immune response and angiogenesis, two factors known to 
strongly influence tumor development.[30] Altogether, our study underscores the remarkable 
disparity in CA and mitosis between patient tumors and model systems, which must be carefully 
considered when designing experiments to study these phenomena. 
 
Reports indicate that hypoxia, which is known to induce overexpression of HIF1-α, 
increases Aurora A/STK15 protein levels, which has been well documented to induce CA.[31-33] 
Our study demonstrates that cells grown under hypoxic conditions exhibit higher CA, Aurora A 
and PLK4 levels compared with cells grown under normoxic conditions. Although it is possible 
that hypoxia may favor the proliferation or survival of cancer cells with extra centrosomes and 
therefore favor the maintenance of CA in the population, our results support the notion that hypoxia 
induces CA perhaps via promoting overexpression of proteins such as PLK4. Our findings clearly 
suggest that HIF-1 directly regulates expression of PLK4 and increase in PLK4 levels in response 
to hypoxia results in higher CA in various cancer cells. Based on our studies, we speculate that 
hypoxia enhances the metastatic potential of cancer cells by inducing CA through upregulation of 
proteins such as Aurora A, PLK4, and Cyclin E, although a more comprehensive study is needed 
to investigate this tantalizing research question. Many studies have demonstrated that hypoxia is 
associated with an increased capacity for metastasis.[34, 35] We[36] and others[8, 37] have shown 
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that supernumerary centrosomes confer cytoskeletal advantages on the cells that harbor them; this 
could increase directional migration and invasiveness and thus enhance metastatic potential. 
 
While these preclinical models (both established tumor cell lines and tumor cell line 
xenografts) are far from ideal, they have been widely used given that the rapid doubling times in 
such models permit a fast-tracked drug-development timeline. Nonetheless, this perceived 
advantage rather puts us at a loss when the doubling time itself is in the spotlight and the drug’s 
activity relies on the preponderance of the mitotic population, which hinges on doubling rate. The 
brisk doubling times of the preclinical models explain why drugs targeting mitosis proved active 
in these models but were ineffective against patient tumors.[1, 2, 25] Our study highlights the 
importance of low-passage patient-derived cell line systems as being most representative of the 
clinical scenario and thus constituting an invaluable experimental model that could better guide 
drug development and clinical trial design. 
Centrosome amplification is now well established as a hallmark of cancer. However, the 
presence of more than two centrosomes within a cell can be problematic as it may lead to formation 
of multipolar spindles leading to “mitotic catastrophe”[4] and cell death. To avoid multipolar 
spindle formation and subsequent mitotic catastrophe, cancer cells cluster supernumerary 
centrosomes into two polar groups to allow formation of a “pseudobipolar” mitotic spindle and 
produce viable daughter cells.[6, 38] Since our study clearly demonstrates that human tumors 
display a high frequency of CA, inhibition of centrosome clustering could have afflicted tumor 
cells to succumb to mitotic catastrophe and be eliminated. Given that cells with CA are suspected 
to have metastatic potential, antagonizing centrosome clustering could prove to be a strategy to 
suppress metastasis. Recently, many drugs have been shown to have centrosome declustering, 
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including griseofulvin, noscapine and several of its derivatives (e.g., bromonoscapine and reduced 
bromonoscapine), the PARP inhibitor PJ-34, and HSET inhibitors like AZ82 and CW069.[9-12] 
To discern meaningful activity of these drugs before they are tested in clinical trials as potential 
centrosome declustering dugs, it is imperative that we consider the shortcomings of our existent 
cell line models and rather develop robust and relevant preclinical models that mimic cellular traits 
observed in patient tumors. Our study clearly shows that established tumor cell lines exhibit lower 
CA than patient tumors and thus may be inferior model systems for testing centrosome targeted 
drugs than early-passage patient-derived tumor cell lines, which exhibit similar CA to patient 
tumors.  
Undoubtedly the incongruity in CA between patient tumors and established tumor cell lines 
depreciates the importance of centrosomes as viable attractive targets and rather overstates mitosis 
as a target, perhaps resulting in the drug development process being blindsided. Our findings thus 
underscore the critical need to cautiously identify models that resemble patient tumors more 
closely in those characteristics/traits that are being targeted and are thus more clinically relevant. 
This is the first report to substantiate the previously unrecognized discordance associated with 
mitotic frequency and the extent of CA between various model systems. Our study emphasizes the 
limitations of in vitro cultures perhaps owing to genomic convergence upon continuous passaging 
and highlights the importance of low-passage patient-derived cell line system as most 
representative of the clinical scenario and thus a good preclinical model to study the therapeutic 
potential of centrosome targeting drugs compared to conventional continuous cell lines. Our study 
also underscores the significance of CA as a superior chemotherapeutic target and delineates the 
molecular mechanism whereby HIF-1α strongly upregulates PLK4 expression and drives rampant 
CA in these tumors. Therefore, our findings indicate that HIF-1α-mediated upregulation of PLK4 
tumors drives its distinct tumor biology and establishes a causative link between two biological 
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phenomena – hypoxia and CA – that co-occur in many solid tumors. Based upon our findings, we 
suggest that low-passage patient-derived tumor cells and tumor xenografts could serve as good 
preclinical models for testing these drugs since the degree of CA found in these models closely 
resembles that in patient tumors. Taken together, our results suggest that CA could prove to be a 
better therapeutic target than mitosis owing to its higher incidence in human tumors, which perhaps 
occurs in low oxygen hypoxic tumor environment.  
2.6 References 
1. Komlodi-Pasztor, E., et al., Mitosis is not a key target of microtubule agents in patient 
tumors. Nat Rev Clin Oncol, 2011. 8(4): p. 244-50. 
2. Komlodi-Pasztor, E., D.L. Sackett, and A.T. Fojo, Inhibitors targeting mitosis: tales of 
how great drugs against a promising target were brought down by a flawed rationale. 
Clin Cancer Res, 2012. 18(1): p. 51-63. 
3. Orth, J.D., et al., Analysis of mitosis and antimitotic drug responses in tumors by in vivo 
microscopy and single-cell pharmacodynamics. Cancer Res, 2011. 71(13): p. 4608-16. 
4. Godinho, S.A. and D. Pellman, Causes and consequences of centrosome abnormalities in 
cancer. Philos Trans R Soc Lond B Biol Sci, 2014. 369(1650). 
5. Ogden, A., P.C. Rida, and R. Aneja, Heading off with the herd: how cancer cells might 
maneuver supernumerary centrosomes for directional migration. Cancer Metastasis Rev, 
2013. 32(1-2): p. 269-87. 
6. Ganem, N.J., S.A. Godinho, and D. Pellman, A mechanism linking extra centrosomes to 
chromosomal instability. Nature, 2009. 460(7252): p. 278-82. 
7. Godinho, S.A., M. Kwon, and D. Pellman, Centrosomes and cancer: how cancer cells 
divide with too many centrosomes. Cancer Metastasis Rev, 2009. 28(1-2): p. 85-98. 
8. Kwon, M., et al., Mechanisms to suppress multipolar divisions in cancer cells with extra 
centrosomes. Genes Dev, 2008. 22(16): p. 2189-203. 
9. Castiel, A., et al., A phenanthrene derived PARP inhibitor is an extra-centrosomes de-
clustering agent exclusively eradicating human cancer cells. BMC Cancer, 2011. 11: p. 
412. 
10. Raab, M.S., et al., GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor 
cell growth in vitro and in vivo. Cancer Res, 2012. 72(20): p. 5374-85. 
11. Watts, C.A., et al., Design, synthesis, and biological evaluation of an allosteric inhibitor 
of HSET that targets cancer cells with supernumerary centrosomes. Chem Biol, 2013. 
20(11): p. 1399-410. 
12. Wu, J., et al., Discovery and mechanistic study of a small molecule inhibitor for motor 
protein KIFC1. ACS Chem Biol, 2013. 8(10): p. 2201-8. 
13. Vaupel, P. and L. Harrison, Tumor hypoxia: causative factors, compensatory 
mechanisms, and cellular response. Oncologist, 2004. 9 Suppl 5: p. 4-9. 
14. Chan, J.Y., A clinical overview of centrosome amplification in human cancers. Int J Biol 
Sci, 2011. 7(8): p. 1122-44. 
56 
 
 
15. Nigg, E.A., Origins and consequences of centrosome aberrations in human cancers. Int J 
Cancer, 2006. 119(12): p. 2717-23. 
16. Semenza, G.L., The hypoxic tumor microenvironment: A driving force for breast cancer 
progression. Biochim Biophys Acta, 2016. 1863(3): p. 382-91. 
17. Generali, D., et al., Hypoxia-inducible factor-1alpha expression predicts a poor response 
to primary chemoendocrine therapy and disease-free survival in primary human breast 
cancer. Clin Cancer Res, 2006. 12(15): p. 4562-8. 
18. Bao, B., et al., The biological kinship of hypoxia with CSC and EMT and their 
relationship with deregulated expression of miRNAs and tumor aggressiveness. Biochim 
Biophys Acta, 2012. 1826(2): p. 272-96. 
19. Liu, Z.J., G.L. Semenza, and H.F. Zhang, Hypoxia-inducible factor 1 and breast cancer 
metastasis. J Zhejiang Univ Sci B, 2015. 16(1): p. 32-43. 
20. Yuan, Y., et al., Cobalt inhibits the interaction between hypoxia-inducible factor-alpha 
and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha. J 
Biol Chem, 2003. 278(18): p. 15911-6. 
21. Botusan, I.R., et al., Stabilization of HIF-1alpha is critical to improve wound healing in 
diabetic mice. Proc Natl Acad Sci U S A, 2008. 105(49): p. 19426-31. 
22. Kaluz, S., M. Kaluzova, and E.J. Stanbridge, Proteasomal inhibition attenuates 
transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the 
HIF-1alpha C-terminal activation domain. Mol Cell Biol, 2006. 26(15): p. 5895-907. 
23. Eustace, A., et al., A 26-gene hypoxia signature predicts benefit from hypoxia-modifying 
therapy in laryngeal cancer but not bladder cancer. Clin Cancer Res, 2013. 19(17): p. 
4879-88. 
24. Buffa, F.M., et al., Large meta-analysis of multiple cancers reveals a common, compact 
and highly prognostic hypoxia metagene. Br J Cancer, 2010. 102(2): p. 428-35. 
25. Ogden, A., et al., Interphase microtubules: chief casualties in the war on cancer? Drug 
Discov Today, 2014. 19(7): p. 824-9. 
26. Mittal, K., et al., Amplified centrosomes may underlie aggressive disease course in 
pancreatic ductal adenocarcinoma. Cell Cycle, 2015: p. 0. 
27. Cosenza, M.R. and A. Kramer, Centrosome amplification, chromosomal instability and 
cancer: mechanistic, clinical and therapeutic issues. Chromosome Res, 2016. 24(1): p. 
105-26. 
28. Baak, J.P., et al., Multivariate prognostic evaluation of the mitotic activity index and 
fibrotic focus in node-negative invasive breast cancers. Eur J Cancer, 2005. 41(14): p. 
2093-101. 
29. Cheng, G.M. and K.K. To, Adverse Cell Culture Conditions Mimicking the Tumor 
Microenvironment Upregulate ABCG2 to Mediate Multidrug Resistance and a More 
Malignant Phenotype. ISRN Oncol, 2012. 2012: p. 746025. 
30. Thomas, S., et al., CD24 is an effector of HIF-1-driven primary tumor growth and 
metastasis. Cancer Res, 2012. 72(21): p. 5600-12. 
31. Lukasiewicz, K.B. and W.L. Lingle, Aurora A, centrosome structure, and the centrosome 
cycle. Environ Mol Mutagen, 2009. 50(8): p. 602-19. 
32. Zhou, H., et al., Tumour amplified kinase STK15/BTAK induces centrosome 
amplification, aneuploidy and transformation. Nat Genet, 1998. 20(2): p. 189-93. 
57 
 
 
33. Katayama, H., et al., Interaction and feedback regulation between STK15/BTAK/Aurora-
A kinase and protein phosphatase 1 through mitotic cell division cycle. J Biol Chem, 
2001. 276(49): p. 46219-24. 
34. Le, Q.T., N.C. Denko, and A.J. Giaccia, Hypoxic gene expression and metastasis. Cancer 
Metastasis Rev, 2004. 23(3-4): p. 293-310. 
35. Subarsky, P. and R.P. Hill, The hypoxic tumour microenvironment and metastatic 
progression. Clin Exp Metastasis, 2003. 20(3): p. 237-50. 
36. Pannu, V., et al., Rampant centrosome amplification underlies more aggressive disease 
course of triple negative breast cancers. Oncotarget, 2015. 6(12): p. 10487-97. 
37. Godinho, S.A., et al., Oncogene-like induction of cellular invasion from centrosome 
amplification. Nature, 2014. 510(7503): p. 167-71. 
38. Marthiens, V., M. Piel, and R. Basto, Never tear us apart--the importance of centrosome 
clustering. J Cell Sci, 2012. 125(Pt 14): p. 3281-92. 
39. Mittal, K., et al., A centrosome clustering protein, KIFC1, predicts aggressive disease 
course in serous ovarian adenocarcinomas. J Ovarian Res, 2016. 9: p. 17. 
40. Yan, Q., et al., The hypoxia-inducible factor 2alpha N-terminal and C-terminal 
transactivation domains cooperate to promote renal tumorigenesis in vivo. Mol Cell 
Biol, 2007. 27(6): p. 2092-102. 
41. Ran, F.A., et al., Genome engineering using the CRISPR-Cas9 system. Nat Protoc, 2013. 
8(11): p. 2281-308. 
 
  
58 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright by 
Karuna Mittal 
                                                                          2018
59 
 
 
 
3 AMPLIFIED CENTROSOMES MAY UNDERLIE AGGRESSIVE DISEASE 
COURSE IN PANCREATIC DUCTAL ADENOCARCINOMA 
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3.1 Abstract 
Centrosome amplification (CA), the presence of centrosomes that are abnormally 
numerous or enlarged, is a well-established driver of tumor initiation and progression associated 
with poor prognosis across a diversity of malignancies. Pancreatic ductal adenocarcinoma (PDAC) 
carries one of the most dismal prognoses of all cancer types, and a majority of these tumors are 
characterized by numerical and structural centrosomal aberrations; therefore, CA may underlie the 
nearly unsurpassed aggressiveness of this disease. In this study, we sought to determine whether 
CA was associated with worse clinical outcomes, poor prognostic indicators, markers of epithelial-
mesenchymal transition (EMT), and ethnic health disparity in PDAC. We also evaluated whether 
CA could precipitate more aggressive phenotypes in a panel of cultured pancreatic cancer cell 
lines. Using publicly-available datasets, we examined the association between the expression of 
genes whose dysregulation drives CA and overall survival and the expression of EMT markers in 
PDAC patients. We found that increased expression of these CA-related genes was associated with 
worse overall survival and increased EMT marker expression. Quantitative analysis of 
centrosomal profiles in pancreatic cancer cell lines and tissue sections uncovered that pancreatic 
cell lines exhibited different levels of CA, and markers of CA were associated with the expression 
of EMT markers. We induced CA in pancreatic cancer cells and found that CA empowered the 
cells with enhanced invasive and migratory capabilities. In addition, we discovered that PDACs 
from African American (AA) patients exhibited a greater extent of both numerical and structural 
CA than PDACs from European American (EA) patients. Taken together, these findings suggest 
that CA may fuel a more aggressive disease course in PDAC patients. Given the prevalence of CA 
among pancreatic tumors,  
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especially ones from AA patients, future studies should test their susceptibility to centrosome 
declustering drugs, which could offer urgently needed targeted therapy with potentially low 
toxicity. 
3.2 Introduction 
Pancreatic cancer is the fourth most fatal cancer in the United States, although it constitutes 
only 2.7% of new cancer cases [1]. Greater than 90% of all pancreatic neoplasms derive from 
ductal cells, and ~85% of these are invasive PDACs [2]. Over the past 30 years, improvements in 
survival for PDAC patients have paled in comparison with improvements for patients suffering 
from other cancers. This unsettling trend is expected to continue in the near future, and it is 
projected that by 2030 pancreatic cancer will depose colorectal cancer to become the second-
leading cause of cancer-related death in the United States [3, 4]. A leading cause for the 
exceptionally high mortality of PDAC is its general lack of clinically useful prognostic markers 
and therapeutic targets, which contrasts with many other malignancies (such as breast and lung), 
in which much greater strides in precision medicine have been made. Surgical resection is the only 
treatment to date that appreciably extends survival in PDAC, with a median survival of ~18 months 
for patients who undergo complete resection compared with only ~6 months for patients with 
unresectable tumors [5]. Gemcitabine is the standard of care for patients with advanced disease, 
although it improves survival only by about one month [6]. Therefore, it is critical to identify 
prognostic and predictive indicators and clinically actionable drivers of disease aggressiveness in 
PDAC. Such an approach has achieved breakthroughs for other highly aggressive, treatment-
refractory cancers, such as melanoma [4], by enabling risk stratification of patients and the 
administration of targeted therapies. A deluge of gene expression and proteomic studies has 
implicated ~10% of the exome in pancreatic cancer [7], but the size and complexity of these data 
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have so far thwarted their integration into an actionable portrait of the disease. Indeed, at present 
there is only one FDA-approved biomarker for pancreatic cancer, carbohydrate antigen 19-9; 
however, it has low prognostic value before surgery or chemotherapy, so its utility is mostly 
limited to post-treatment monitoring of disease progression [8]. Furthermore, only one FDA-
approved targeted therapy is available for PDAC, erlotinib (in combination with gemcitabine), 
although it improves survival by less than 2 weeks and, thus, is rarely prescribed [4]. Consequently, 
there is a critical need for improved prognostic biomarkers and therapeutic targets for PDAC. 
Biomarkers and drug targets are generally sought at “omics” levels of late, but a seemingly 
overlooked pool of candidates is comprised of organelles. These structures constitute the output of 
the cell’s own integration of the staggeringly complex molecular signaling events within it, so 
organelles represent particularly comprehensive and clinically significant biomarkers and drug 
targets. Investigation of organelle-level variations among PDACs of differing aggressiveness 
represents entirely uncharted territory. The centrosome has emerged as a central driver of tumor 
aggressiveness across cancer types. CA (the presence of excessively numerous or voluminous 
centrosomes) can initiate tumorigenesis, engenders chromosomal instability, and precipitates 
invasive tumor behavior [9-11]. In order for cancer cells to avail themselves of the advantages of 
CA, however, they must prevent spindle multipolarity during mitosis, lest they succumb to fatal 
mitotic catastrophe. As a result, cancer cells deftly cluster supernumerary centrosomes into two 
diametrically opposed groups in order to achieve pseudo-bipolar spindle geometry and survive. 
The extent of CA correlates positively with aggressiveness across the entire spectrum of cancer 
types [12]. Consequently, it is rational to suspect that CA is involved in PDAC, which is nearly 
unrivaled in its aggressive behavior among malignancies. Furthermore, a small study focused on 
centrosome abnormalities in PDAC revealed a striking difference in the profiles of centrosomes, 
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both in terms of their number and size, as compared with normal pancreas [13]. Another study 
observed that centrosome abnormalities (defined as supernumerary or structurally aberrant 
centrosomes) detected by pericentrin immunofluorescence staining were correlated with nuclear 
abnormalities (namely, bi- or multinucleation or the presence of giant nuclei) in a panel of 
pancreatic cancer cell lines [14]. These studies lend credence to our rationale that CA may underlie 
the more aggressive disease course experienced by PDAC patients and may hold promise as a 
prognostic and therapeutic target in PDAC.  
To address the above-specified line of inquiry, we investigated the association between CA 
and disease aggressiveness in PDAC using publicly available microarray data, with genes whose 
dysregulation is known to drive CA serving as surrogates for amplified centrosomes. Intriguingly, 
we found that high expression levels of these genes were significantly associated with worse 
overall survival and increased expression of EMT markers.  In addition, we performed a 
comprehensive quantitative analysis to ascertain whether structural and numerical CA are 
associated with clinicopathologic features of PDACs or the ethnicity of PDAC patients. We 
discovered that moderately differentiated PDACs exhibited the most extensive CA compared with 
well- and poorly differentiated PDACs, although among well-differentiated PDACs CA was 
significantly associated with duodenal invasion. CA was not associated with other 
clinicopathologic features. Intriguingly, AA PDACs were found to have significantly higher 
numerical and structural CA compared with EA PDACs. Finally, to determine whether CA is 
causally implicated in pancreatic tumorigenesis, we induced CA in cultured pancreatic cancer cell 
lines. We found that supernumerary centrosomes enhanced cell migration and invasion and 
upregulated the expression of EMT markers. Collectively, these observations insinuate that CA 
may be involved in PDAC aggressiveness. 
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3.3  Materials and Methods 
3.3.1 Public microarray data analysis 
Robust Multi-array Average-normalized expression levels of genes whose dysregulation is known 
to drive CA (including AURKA, CCNA2, CCND1, CCNE2, CDK1, CEP63, CEP152, E2F1, E2F2, 
E2F3, LMO4, MDM2, MYCN, NDR1, NEK2, PIM1, PIN1, PLK4, RAD6, and STIL) from the 
primary PDACs of 42 patients were obtained from GEO series GSE28735. Cutoff Finder [17] was 
used to determine optimal cut-points in individual gene expression levels to stratify patients into 
two groups based on overall survival using the log-rank test. The same data were used to obtain 
Pearson’s correlation coefficients between genes whose dysregulation drives CA (AURKA, CDK1, 
STIL, PIM1, PLK4, and NEK2) and EMT markers (PLAUR and MMP3), which were validated 
using gene expression data from 39 PDACs from GEO series GSE15471. SPSS software (IBM) 
was used for the analyses, with P<0.05 indicating statistical significance. 
3.3.2 Clinical tissue samples 
Formalin-fixed paraffin-embedded slides of PDAC and normal pancreatic tissue were procured 
from Emory hospital. The Emory University Institutional Review Board approved all aspects of 
the study.  
3.3.3 Immunofluorescence staining, imaging, and scoring of clinical specimens 
For immunofluorescence staining all tissue slides were deparaffinized by baking at 67°C for 2 h 
followed by 3 xylene washes. Slides were then rehydrated by passing them through a series of 
ethanol baths (100%, 95%, 70%, and 50%). Antigen retrieval was performed by incubating slides 
in citrate buffer (pH 6.0) in a pressure cooker at 15 psi for 3 min. Tissue samples were then 
incubated overnight with primary mouse antibody against γ-tubulin (1:1000 dilution) at 4°C. The 
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samples were then washed with 3X phosphate-buffered saline (PBS) before incubating them in 
secondary antibody (Alexa-488 anti-mouse) at 37°C for 2 h. Samples were washed with 3X PBS 
and then mounted with Prolong-Gold antifade reagent that contained DAPI (Invitrogen). Tissue 
samples were imaged using the Zeiss LSC 700 confocal microscope (Oberkochen, Germany), and 
images were processed with Zen software (Oberkochen, Germany). The percentage of cells with 
CA was quantitated from 10 randomly selected fields, with ~500 cells counted for each sample.   
3.3.4 Immunohostochemistry, scoring, and WI calculation for clinical specimens  
Deparaffinization and antigen retrieval were performed as described for immunofluorescence 
staining. Thereafter, the tissues were immunolabeled using Plk4 and MMP2 antibodies. Enzymatic 
antibody detection was performed with the Universal LSAB + Kit/HRP (DAKO, CA, USA). The 
staining intensity was scored as 0=none, 1=low, 2=moderate, or 3=high, and the percentage of 
cells from 10 randomly selected fields (~500 cells) was determined. The product of the staining 
intensity and the percent of positive cells constituted the WI. Pearson’s correlation coefficients 
between WIs were sought using SPSS.  
3.3.5 Cell culture 
 MIA PaCa-2, Capan-1, CFPAC-1, and HPAF-II cell lines were grown in Dulbecco's 
Modified Eagle's medium supplemented with 10% Hyclone fetal bovine serum and 1% 
penicillin/streptomycin. All cell lines were maintained in humidified 5% CO2 atmosphere at 37°C.  
3.3.6 Cell lysate preparation, immunobloting, immunofluorescence staining, and confocal 
microscopy 
Protein lysates were prepared, and immunoblotting was performed as described earlier [51]. 
Polyacrylamide gel electrophoresis was used to resolve the proteins, which were transferred onto 
polyvinylidene fluoride membranes (Millipore). The Pierce ECL chemiluminescence detection kit 
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(Thermo Scientific) was used to visualize the immune-reactive bands. β-actin was used as loading 
control. For immunofluorescence staining, cells were grown on glass coverslips and fixed with 
ice-cold methanol for 10 min. Blocking was done by incubating with 2% bovine serum 
albumin/1XPBS/0.05% Triton X-100 at 37°C for 1 h. Coverslips were incubated in primary 
antibodies against γ-tubulin and α-tubulin at 1:2000 dilution for 1 h at 37°C. The cells were washed 
with 2% bovine serum albumin/1XPBS for 10 min at room temperature before incubating with a 
1:2000 dilution of Alexa 488- or 555-conjugated secondary antibodies (Invitrogen; Carlsbad, CA). 
Cells were mounted with ProLong Gold Antifade Reagent with DAPI (Invitrogen). Antibodies 
against γ-tubulin and α-tubulin were from Sigma (St. Louis, MO); antibodies against Aurora A 
and β-actin were from Cell Signaling (St. Louis, MO,USA); antibodies against centrin-2 were from 
Santa Cruz Biotechnology (Santa Cruz, CA); and antibodies against Plk4 and MMP2 were from 
Abcam (Cambridge, MA, USA). Horseradish peroxidase-conjugated secondary antibodies were 
from Santa Cruz Biotechnology (Santa Cruz, CA).  
3.3.7 Cell migration assay 
Monolayers of the aphidicolin-treated and control CFPAC-1 cells were scratched with a 
200 µl pipette tip after serum starving for 8 h. Using a 20X objective, images were taken every 
hour using the Zeiss Axio Observer. Image J was used to define the edges of the wound and to 
measure wound area, and the percent change in the wound area was calculated based on the closure 
of wound over time. 
3.3.8  Boyden chamber assay 
Control and aphidicolin-treated CFPAC-1 cells were collected after 48 h and resuspended 
in media at 5 x 104cells/ml.  Transmigration assay was carried out in a Boyden chamber system. 
The upper wells of the chamber were loaded with 200 µl of cell suspension, and 500 µl media 
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containing 20% FBS was added in lower chambers as a chemoattractant. Chambers were incubated 
for 12 h at 37°C and 5% CO2. Cells that migrated to the bottom surface of the filter were fixed 
with 70% methanol, stained with crystal violet, and counted under a microscope in 10 randomly 
selected fields using a 20X objective. 
3.3.9  Statistical Methods 
Unless otherwise stated in the methods and results, statistical analyses were performed using 
Student’s t-test, and the criterion for statistical significance was P<0.05.  
 
3.4 Results 
3.4.1 Increased expression of genes that drive CA is associated with worse overall survival in 
PDAC 
Previous studies have reported an association between CA and chromosomal instability in 
PDAC [15, 16]. Furthermore, liver metastases exhibited a greater extent of CA than the primary 
tumors in an orthotopic implantation model of PDAC [16]. However, the association of CA with 
a more aggressive disease course in PDAC patients has not been explored. As there are currently 
no publicly available datasets with information on CA per se, we instead analyzed expression 
levels of genes whose deregulation is known to drive CA (including AURKA, CCNA2, CCND1, 
CCNE2, CDK1, CEP63, CEP152, E2F1, E2F2, E2F3, LMO4, MDM2, MYCN, NDR1, NEK2, 
PIM1, PIN1, PLK4, RAD6, and STIL). Specifically, we tested the associations between Robust 
Multi-array Average-normalized expression levels of these genes in primary PDACs from 42 
patients and overall survival using Gene Expression Omnibus (GEO) series GSE28735. Survival 
over time was estimated using the Kaplan-Meier method. Cutoff Finder, which applies the log-
rank test to determine an optimal cut-point based on significance [17], was used to stratify patients 
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into low- and high-risk groups. High expression levels of nine genes (specifically, AURKA, 
CCNA2, CCNE2, CDK1, CEP152, NEK2, PIM1, PLK4, and STIL) were found to be associated 
with worse overall survival with P<0.1 Associations with five genes, namely CDK1, NEK2, PIM1, 
PLK4, and STIL, were significant (P<0.05), as depicted in Kaplan-Meier plots in Figure 3.4.1 
Consequently, CA may be associated with worse overall survival in PDAC. We found that genes 
whose dysregulation drives CA and clustering are upregulated in PDACs (n=36) relative to normal 
pancreatic tissue (n=12) using the GEO series GSE16515 (Supplemental Figure 3.7.12). We 
further found that expression levels of AURKA, CDK1, STIL, PIM1, PLK4, and NEK2 in PDACs 
mostly correlate with the expression of the EMT markers PLAUR and MMP3 using GEO series 
GSE28735 (Table 3.4.1), which we validated using GEO series GSE15471 (Table 3.4.2). These 
results suggest that CA may be associated with increased metastatic potential of PDACs and poor 
survival prospects for PDAC patients.  
                                                 
2 All supplemental data, tables, and figures appear in Appendix B for this chapter 
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Figure 3.4.1 Kaplan-Meier plots of overall survival based on low or high expression of 
genes whose dysregulation drives CA in pancreatic ductal adenocarcinomas.  
Expression was categorized as low or high based on whether the value was below or above the 
following cut-points in normalized expression levels, given in parentheses here after each gene: 
A. CDK1 (2.97), B. NEK2 (3.79), C. PIM1 (5.70), D. PLK4 (3.47), and E. STIL (3.06). HR=Hazard 
Ratio 
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Table 3.4.1 Correlation between the expression of CA associated gene and EMT markers in GEO 
series GSE28735. 
Genes whose dysregulation drives centrosome amplification (AURKA, CDK1, STIL, PIM1, PLK4, 
and NEK2), that contribute to centrosome structure (CETN2), or that indicate epithelial-
mesenchymal transition (PLAUR and MMP3). Normalized gene expression levels from breast 
tumors in GEO series GSE28735 were used for the statistical analysis. 
 
  AURKA CDK1 STIL PIM1 PLK4 NEK2 CETN
2 
PLAUR Pearson 
Correlatio
n 
0.311 0.395 0.305 0.539 0.237 0.359 0.403 
Sig. (2-
tailed) 
0.037 0.007 0.042 0.000 0.117 0.015 0.006 
N 45 45 45 45 45 45 45 
MMP3 Pearson 
Correlatio
n 
0.142 0.271 0.506 -0.058 0.248 0.376 0.514 
Sig. (2-
tailed) 
0.353 0.072 0.000 0.705 0.100 0.011 0.000 
N 4
5 
4
5 
4
5 
45 45 45 45 
 
         Table 3.4.2 Correlation between the expression of CA associated gene and EMT markers in GEO 
series GSE15471 
        Genes whose dysregulation drives centrosome amplification (AURKA, CDK1, STIL, PIM1, PLK4,      
and NEK2), that contribute to centrosome structure (CETN2), or that indicate epithelial-
mesenchymal transition (PLAUR and MMP3 
  AURKA CDK1 STIL PIM1 PLK4 NEK2 CETN2 
 
PLAUR 
Pearson 
Correlation 
0.567 0.590 0.578 0.436 0.578 0.454 0.414 
Sig.(2-
tailed) 
0.000 0.000 0.000 0.005 0.000 0.004 0.009 
N 39 39 39 39 39 39 39 
MMP3 Pearson 
Correlation 
0.388 0.429 0.256 0.003 0.450 0.472 0.019 
Sig. (2-
tailed) 
0.015 0.006 0.116 0.985 0.004 0.002 0.909 
N 39 39 39 39 39 39 39 
 
 
 
We next sought correlations between protein levels of an EMT marker (MMP2) and CA driver 
(Plk4) in PDAC samples. To this end, we first immunohistochemically stained 54 PDACs and 
uninvolved adjacent normal tissue for Plk4 and MMP2 and calculated weighted indices (WIs). The 
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staining intensity was scored as 0=none, 1=low, 2=moderate, or 3=high, and the percentage of 
positive cells (i.e., with 1+ staining intensity) from 10 randomly selected fields (~500 cells) was 
determined. The product of the staining intensity and the percent of positive cells constituted the 
WI. Descriptive statistics regarding patient and clinicopathological characteristics and biomarker 
WIs are given in Table 3.4.3. Both Plk4 and MMP2 proteins were overexpressed in PDACs 
(Figure 3.4.2). In addition, a strong positive Pearson’s correlation was found between these 
markers in PDACs (r=0.460, P<0.001).  
 
Figure 3.4.2 Pancreatic ductal adenocarcinomas exhibit higher expression of Plk4 and 
MMP2. 
 A. Representative micrographs showing immunohistochemical staining for Plk4 (a protein 
whose overexpression drives centrosome amplification) and MMP2 (an epithelial-mesenchymal 
transition marker) in uninvolved adjacent normal and tumor tissue from grade-matched PDAC 
patients. Bi. Box-and-whisker plot depicting the MMP2 weighted index in PDACs and normal 
pancreas. Bii. Box-and-whisker plot depicting the Plk4 weighted index in PDACs and normal 
pancreas.  
 
Table 3.4.3Descriptive statistics for PDAC patient and clinicopathologic characteristics in the 
analysis of MMP2 and Plk4 levels in tumors and matched normal tissue. 
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Variable Level Number Percentage 
Race 
AA 23 42.6 
CA 31 57.4 
Tumor Size (cm) 
<=2 8 14.8 
>2 46 85.2 
Tumor Size 
Median 3  
Mean 3.55  
Maximum 12  
Minimum 0.25  
St.dev 1.99  
 1 10 18.5 
Grade 2 31 57.4 
 3 13 24.07 
MMP2 WI 
Median 6  
Mean 4.20  
Maximum 9  
Minimum 0  
St.dev 3.07  
Plk4 WI 
Median 2  
Mean 2.11  
Maximum 9  
Minimum 0  
St.dev 2.17  
MMP2 WI 
Low (<2) 13 24.1 
Moderate (2-6) 34 63.0 
High (>6) 7 13.0 
Plk4 WI 
Low (<2) 25 46.3 
Moderate 
(2-6) 27 50.0 
High (>6) 2 3.7 
PNI 
Yes 43 79.6 
No 10 18.5 
LVI 
Yes 26 48.1 
No 28 51.9 
Age at diagnosis 
Median 64  
Mean 62.05  
Maximum 84  
Minimum 35  
St.dev 9.88  
Duodenum 
Invasion 
Yes 20 37.0 
No 34 63.0 
Soft tissue 
involvement 
Yes 37 68.5 
No 17 31.5 
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3.4.2  Amplified centrosomes enhance the motility and invasiveness of pancreatic cancer 
cells 
Having confirmed an association between a protein whose overexpression drives CA and 
a marker of EMT, we were interested in exploring how CA may transform non-invasive pancreatic 
tumors into aggressive ones that metastasize. Thus, we examined whether CA can enhance the 
motility and invasiveness of pancreatic cancer cells. To this end, we first screened three well-
established pancreatic cancer cell lines (namely, MIA PaCa-2, CFPAC-1, and HPAFII) by 
immunostaining centrosomes (γ-tubulin, green) and microtubules (α-tubulin, red) and 
counterstaining nuclei with 4′,6-diamidino-2-phenylindole (DAPI) (blue) (Figure 3.4.3A). We 
found that HPAFII cells exhibited the greatest extent of numerical CA (~20% of cells), followed 
by MIA PaCA-2 (~15% of cells) and CFPAC-1 (~10% of cells) (Figure 3B). We also evaluated 
the expression of centrosome-related proteins in these cell lines using immunoblotting methods. 
We found that the cell lines with high CA expressed elevated levels of centrosome structural 
proteins (centrin-2 and γ-tubulin) and proteins whose dysregulation is known to drive CA (Aurora 
A and Plk4) (Figure 3.4.3C). We next asked if aberrations in centrosome number translate into 
aberrations in mitotic spindle geometry. We found that all three cell lines exhibited a significantly 
lower proportion of cells with multipolar spindles in comparison with the proportion of cells with 
supernumerary centrosomes (Figure 3.4.3B). This discordance corroborates the hypothesis that 
cancer cells deal with supernumerary centrosomes by clustering them to form pseudobipolar 
spindles. Taken together, our data suggest that cultured pancreatic cancer cells are characterized 
by CA, which they are generally successful in managing by executing centrosome clustering. 
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Figure 3.4.3 Pancreatic cancer cells with high levels of centrosome amplification (CA) 
express high levels of centrosome structural proteins and proteins whose dysregulation 
drives CA. 
A. Immunofluorescence micrographs showing MIA PaCa-2, HIFA-II, and CFPAC-1 cells in 
interphase and mitosis stained for γ-tubulin (green), α-tubulin (red), and nuclei (blue). B.  Bar 
graph representing the percentage of cells with CA in MIA PaCa-2, CFPAC-1, and HPFA-II cells. 
C. Immunoblots depicting the levels of centrosome structural proteins (γ-tubulin and centrin-2) 
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and proteins whose dysregulations drives CA (Aurora A, Plk4, and Cyclin E) in MIA PaCa-2, 
HPFA-II, and CFPAC-1 cells. 
Next, we were curious to learn whether inducing CA via pharmacological means would 
enhance the motility of pancreatic cancer cells with lower levels of CA. To this end, we induced 
CA in CFPAC-1 pancreatic cancer cells (~10% of which have CA, the lowest level in the lines we 
surveyed) by treating them with 25 µm aphidicolin for 48 h. Aphidicolin arrests cells in G1/S phase 
by inhibiting DNA polymerase [18, 19]. After treatment ~22% of cells exhibited amplified 
centrosomes. We then performed a wound-healing assay, which revealed that pharmacological 
induction of CA stimulated migration, as the wound was filled in about half the time taken by 
control cells (Figure 3.4.4A and Bi). Thereafter, we examined the invasive capabilities of cells 
with supernumerary centrosomes by performing a classical Boyden chamber assay. We observed 
that 80% of the CFPAC-1 cells in which CA was induced invaded the Matrigel in 12 h in contrast 
with only 53% of control cells (that is, CFPAC-1 cells not treated with aphidicolin) (Figure 
3.4.4Bii and C). We confirmed that CA was induced in aphidicolin-treated cells by 
immunoblotting for centrin-2 and Plk4 levels (Figure 3.4.4D). In addition, we noted that cells 
treated with aphidicolin expressed higher levels of N-cadherin (Figure 3.4.4D), suggesting that 
these cells may have attained a more mesenchymal phenotype. In summary, our findings that CA 
upregulates N-cadherin levels, invasive capacity, and wound-healing imply that CA may 
contribute to epithelial-mesenchymal transition in pancreatic cancer cells.  
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Figure 3.4.4 Cells with centrosome amplification (CA) migrate more rapidly in a wound-
healing assay.  
A. Bright-field micrographs showing the wound-healing capacity of CFPAC-1 control (untreated) 
and aphidicolin-treated cells at 0, 12, and 36 h. Bi. Bar graphs representing the percent of 
aphidicolin-treated and control (untreated) CFPAC-1 cells in the wound. Bii. Bar graphs 
representing the percent of aphidicolin-treated and control CFPAC-1 cells that invaded the Boyden 
chamber. C. Brightfield micrographs showing the invasion capacity of CFPAC-1 control and 
aphidicolin-treated cells after 24 h. D. Immunoblots of centrosome structural proteins (centrin-2), 
a protein whose dysregulation drives CA (Plk4), and epithelial-mesenchymal transition markers 
(N-cadherin and MMP2) in CFPAC-1 control and aphidicolin-treated cells. 
3.4.3 Amplified centrosomes distinguish AA PDACs from EA PDACs 
A previous study of 13 PDACs uncovered that a greater proportion of PDAC cells have 
CA, both numerical and structural, than normal pancreas [20]. However, the association of CA 
with poor prognostic indicators in pancreatic cancer is unknown. To address this, we examined the 
centrosomal profiles of 64 PDACs and sought associations with clinicopathologic parameters 
including age, sex, ethnicity, tumor size, grade/extent of differentiation, stage, lymphovascular and 
perineural invasion, lymph node metastasis, and surgical margin status. Descriptive statistics 
regarding patient and clinicopathologic characteristics are given in Table 3.4.4. Formalin-fixed 
tissue sections from the PDACs were immunostained for centrosomes (γ-tubulin) and nuclei were 
counterstained with DAPI (Figure 3.4.5A). Centrosome number and volume were quantitated in 
tumor areas pre-marked by a gastrointestinal pathologist using confocal microscopy. Tumor cells 
with more than two centrosomes or centrosomes greater than 0.56 μm3 in volume were regarded 
as having numerical or structural CA, respectively. The volume of 0.56 μm3 was used as a cut-
point because that was the maximum centrosome volume found in normal pancreatic cells using 
the 3D volume measurement module from the Zeiss imaging software. The percentage of cells 
exhibiting centrosomal aberrations was quantitated from 10 randomly selected fields 
(approximately 500 cells) for each sample. The mean volume of the γ-tubulin spots observed in 
pancreatic cancer tissues was 1.75 μm3, which was ~9 times greater than the mean volume in 
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normal pancreatic cells. Pancreatic tumors also exhibited extensive numerical CA, with ~25-40% 
of cells bearing extra centrosomes, unlike normal pancreatic tissue, in which only ~5% of cells 
had extra centrosomes. When we compared the extent of CA between tumors of different levels of 
differentiation, we found that moderately differentiated tumors exhibited the highest CA when 
compared with well- and poorly differentiated tumors (Figure 3.4.5B); however, the results were 
not statistically significant, perhaps due to the paucity of well-differentiated tumors in our dataset 
(n=6), as PDACs are most often moderately to poorly differentiated. While CA was associated 
with duodenal invasion in well-differentiated PDACs (r=0.772, p=0.042), it was not associated 
with tumor size, stage, perineural or lymphovascular invasion, or number of positive lymph nodes 
in PDACs of any degree of differentiation. In summary, CA clearly differentiates PDACs from 
adjacent normal tissue and is associated with duodenal invasion in well-differentiated PDACs.  
Table 3.4.4 Descriptive statistics for PDAC patient and clinicopathologic characteristics in the 
analysis of centrosome amplification in tumors and matched normal tissue. 
Variable Level Number Percentage 
Race 
AA 30 46.88 
CA 34 53.13 
Centrosomal 
amplification 
Low (<10%) 14 21.88 
Moderate (10 
~40%) 38 59.38 
High (40%<) 12 15.63 
Tumor 
Differentiation 
Well 6 9.38 
Moderate 40 62.50 
Poor 14 21.88 
Tumor 
<=2 10 14.49 
>2 54 78.26 
Tumor in size 
(cm) 
Median 3.1 - 
Mean 3.60 - 
Maximum 12 - 
Minimum 1 - 
St.Dev 1.9 - 
Age at 
diagnosis 
Median 66         - 
Mean 64.4307692 - 
Maximum 87 - 
Minimum 35 - 
St.Dev 10.8147788 - 
Median 36.33 - 
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% Centrosome 
amplification 
Mean 36.19 - 
Maximum 72.22 - 
Minimum 1.40 - 
St.Dev 18.00 - 
Duodenum 
Invasion 
Yes 32 50 
No 32 50 
Soft tissue 
involvement 
Yes 50 50 
No 14 21.875 
PNI 
Yes 55 85.9375 
No 10 15.625 
LVI 
Yes 26 40.625 
No 38 59.375 
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Figure 3.4.5Centrosome amplification (CA) in PDACs and normal pancreatic tissue.  
A. Representative confocal micrographs depicting centrosomal profiles in well-, moderately, and 
poorly differentiated PDACs and adjacent normal pancreatic tissue. Centrosomes were 
immunostained (γ-tubulin, green) and nuclei were counterstained with DAPI (blue). B. Bar graph 
representation of the percentage of cells showing CA in well-, moderately, and poorly 
differentiated PDACs and normal pancreatic tissue samples. ~500 cells were counted in each case. 
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Finally, because AA ethnicity is a risk factor for the development of PDAC [21], we were 
interested in determining whether centrosomal profiles from AA patients differed from those of 
EA patients. Interestingly, when we immunostained moderately differentiated pancreatic tumor 
samples from AA and EA PDAC patients (n=20 for each group) (Figure 3.4.6A) and compared 
their centrosomal profiles, we found that numerical and structural CA in AA tumors were 
significantly higher than in EA tumors (Figure 3.4.6B and C, respectively).  
 
Figure 3.4.6 Centrosome amplification (CA) in PDACs and normal pancreas specimens 
from AA and EA patients. 
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 A. Representative confocal micrographs depicting centrosomal profiles in grade-matched AA and 
EA PDACs and adjacent normal tissues. Centrosomes were immunostained for γ-tubulin (green) 
and nuclei were counterstained with DAPI (blue). B. Bar graphs representing the percent of cells 
showing numerical CA in AA and EA tissue samples. C. Bar graphs representing the percent of 
cells showing structural CA in AA and EA PDAC tissue samples. ~500 cells were counted in each 
case. 
3.5  Discussion  
Five-year survival rates in PDAC hover around 5% notwithstanding about a half century of 
research into the etiology of its aggressive nature and potential therapeutic interventions [22]. Out 
of this burgeoning body of research has emerged an appreciation of the remarkably complex 
mutational landscape of PDACs, their extensive intratumor heterogeneity due to chromosomal 
instability, and their extraordinary propensity to metastasize [22, 23], although this knowledge has 
not translated into considerable improvements in patient outcomes. Chromosomal instability 
appears to be an early event in the development of PDAC [24], which no doubt contributes to its 
exceptional aggressiveness. Efforts to identify sources of genetic dysfunction in this cancer type 
have mostly focused on individual genes or gene signatures without much consideration for 
potential organelle-level abnormalities. However, CA is a well-established mediator of 
chromosomal instability [25], and the extent of CA correlates with chromosomal instability in 
pancreatic cancer cells [26]. Furthermore, CA has been causally implicated in chromosomal 
instability, as induction of CA in BJ fibroblasts and RPE1 cells via treatment with cytochalasin D 
(a cytokinesis inhibitor) significantly increases the rate of chromosome missegregation [10]. It has 
been found that the vast majority of PDACs exhibit CA [15], suggesting that CA is a hallmark of 
these tumors. Therefore, it seems likely that in PDAC CA is at least partly responsible for 
intratumor heterogeneity, which is associated with adverse outcomes, and it is rational to suspect 
that CA is associated with worse clinicopathology and survival rates in PDAC. Our study is the 
first to demonstrate that high expression levels of genes whose dysregulation drives CA are 
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associated with worse overall survival in this cancer type, although CA itself was not significantly 
associated with worse clinicopathology aside from an association with duodenal invasion in well-
differentiated tumors.  
In addition to being characterized by genomic complexity and chromosomal instability, 
PDAC is also typified by a high propensity to metastasize. At diagnosis 80% of patients have 
advanced tumors, almost two-thirds of which have metastasized distantly [27]. Moreover, among 
patients who receive a potentially curative resection, ~70-80% will experience a local or distant 
recurrence regardless of whether chemotherapy is administered [28]. CA is a primary suspect in 
conferral of metastatic abilities to tumors, as induction of CA via overexpression of Plk4 or 
treatment with dihydrocytochalasin B (a cytokinesis inhibitor) has been demonstrated to prompt 
invasiveness in MCF10A breast epithelial cells and non-transformed keratinocytes [11]. 
Specifically, CA precipitates the formation of matrix protein-degrading invasive protrusions and 
antagonizes intercellular adhesion via augmented microtubule nucleation and Rac1 activation. 
Nonetheless, it was previously unknown whether CA contributes to invasiveness or enhanced 
migratory capacity in PDAC. In the present study, we discovered that induction of CA via 
treatment with aphidicolin enhanced pancreatic cancer cell invasion and migration, suggesting that 
CA may promote metastasis in PDAC, which is congruent with our finding that CA was associated 
with duodenal invasion in well-differentiated PDACs. Furthermore, we found that induction of 
CA upregulated N-cadherin expression, consistent with EMT. The expression of genes whose 
dysregulation drives CA mostly correlated with the expression of the PLAUR and MMP3 genes, 
and the extent of CA correlated with expression of the MMP2 protein. Furthermore, induction of 
CA upregulated MMP3 and N-cadherin protein levels. PLAUR encodes the urokinase-type 
plasminogen activator receptor (uPAR), which promotes pancreatic cancer cell migration and 
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invasion in vitro and hepatic metastases and retroperitoneal invasion in vivo [29], and amplification 
of the PLAUR gene is associated with decreased survival in PDAC [30]. The ligand of uPAR, 
urokinase, cleaves plasminogen to plasmin, which then cleaves pro-MMPs to active MMPs that, 
together with plasmin, degrade the extracellular matrix to facilitate invasion of tumor cells [31]. 
The MMP3 protein has been demonstrated to stimulate pancreatic cancer cell invasion [31], and, 
similar to the uPAR and N-cadherin proteins, both MMP2 and MMP3 are considered to be EMT 
effector proteins [32, 33]. Based on our findings, it appears that CA may encourage EMT, which 
is further substantiated by our finding that induction of CA enhances migration and invasion of 
pancreatic cancer cells. These findings corroborate the hypothesis that amplified centrosomes 
compel metastatic dissemination in PDAC [34].  
Previous studies have shown that cancer cells manage the excessive centrosomal load by 
forming juxtanuclear supercentrosomal clusters, which they maintain all through interphase and 
then disperse transiently in prophase, followed soon by tight reclustering [35]. Centrosome 
declustering drugs, such as the non-toxic antifungal griseofulvin and antitussive noscapine, 
disaggregate the centrosomal clusters, forcing the mitotic spindle to assume a persistently high-
grade multipolar configuration that is incompatible with cell survival [36]. A previous study 
discovered that the CFPAC-1 cell line exhibits considerable centrosome clustering, with more than 
half of mitoses in cells with CA assuming a pseudobipolar configuration [37], similar to our 
findings. Together, these suggest that pancreatic cancer cells tend to cluster their supernumerary 
centrosomes. As a corollary, it seems that centrosome declustering drugs could prove 
advantageous in PDAC, an intriguing hypothesis that merits testing. 
We discovered that AA PDACs exhibited more extensive numerical and structural CA 
compared with EA PDACs. The age-adjusted incidence of PDAC is ~30% higher among AA than 
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EA [38], and AA race is an established risk factor for PDAC [21]. Various socioeconomic and 
lifestyle factors that may contribute to the development of PDAC are more common in the AA 
population [21], as are certain K-Ras mutations and possibly strong HER2 expression [39]. 
Intriguingly, it has been demonstrated that K-RasG12D induces CA in mammary epithelial cells [40] 
and head and neck papilloma cells [41]. One study found that this mutation is more prevalent 
among AA than EA (47% vs. 34%), although the difference did not reach statistical significance 
[39], perhaps due to the relatively small sample size. K-RasG12V, on the other hand, was 
significantly more prevalent among AAs in this study, but we are unaware of any data regarding 
the impact of this mutation on CA. What might be considered indirect evidence that K-RasG12V 
promotes CA is the recent finding by Hu and colleagues that this mutation increases the frequency 
of multipolar anaphases and apoptosis following treatment of ED-1 murine lung cancer cells with 
seliciclib, a cyclin-dependent kinase inhibitor [42]. CA renders cancer cells vulnerable to 
multipolar mitosis [36], so cells undergoing multipolar anaphase might have supernumerary 
centrosomes, although this was not directly tested in that study. The relationship between ethnicity 
and mutations in genes whose dysregulation is known to drive CA that are common in PDAC (e.g., 
TP53 [43, 44], SMAD4 [41], CDKN2A [45], CHEK2 [46], depicted in Supplemental Figure 3.7.2) 
merits investigation. One study found that a greater proportion of AA PDACs displayed strong 
HER2 expression than EA PDACs [39], and HER2 overexpression is associated with CA in breast 
cancer [47, 48]; thus, HER2 overexpression may contribute to the greater extent of CA we 
uncovered in AA PDACs. More research is needed to confirm the CA-promoting role of ethnicity-
associated gene amplifications and mutations in PDAC, although it is tempting to speculate that 
they underlie the differences in centrosome profiles we observed between AAs and EAs. The 
diversity of factors that may confer increased PDAC risk that are associated with AA ethnicity are 
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depicted in Supplemental Figure 3.7.3. Although CA is a well-defined risk factor for cancer 
aggressiveness [36], the literature reports that AAs with PDAC do not experience worse overall 
survival in multivariate analyses accounting for a variety of factors, such as treatment received and 
socioeconomic status, as detailed by a recent review of nine relevant studies [49]. This discrepancy 
cannot be resolved based on existing data and deserves further exploration. Regardless, it stands 
to reason that AA ethnicity might predict therapeutic response to declustering drugs, and clinical 
trials testing these drugs clearly should consider ethnicity in their assessment of drug efficacy. 
In summary, our microarray analysis suggests that higher levels of certain genes whose 
dysregulation promotes CA are associated with worse overall survival, although further study is 
needed to confirm that CA itself is indeed associated with worse clinical outcomes. In line with 
these in silico results, we found that induction of CA in PDAC cell lines resulted in more 
aggressive cellular behavior, such as increased motility and invasiveness. For the most part, 
however, we did not find that CA was associated with worse clinicopatholgic features in PDACs 
aside from lymphovascular invasion in well-differentiated tumors. A larger sample size is needed 
to confirm these immunohistochemical findings, which seem generally to conflict with us in silico 
and in vitro findings. It is possible that the relationship between CA and clinicopathologic features 
is complex, and some weighted combination of the numerical and structural CA values would be 
more strongly associated with clinicopathologic features like the extent of differentiation, tumor 
size, and lymph node positivity. Furthermore, we did not consider subtypes in this study, but it is 
possible that CA is a prognostic factor only within certain subtypes. Gene expression studies have 
shown that PDACs can be divided into three subgroups: classical, quasimesenchymal, and 
exocrine-like [50]. It would be intriguing to evaluate whether quasimesenchymal tumors evince 
the most extensive CA because this subtype is defined by the expression of genes that promote a 
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mesenchymal phenotype, which we found was promoted by induction of CA. Interestingly, the 
quasimesenchymal subtype is associated with the poorest overall survival after resection [50]. In 
future studies, it will be important to test whether PDACs are susceptible to centrosome 
declustering drugs and to identify whether certain subtypes of this cancer have more profound 
centrosome abnormalities and thus might be more susceptible to these drugs. Ultimately, our study 
establishes CA, a long-standing cancer cell-selective trait, as a quantifiable cell biological property 
in PDAC that undoubtedly merits further investigation. 
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4 A QUANTITATIVE CENTROSOMAL AMPLIFICATION SCORE (CAS) 
PREDICTS LOCAL RECURRENCE IN DUCTAL CARCINOMA IN SITU 
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(staining, imaging and analysis of the discovery cohort), analyzed and interpreted the 
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3. Jaspreet Kaur: Performed staining and imaging for validation cohort. 
4. Michael Shawky Toss: Provided all the tissue samples and associated clinical data 
helped in calculating the VNPI index for the samples. 
5. Da Hoon Choi: Performed image analysis for the validation cohort.  
6. Remus. M. Osan: Guided in the statistical analysis and building of the mathematical 
model and equation for CAS score. 
7. Emad A. Rakha: Provided all the tissue samples and provided feedback and 
suggestions on data presentation. 
8. Emiel A. M. Janssen: Contributed tissue samples, associated clinical data and scientific 
guidance on the study design. 
9. Padmashree C. G. Rida: Co-corresponding author on the study -helped in designing 
the study and critically revised the manuscript. 
10. Ritu Aneja: Co-corresponding author of the study- helped in designing the study and 
critically revised the manuscript. 
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4.1 ABSTRACT 
About 60-80% of ductal carcinoma in situ (DCIS) cases are high-grade (HG) DCIS with an 
elevated risk of local recurrence (LR) even after a lumpectomy. Due to the lack of accurate 
recurrence risk prediction model’s patients are often under or over treated. Current prognostic 
models such as Oncotype DX and VNPI lack consistency and are limited to a specific subset 
of patients. Here in this study, we show that the extent of centrosome amplification (CA) in a 
DCIS lesion can predict the risk of LR after lumpectomy. By evaluating the severity and 
frequency of CA in two different cohorts (n=133 and n=207 respectively) we have developed 
a quantitative Centrosomal Amplification Score (CAS) for each tumor sample. Our results 
show that the DCIS patients with recurrence exhibited higher CAS and higher CAS was 
associated with the risk of developing ipsilateral breast event (HR=7.58 for DC and HR=5.8 
for VC, p<0.0001) which stayed significant (HR=8.5, p<0.0001) after taking in account the 
other confounding factors like age, tumor size, comedo necrosis and radiotherapy. For the 
high and low CAS groups, the 5-year risks of recurrence were 87.5% and 12.5% respectively 
(p<0.001). Mixed DCIS cases exhibited higher CAS when compared with pure DCIS 
suggesting presence of the CA as early as in premalignant condition which became 
significantly higher in the invasive lesions confirming the role of CA in tumor progression. 
Thus, our data shows that CAS quantifies the risk of recurrence in DCIS with the highest 
concordance and provides a new tool to help tailor the treatment according to individuals risk 
of recurrence in DCIS patients.  
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4.2 Introduction 
About 25% of breast cancers (BCs) are DCIS, a pre-invasive form of BC wherein malignant cells 
are confined to the lumen of a mammary duct with no evidence of invasion beyond the epithelial 
basement membrane into the adjacent breast stroma. While approximately 60,000 cases of DCIS 
are diagnosed in the United States each year, 20%-53% of women with untreated DCIS will 
progress to invasive BC over the course of ≥10 years[1]. Since the progressive potential of a DCIS 
lesion cannot be reliably determined, surgery (lumpectomy) and radiation is the common course 
of treatment, with the addition of hormonal therapy in some cases[2]. Unfortunately, despite a 
lumpectomy, ~35% of DCIS patients present with a local recurrence (LR)[3]. The major 
challenges in improving the clinical maintenance of the DCIS patients reside in the tailoring of 
treatment according to individual risks of recurrence to avoid the undertreatment of cases with 
high risk of recurrence and overtreatment of patients with low risk. Therefore, accurate prognostic 
markers are required which can improve the recurrence risk stratification for DCIS patients.  
Current recurrence predictors such as Van Nuys index[4] and DCIS nomogram[5] (from Memorial 
Sloan Kettering) based on commonly used histopathological parameters such as histologic grade, 
tumor margins, and age lack consistency and reproducibility in LR risk prediction[6, 7]. In 
addition, these tools fail to integrate the molecular predictors, underestimating the heterogeneity 
of DCIS lesions. Furthermore, the individual prognostic markers have not been successful in 
predicting risk as they are limited to a specific cohort of patients, lacks external validation and fail 
to incorporate the histological parameters. Although studies have shown that commercially 
available and expensive gene-expression based assay Oncotype DX DCIS score has some value in 
predicting recurrence but the key drawbacks of this score are its limited applicability to a set of 
patients (ECOG 5194 study) and the poor stratification of high and intermediate- risk patients thus 
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leaving the actual prognostic value of this tool questionable[8]. Therefore, a pressing clinical need 
for prognostic indices that incorporate clinical, histopathological and molecular biomarkers taking 
into account the heterogeneous nature of DCIS lesions persists.  
 
Studies have shown that extensive genetic and phenotypic intratumoral heterogeneity (ITH) is 
present in DCIS lesions and greater the ITH present in a pre-invasive lesion, the greater is the 
likelihood of LR and invasive BC[9]. Chromosomal instability (CIN) is well-recognized as a driver 
of ITH and amplified centrosomes underlie erroneous mitoses and fuel CIN[10, 11]. While normal 
cells have one centrosome prior to S-phase and two centrosomes after S-phase, cancer cells display 
centrosome amplification[12] (CA) - an abnormal increase in the number and/or volume of 
centrosomes. Studies have shown that CA correlates with increased tumor grade, size, metastasis, 
and/or recurrence in multiple malignancies[13]. Moreover, studies have shown that within DCIS 
precancerous and preinvasive lesions (including DCIS), indicating that CA is an early event in 
tumorigenesis[14, 15]. Studies have reported that CA increases with the grade in DCIS and have 
higher expression of Aurora-A and Nek2 kinases which play key role in centrosome cycle. Also, 
multiple studies have highlighted the role of genes associated with centrosomes including cyclin-
d, cyclin-E, and genes regulating centrosome cycle such as p53, p21 to predict the risk of 
recurrence in DCIS[16]. 
 
Given the evidence supporting i) the presence of CA in DCIS and ii) that many of the signaling 
pathways whose deregulation has been previously implicated in the induction of CA are 
deregulated in DCIS it is reasonable to postulate that the organellar-level differences may exist 
between recurrent and nonrecurrent DCIS. In this study, we present a novel methodology to 
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quantitate both numerical and structural centrosomal aberrations in tumor samples. Our analytical 
pipeline allows robust interrogation of the ability of centrosomal overload to predict the risk of LR 
after lumpectomy. The algorithm developed quantitates the frequency/prevalence and severity of 
CA (numerical and structural) in clinical samples, and computes a score called the centrosome 
amplification score (CAS). In this study, we observed that CAS is significantly different for 
recurrence and no recurrence DCIS patients and that higher CAS was associated with poorer RFS 
in both discovery and validation cohort. CAS score was able to stratify the patients in high risk 
and low-risk groups of recurrence with highest concordance (76%; 87.5% of patients with 
recurrence were in high CAS group) among that reported for all other available recurrence 
predictive tools. Furthermore, when we incorporated the clinical and histological parameters which 
are commonly used in the clinics the concordance of CAS increased to 82% thus giving us a tool 
which incorporates the contribution of clinical, histopathological and molecular biomarkers all in 
one score and can help tailor the treatment according to the risk of recurrence for DCIS patients. 
In addition, we observed that the mixed DCIS exhibited higher CAS when compared to the pure 
DCIS that confirming role of CA in tumor progression.  
4.3 Materials and Methods  
4.3.1 Clinical tissue sample  
Formalin-fixed paraffin embedded DCIS tissue sections (ICART5 cohort) were procured 
from the Nottingham City Hospital DCIS series. Patients were diagnosed between year 1987 to 
2012.  Samples used in the discovery cohort (n=133) were restricted to pure DCIS cases treated 
with breast conserving, rather than complete mastectomy, surgery (BCS). Whereas for the 
validation cohort (n=120) pure DCIS cases treated with either lumpectomy or masectomy were 
included. DCIS lesions without involvement of invasive component were confirmed by three 
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independent pathologists. The mixed DCIS (n=87) cohort consisted of tissue sections from patients 
which were presented with coexisting pure DCIS and invasive lesions. The samples were 
accompanied by data pertaining to their clinicopathologic variables such as age, Nottingham grade, 
TNM stage, Ki67 Index, menopausal status, and information about, treatment (adjuvant and 
radiotherapy), overall survival, progression-free survival, recurrence-free survival (RFS) and date 
of initial diagnosis, date of surgery, and patient status at last contact. The Institutional Review 
Board of Nottingham City Hospital approved all aspects of the study. Methods were carried out in 
“accordance” with approved guidelines stipulated in MTAs and DUAs between Nottingham City 
Hospital, Nottingham, UK and Georgia State University. Informed consent was obtained from all 
subjects. 
 
4.3.2 Immunofluorescence imaging of clinical samples 
Centrosomes in formalin fixed paraffin-embedded DCIS tissues were immunofluorescently 
stained for γ-tubulin (red) and nuclei (with DAPI). Images of tissue samples were acquired with 
Zeiss LSM 700 confocal microscope (using 63x oil emersion lens with numerical aperture of 1.4 
and 1.5x optical zoom). All imaging parameters were fixed across all samples. Some imaging 
parameters that require special attention include fluorophore saturation, detector saturation, offset, 
and sampling. For optimal results, laser power is adjusted to the minimum level wherein 
fluorophore emission is saturated. For detector saturation, the gain (master) is adjusted such that 
the detector registers the target fluorophores in each channel within full range of detector settings 
(8-bit, 12-bit, 16-bit) to prevent over and under saturation that can result in inaccurate data. The 
offset was adjusted to minimize the background present in the sample. Given the fact that fine 
structural details cannot be compromised, we used 1.5X digital zoom setting that results in a 
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sampling size of 0.07 um/pixel, which is the maximum level of detail a detector can detect. The 
premarked (by pathologist) DCIS/tumor areas were imaged to obtain at least 10 regions of interest 
(ROIs) each containing 20-30 nuclei and associated centrosomes.   
4.3.3 Scoring of clinical samples 
Next, raw 3D image data was processed using IMARIS Biplane 8.2 3D volume rendering software 
to determine volume of each centrosome within each ROI. “Volume rendering” refers to 
transforming a 2D image stack for 3D visualization and subsequent analysis. To exclude non-
specific signals, a common background subtraction was applied to all images. This parameter is 
determined by first measuring the average diameter of ~100 centrosomes in 10 ROIs, and then 
using this measurement as the background subtraction threshold. Automatic detection based on 
this measurement helped us to eliminate user bias by providing the same level of background 
subtraction to all samples. Surfacing of target objects (centrosomes) helped us to correct point 
spread function and to define contours of centrosomes. Next, we applied splitting function where 
any clustered centrosomes mistakenly detected as single bodies were split by the software into 
individual centrosomes. Finally, data from all optical sections was ordered to enable volume 
measurement for each centrosome. The final data of volumes of all centrosomes was then 
compared to a maximum intensity projection image and centrosomes for each cell are quantified 
based on proximity to their associated nuclei. The number and volume of all centrosomes 
associated with each nucleus in the tumor area was recorded.    
4.3.4 Analysis 
Centrosomes in breast tissues (normal, DCIS or tumor) were categorized into individually 
distinguishable centrosomes (iCTRs) and megacentrosomes (mCTRs). iCTRs are defined as 
centrosomes that stain positive for γ-tubulin, with centrosomes numbers and boundaries clearly 
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distinguishable and volumes that lie within the range of centrosome volumes found in normal 
breast tissue stained for γ-tubulin. mCTRs are centrosomes in a neoplastic region that stain positive 
for γ-tubulin and whose volume is greater than the upper limit of the centrosome volume range 
found in corresponding normal tissue immunostained for γ-tubulin. mCTRs are the centrosomes 
with aberrantly large volumes. Volume range for a normal centrosome in breast tissue was 
determined by analyzing volumes of both adjacent uninvolved tissue from cancer patients and 
normal tissue for disease-free individuals for each cancer type.  
4.3.5 Determination of normal volume of centrosomes 
To determine the normal range of volume, we analyzed volume of 500 centrosomes for each 
sample in adjacent uninvolved tissue from cancer patients (n=40) and in normal tissues (n=40) 
from reduction mammoplasties. We evaluated the volume of centrosomes as described in analysis 
section. Interestingly we observed that the mean centrosome volume for the adjacent uninvolved 
tissue sections was higher when compared to the normal tissues from reduction mammoplasty. 
Thus, chose the smallest and largest values for iCTR volume of normal tissues as “normal 
centrosome volume range” for breast tissue. Mean volumes of centrosomes in normal breast 
epithelial cells ranged from 0.02-0.74 µm3.  All centrosomes in each ROI are thus categorized as 
iCTRs or mCTRs.   
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Figure 4.3.1 Representative immunographs of normal and normal adjacent breast tissue 
sections for centrosomes. 
Representative H&E images of the ducts of the DCIS recurrence and no recurrence cases. (Images 
were captured at 20x magnification). (B) Confocal micrographs showing numerical and structural 
CA in recurrence and no recurrence DCIS tissue sections. 
 
4.3.6 Algorithm-based analytics 
A cumulative Centrosome Amplification Score (CAS) was computed for each sample on the basis 
of the formula:  CAStotal =CASi + CASm, where CASi and CASm are scores that describe 
numerical and structural CA phenotypes, respectively, in the sample.   
Equation 1 for CASi represents how an aggregate value reflecting both frequency and severity of 
numerical CA is derived for the sample:  
𝐶𝐴𝑆𝑖 = 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 (
𝑁𝑖 − 𝑅𝑡ℎ
𝑅
) ∗
𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒(𝑁𝑖 > 𝑅𝑡ℎ)
𝑠𝑐𝑎𝑙𝑖𝑛𝑔 𝑓𝑎𝑐𝑡𝑜𝑟 𝛽𝑖
 
= (
∑ (𝑁𝑖 − 2)
𝑁
𝑖=1,𝑁𝑖>2
∑ 𝐼(𝑁𝑖 > 2)
𝑁
𝑖=1
∗
1
𝑅
) ∗
𝑝𝑖
𝛽𝑖
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where: Rth is the threshold for number of centrosomes, which is 2 here. pi is the percentage of cells 
with >2 iCTRs; ßi is a scaling factor that may be used to ensure that both CASi and CASm are 
given equal weight in the formula for CAStotal; R is the range for normal distribution from 0 to 2, 
which is 2 here; Ni is the number of iCTRs in a cell that contains more than 2 iCTRs; N is the total 
number of cells analyzed in the sample; i in Ni is used to indicate taking the average over cells 
with numerical CA.  
The “severity” component of CASi, (i.e., 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 (
𝑁𝑖−𝑅𝑡ℎ
𝑅
) quantifies how “severe” the 
numerical CA is [i.e., the extent to which the numerical CA exceeds the baseline value of 2 in cells 
that carry three or more iCTRs (i.e., Ni >2)].  Therefore, cancer cells with 1 and 2 iCTRs do not 
contribute to this component.  Since cells with larger numbers of iCTRs represent a more severe 
numerical CA, a linear measurement was implemented to provide a measure of the number of 
iCTRs (above the baseline value of 2) in a given cell by computing the score (Ni - 2) for each cell.  
Finally, an average of all these scores is determined.  The “frequency” component of the CASi 
score (i.e., pi/ßi) provides the scaled frequency of numerical CA in the sample.  CASi scaling 
factor 𝛽𝑖 value we used here is 0.1 for breast tissue. Equation II for CASm represents how an 
aggregate value reflecting both frequency and severity of structural centrosome amplification, is 
derived for the sample:  
 
𝐶𝐴𝑆𝑚 = 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 (
𝑉𝑖𝑚 − 𝑉𝑡ℎ
𝜎𝑉𝑖𝑚
) ∗
𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒(𝑉𝑖𝑚 > 𝑉𝑡ℎ)
𝑠𝑐𝑎𝑙𝑖𝑛𝑔 𝑓𝑎𝑐𝑡𝑜𝑟 𝛽𝑚
 
=
∑ ∑ (𝑉𝑖𝑚 − 0.735) ∗ 𝐼((𝑉𝑖𝑚 > 0.735)
𝑁𝑖
𝑚=1
𝑁
𝑖=1
𝜎𝑉𝑖𝑚
∗
𝑝𝑚
𝛽𝑚
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where: pm is the percentage of cells with mCTRs; 𝑉𝑖𝑚is the volume of a megacentrosome 
associated with a cell nucleus of 𝑚𝑡ℎ centrosome in 𝑖𝑡ℎ nucleus; where a megacentrosome is 
defined as a centrosome whose volume exceeds the 𝑉𝑡ℎ critical for that tissue; 𝑉𝑡ℎ critical for 
a given tissue is the maximum volume of a normal centrosome in that tissue which was 0.735 
for breast tissue; ßm is a scaling factor used to ensure that both CASi and CASm are given 
equal weight in the formula for CAStotal. value of ßm used here is 0. 148.. 𝜎𝑉𝑖𝑚 is the standard 
deviation of centrosomes? 
 
For each mCTR (centrosome whose volume exceeds the upper limit of the normal centrosome 
volume range for that tissue), a z-score is computed based on the formula below, reflecting the 
extent to which the volume of that mCTR exceeds the maximal normal value (i.e., the value for 
𝑉𝑖𝑚 − 𝑉𝑡ℎcritical is computed) relative to the baseline (achieved by dividing by the 𝜎𝑉𝑖𝑚 the 
standard deviation):  
z =
𝑉𝑖𝑚 − 𝑉𝑡ℎ
𝜎𝑉𝑖𝑚
 
Next, this value is multiplied by the number of mCTRs per nucleus.  Finally, all these values 
are averaged in order to obtain the severity score. The frequency component of CASm has 
essentially the same overall mathematical formula as the corresponding term in the CASi 
component. In the present form of the algorithm, the components CASi and CASm, contribute 
equally to the total CAS score and are thus given equal weight.   
4.3.7 Statistical Analysis 
The test of group mean differences shown in Box-Whisker Plots is based on nonparametric 
Wilcoxon Rank Sum Tests and Kruskal-Wallis Tests depending on the number of groups. 
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Recurrence free survival was used as the endpoint for the survival analysis. Log-rank test of 
equality over strata was applied to test the differences among the Kaplan Meier survival curves. 
Cutoff points selected for all CAS scores in discovery set were kept same for validation cohort as 
well. To estimate the effect of related variables on Hazard Ratios(HRs) together with 95% 
confidence intervals, we used univariate or multivariate cox proportional hazard regression model. 
Statistical analysis was performed using SAS software 9.4 (SAS Institute Inc., Cary, NC). 
Statistical significance we claimed was based on p< 0.05 for each test we conducted. 
4.4 Results 
4.4.1 Traditional histopathological parameters fail to predict recurrence in DCIS patients 
from the discovery set 
In our discovery dataset, there were 133 (ICART5 cohort) patient samples with sufficient tissue 
for CA analysis. Out of these 133 samples 32 patients presented with ipsilateral recurrence. Patient 
cohort details are shown in Table 1. The median age of the 133 patients in the discovery group 
was 58, and the median follow up was 24 months. Comedo necrosis was present in 111 and no 
necrosis in 22 patients. Out of 133 patients, 118 were nuclear grade 3, 10 were nuclear grade 2, 
and 5 were nuclear grade 1. 3% of patients had close excision margins (1mm or less). Out of 133 
patients, 55 received patients received radiotherapy, and none of the patients were treated with 
adjuvant chemo or hormonal therapy. Tumor high grade, the presence of comedo necrosis and 
radiotherapy were three clinicopathological parameters which showed significant proportional 
differences within the recurrence group and who remained recurrence-free (Table 4.4.1) in the 
subgroups. However, when we performed univariate Cox regression analysis none of these 
parameters showed any significant association with RFS (Table 4.4.2). Thus, indicating the limited 
role of the histopathological parameters in predicting recurrence in this dataset.   
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Table 4.4.1 Descriptive statistics of clinicopathological characteristics for DCIS patients 
(ICART5 cohort) based on the recurrence status in the discovery cohort. 
 
4.4.2 Recurrent DCIS exhibits higher CAS compared to non-recurrent DCIS  
First, we immunofluorescently stained (details in materials and methods section) formalin fixed 
paraffin embedded resection samples from DCIS patients (n=133) for centrosomes using an 
antibody against γ-tubulin, and co-stained with DAPI for nuclei. As described in the materials and 
methods section employing confocal microscopy we imaged the immune-stained slides and 
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processed the raw 3D image data using IMARIS Biplane 8.2 3D volume rendering software. Next, 
we calculated the centrosome number and volume in ~250 cells of each sample and finally, with 
the help of mathematical equation, we integrated the numerical (CASi) and structural (CASm) 
aberrations to generate a composite CAS total value for each sample. We observed that the DCIS 
cases with recurrence (mean score 1.3055) exhibited significantly higher CASi when compared 
with the no recurrence samples (mean score 0.73196) (p=0.0002; Figure.4.4.1C) (Note: values 
indicated in the boxplots are based on Wilcoxon’s rank test). As mentioned in materials and 
method section CASi is a combination of the severity and frequency of CA. When we looked at 
them separately, DCIS cases with recurrence showed higher severity (p=0.09 Figure.4.4.2A) and 
significantly higher frequency (p=0.0001 Figure.4.4.2B). Furthermore, when we looked at the 
structural amplification the value of CASm was significantly higher (p=0.0280, Figure.4.4.1D) in 
recurrence (mean score 1.09586) cases when compared with the no recurrence (mean score 
0.80612) cases. Not only this further when CASm was broken in the severity and frequency we 
found that DCIS cases with recurrence exhibited significantly higher severity (p=0.0070, 
Figure.4.4.2C) and frequency (p=0.0468, Figure.4.4.2D) for structural amplification. Lastly, when 
we combined the CASi and CASm to generate the CAS total values as mentioned in materials and 
methods section, we observed that the CAS total was significantly higher in the recurrence (mean 
score 2.4050) group when compared with the no-recurrence group (mean score 1.5381). Thus, 
collectively our data suggests that a significant difference in centrosomal aberrations exist between 
the recurrence and recurrence-free DCIS samples. 
 
 
104 
 
 
 
Figure 4.4.1 DCIS with ipsilateral recurrence exhibit higher CAS. 
 (A) Representative H&E images of the ducts of the DCIS recurrence and no recurrence cases. 
(Images were captured at 20x magnification). (B) Confocal micrographs showing numerical and 
structural CA in recurrence and no recurrence DCIS tissue sections.  DCIS tissue sections were 
immunostained for centrosomes (γ-tubulin, red) and counterstained with DAPI (blue). Scale bar 
(white), 20μm. (C) Representative Beeswarm Box plots for the pure DCIS (n=133) cases with 
recurrence (n=32) and no-recurrence (101) for CASi. (D) Representative Beeswarm Box plots for 
the pure DCIS (n=133) cases with recurrence (n=32) and no-recurrence (101) for CASm, (E) 
Representative Beeswarm Box plots for the pure DCIS (n=133) cases with recurrence (n=32) and 
no-recurrence (101) for CAStotal. p<0.05 was considered statistically significant.  
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Figure 4.4.2  DCIS with ipsilateral recurrence exhibit higher CAS 
Representative Beeswarn Box plots for the pure DCIS (n=133) cases with recurrence (n=32) and 
no-recurrence (101) for different CAS values. A) CASi severity distribution, B) CASi frequency 
distribution, C) CASm severity distribution, D) CASm frequency distribution. p<0.05 was 
considered significant.  
 
Next, we co-immunolabelled 15 DCIS samples with the centrosomes and centrioles respectively 
with γ-tubulin and centrin-2 and performed the quantitation as described above. We found that 
γ-tubulin foci invariably overlapped with centrin-2 foci in all the samples confirming that the 
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structural amplified centrosomes represent enlarged γ-tubulin foci are bona fide centrosomes 
and not just fragments of the pericentriolar material. In addition, we observed that there were 
no supernumerary centrin-2 foci were present, suggesting that the enlarged γ-tubulin foci 
represent structurally augmented centrosomes and not supernumerary centrosomes so tightly 
clustered as to be indistinguishable (Fig 4.4.3). 
 
Figure 4.4.3 Representative immunographs DCIS tissue sections immunolabeled for 
centrin-2 (red) and γ-tubulin (green) and DAPI (blue) in split form. 
 
4.4.3 CAS can stratify high- grade DCIS patients into subgroups with the high and low risk 
of recurrence 
Further, when we stratified all the patients into low- and high-CAS groups (threshold used was the 
one that minimized log-rank p-value) (Figure. 4.4.4), we observed that high-CASi 
(threshold=0.09) DCIS patients were associated with poorer RFS (p<0.001, HR=4.802; for CASisi 
p=0.0879,  HR=2.77, threshold= 1.09; for CASifi p<0.0001, HR=4.766, threshold= 0.08) when 
compared with the low CASi group. Similarly, we observed that high CASm (threshold=0.0877) 
group was associated with poorer RFS (p=0.0243, HR=2.396; for CASmsi p=0.0055, HR=5.409, 
threshold=.3133, CASmfi p=0.069, HR=2.446, threshold=0.171) when compared with the low 
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CASm group. Total CAS (threshold= 1.435) value was able to stratify the high-risk and low-risk 
DCIS patients with highest significance and Hazard ratio (p<0.001, HR= 7.185) (Fig4.4.4 and 
4.4.5). Interestingly, we observed that 93% of the cases with recurrence were in high CAS group. 
This association with CAS stayed significant (p<0.001, HR=8.51) even after accounting for the 
confounding factors like comedo necrosis, tumor grade, tumor size, age and the radiotherapy status 
of the patient’s Table 4.4.2. As shown in Table 4.4.2 none of the clinicopathological parameters 
showed any significant association with the recurrence except the CAS in both univariate and 
multivariate analysis.  
Furthermore, we performed the concordance analysis using SAS PROC PHREG procedures. This 
procedure is based on the Harrell’s concordance index. Herein higher the C-statistics values, the 
better the model can discriminate between patients who will present recurrence and patients who 
do not. The results from this statistical test indicated that for any patient who has poorer/lower 
RFS it would have a probability of 72.6% to be in CAS total high group. 
 
Figure 4.4.4  Higher CAS is associated with poorer RFS in DCIS patients 
Kaplan Meier survival curves representing the RFS in DCIS patients: (A) CASi high and low 
groups, (B) CASm high and low groups, (C) CASt high and low groups. N is the total number of 
patients in each group and R represents the number of patients who showed recurrence. % 
calculated represents percentage/proportion of the recurrence patients out of the total number of 
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recurrence patients in both groups. p<0.05 is considered significant.
 
Figure 4.4.5 Higher CAS is associated with poor RFS in DCIS patients 
Kaplan Meier survival curves representing the RFS in DCIS patients: (A) CASi high and low 
groups based on the severity component, (B) CASi high and low groups based on the frequency 
component, (C) CASm high and low groups based on the severity component, (D) CASm high 
and low groups based on the frequency component. N is the total number of patients in each group 
and R represents the number of patients who showed recurrence. % calculated represents 
percentage/proportion of the recurrence patients out of the total number of recurrence patients in 
both groups. p<0.05 is considered significant.  
 
Table 4.4.2 Univariate and Multivariate Cox proportional regression analysis for the risk 
of recurrence in DCIS patients treated with lumpectomy comparing the influence of 
common clinicopathological variables along with the CAS total model. 
Variables 
 
Univariate Analysis Multivariate Analysis  
Pr > C
hiSq 
Hazard 
Ratio 
95% 
Hazard Ratio 
Confidence 
Limits 
Pr > Chi
Sq 
Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits 
CAS total CASt High 
vs low 
<
0.001 
7.58 2.893 24.164 <.0001 8.361 2.893 24.16
4 
Age Age High vs 
low  
0.8532 
 
0.935 0.459 1.904 0.6345 0.837 0.402 1.742 
Tumor size Tumor size 
High vs low 
0.3032 1.466 0.708 3.306 0.4269 1.354 0.641 2.858 
Grade Grade High 
vs low  
0.0921 0.317 0.134 0.752 0.0927 0.440 0.169 1.146 
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Comedo 
Necrosis  
Comedo 
present vs 
absent  
0.0603 2.441 1.149 5.185 0.0714 2.106 0.937 4.733 
Radiothera
py 
Radiotherap
y No 
0.1405 1.959 0.870 4.414 0.3472 1.530 .630 .714 
 
 
4.4.4 CAS can stratify the DCIS patients in recurrence and recurrence-free group with 
higher significance than the Van Nuys Prognostic Index (VNPI) 
VNPI is based on clinical and histopathological markers like tumor size, margin width, pathologic 
classification (based on nuclear grade and presence/absence of comedo necrosis) and age of the 
patients. This index has been used in clinics to decide the treatment strategy for the patients 
presented with DCIS. Therefore, to test the performance of this test in our cohort we calculated 
VNPI based on the scoring methods described in the literature. Briefly, each of the factors is 
assigned a score between 1-3, and the sum total of values for the four parameters is taken as final 
score further stratify the patients in high, low and intermediate risk groups of the recurrence. 
Herein, we used the binary cutoff score of 8. Next, we performed univariate and Kaplan Meier 
Survival analysis to compare the performance of the VNPI index in the discovery cohort (n=100 
as VNPI index was available only for 100 patients out of total 133) (Fig 4.4.6A and B). We 
observed that there was no significant association of higher VNPI with the poor RFS and that 
VNPI was not able to stratify the patients in the high and low-risk for recurrence. In contrast, CAS 
for the same patients was able to stratify the patients in high and low risk group and was able to 
predict recurrence with higher significance and HRs (CAS- 8.8 vs. VNPI 0.959) (Table 4.4.3). 
Moreover, when we performed multivariate analysis taking in account the other confounding 
factors like tumor size, presence of comedo necrosis, age and radiotherapy along with VNPI, CAS 
presented highest association with RFS with HR=10.41. These findings suggest that the CAS 
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model is better than the traditional VNPI index in predicting the recurrence in DCIS patients. 
 
Figure 4.4.6 Kaplan Meier survival curves representing the RFS in DCIS patients based on 
the VNPI and CAS. 
N is the total number of patients in each group and R represents the number of patients who 
showed recurrence. % calculated represents percentage/proportion of the recurrence patients out 
of the total number of recurrence patients in both groups. p<0.05 is considered significant. 
 
Table 4.4.3  Univariate analysis for the risk of recurrence in DCIS patients treated with 
lumpectomy comparing the performance of VNPI and CAS models. 
Variables 
 
Univariate Analysis 
p-value Hazard 
Ratio 
95% Hazard Ratio Confidence 
Limits 
CAS total  High vs low 0.0034 8.847 2.0671 37.93  
VNPI High vs low  0.9291 
 
0.959 0.377 2.436 
4.4.5 CAS combined with age, tumor size and comedo necrosis is a superior model for 
prediction of recurrence in DCIS patients 
To further test the clinical significance of CAS score, we evaluated the associations of CAS with 
the clinicopathological parameters used traditionally in clinical practice. In line with the 
understanding that CA is associated with the more aggressive phenotype of the disease, we 
observed that the CAS association with the recurrence risk (RR) in these subgroup analyses was 
similar to that of the overall group of patients. Herein, in the recurrence rate forest plot (Fig 4.4.7) 
it is shown that the high age group (red boxes) which is regardless of CAS is at high risk of 
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recurrence (0.44) compared to that for overall patients (0.33). When we further stratified this group 
in high and low CAS groups we observed that the recurrence rates for the high CAS group (green 
boxes- RR-0.73) and low (blue boxes-RR- 0.10) (Fig 4.4.7) suggesting that CAS was further able 
to stratify high and low age group in high and low-risk groups as with better RR. Similar trends 
were observed for the tumor size, tumor grade, radiotherapy and comedo necrosis. 
Thus, collectively these findings suggested that CAS compliments the traditional histopathological 
parameters and is able to further stratify the patients in high and low-risk group of recurrence with 
better RR.  Next, to analyze if the compounded effect of CAS plus other parameters is able to 
further stratify the patients’ estimated recurrence rate with more significant RFS difference among 
hazard ratios we constructed a multivariate logistic regression model using CASi, CASm, 
Age(High/Low), Comedo Necrosis(presence/absence), and Size(Large/Small) to estimate whether 
recurrence will happen or not. Here we defined odds as ratio of Recurrence against Recurrence 
free and computed the log odds value using following mathematical equation.  
Log(Odds)=-3.1807+1.6072*CASi+0.7823*CASm-0.4757*I(age=High) 
+0.9535*I(Comedo=present) +0.3230*I(Size=Large) 
Here based on log(odds) value we classified patients in recurrence and recurrence free groups. 
Wherein if log odds is positive, then we classify that case into recurrence group, and if it is 
negative, it falls in into recurrence free group. When we compared our prediction result with true 
final recurrence status, we observed 83.02% concordance rate. This multivariate model greatly 
improves prediction accuracy compared with the model using CAS as predictor only, which has 
74.47% of concordance. Thus, collectively these findings suggest that the CAS compliments the 
traditional histopathological parameters and if combined with these clinical parameters is a 
superior model.  
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Figure 4.4.7 Recurrence rate for the clinically relevant parameters based on CAS total 
 Forest plot representing the estimates of the 5- year recurrence rate (with 95% confidence interval) 
according to the CAS high and low risk subgroups for the clinical and pathological parameters. 
Black box represents overall recurrence rate in patients (.39) Red box represents the recurrence 
rate presented for the specific clinical parameter regardless of CAS. Green box represents the 
recurrence rate in the high CAS group and blue represents recurrence rate in CAS low group in 
every specific subgroup. 
 
4.4.6 Recurrent DCIS cases exhibit higher CAS compared to the non-recurrence cases, and 
high CAS is associated with worse RFS, in the validation cohort 
 Next, to confirm the legitimacy of the prediction of CAS and the CAS plus score (CP) model we 
tested its performance on an exclusively different cohort of DCIS patients. Our validation cohort 
consisted of 120 patient samples out of which 27 patients presented with ipsilateral recurrence. 
Patient cohort details are shown in Table 4.  The median age of the 120 patients in the discovery 
group was 56, and the median follow up was 19 months. Relative to the discovery cohort patients 
were equally distributed in subgroups based on Comedo necrosis and grades. Where Comedo 
necrosis was present in 67 and no necrosis in 53. Out of 120 Patients, 60 were nuclear grade 
high, 37 were grade median and 23 were low grade. 1.7% of patients had close excision margins 
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(1mm or less). Only 14 patients were treated with the radiotherapy out of 120. In this cohort, the 
clinicopathological parameters like tumor size, presence of the comedo necrosis and no 
radiotherapy were three clinicopathological parameters which showed significant proportional 
differences within the recurrence group as well as when compared with the patients who remained 
recurrence-free and they were also associated with the RFS.  
Employing the same methodology as mentioned for discovery cohort we 
immunofluorescently stained 120 formalin fixed paraffin embedded resection samples from DCIS 
patients to visualize centrosomes and calculated the CAS scores. Similar to the discovery cohort 
we observed that regardless of grade DCIS cases with recurrence exhibited significantly higher 
CAS total when compared with the no recurrence samples (p<0.0001) (Figure.4.4.8B). Further we 
observed similar trends for the other CAS values as we observed in discovery cohort where 
significant higher CAS values were noted between the ranked mean score values of CASi 
(p<0.0001) and CASm (p<0.0001) including the severity (CASi- p=0.0046, CASm-p=0.0037) and 
frequency (CASi- p<0.0001, CASm-p<0.0001) for recurrence group when compared with the no 
recurrence group (Figure 4.4.8 and 4.4.9).  
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Table 4.4.4 Descriptive statistics of clinicopathological characteristics for DCIS patients 
(ICART5 cohort) based on the recurrence status in the validation cohort.  
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Figure 4.4.8 DCIS with ipsilateral recurrence exhibit higher CAS in validation cohort 
(A) Confocal micrographs showing numerical and structural CA in recurrence and no recurrence 
DCIS tissue sections. DCIS tissue sections were immunostained for centrosomes (γ-tubulin, red) 
and counterstained with DAPI (blue). Scale bar (white), 20μm. (B) Representative Box-whisker 
plots for the pure DCIS (n=120) cases with recurrence (n=27) and no-recurrence 93) for CASi. (C) 
Representative Box-whisker plots for the pure DCIS (n=120) cases with recurrence (n=27) and 
no-recurrence 93) for CASm. (D) Representative Box-whisker plots for the pure DCIS (n=120) 
cases with recurrence (n=27) and no-recurrence 93) for CAS total. p<0.05 was considered 
statistically significant.  
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Figure 4.4.9 DCIS with ipsilateral recurrence exhibit higher CAS 
 Representative Box-whisker plots for the Grade matched (grade 3) pure DCIS (n=127) cases with 
recurrence (n=30) and no-recurrence (93) for different CAS values. A) CASi distribution, B) CASi 
severity distribution, C) CASi frequency distribution, D) CASm distribution, E) CASm severity 
distribution, F) CASm frequency distribution. p<0.05 was considered significant. 
 
Furthermore, in line with the findings in discovery cohort, when we looked at the RFS based on 
the predefined CAS cutoffs for discovery cohort, we observed that CAS values were able to stratify 
patients in high and low risk of recurrence with great significance. As shown in the Fig 8A high 
74% of the recurrence patients fall into high CASi group whereas only 23% of the no recurrence 
patients fall in this group. 92% of patients from the recurrence-free group are classified in the low 
CASm group. Similarly, for CAS total significantly higher proportion of recurrence-free patients 
i.e. 73% falls in the low CAS group whereas the significantly higher proportion of recurrence 
group, i.e. 66.96% of recurrence falls in the high CAS total group. Though lower than the discovery 
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cohort the hazard ratios of CAS total (p<0.001, HR=4.127) on the validation cohort are still higher 
than the other clinicopathological parameters (Table 4.4.5). This association stays significant even 
after controlling the other confounding factors like age, tumor size, grade, comedo necrosis and 
radiotherapy. Thus, the results collectively indicate that the CAS can significantly predict 
recurrence in DCIS patients from two different cohorts.  
 
Figure 4.4.10  Higher CAS is associated with poor RFS in DCIS patients 
Kaplan Meier survival curves representing the RFS in DCIS patients form validation cohort (A) 
CASi high and low groups, (B) CASm high and low groups, (C) CASt high and low groups. N is 
the total number of patients in each group and R represents the number of patients who showed 
recurrence. % calculated represents percentage/proportion of the recurrence patients out of the 
total number of recurrence patients in both groups. p<0.05 is considered significant. 
 
Table 4.4.5 Univariate and Multivariable Cox proportional regression analysis for the risk 
of recurrence in DCIS patients treated with lumpectomy comparing the influence of common 
clinicopathological variables along with the CAStotal model for validation cohort.  
Variables 
 
Univariate Analysis Multivariate Analysis  
p-value Haza
rd 
Ratio 
95% Hazard Ratio 
Confidence 
Limits 
p-value Hazard 
Ratio 
95% 
Hazard Ratio 
Confidence 
Limits 
CAS total  CASt High 
vs low 
<0.001 4.127 1.870 9.111 <.0048 3.391 1.451 7.926 
Age Age High 
vs low  
0.1289 
 
0.523 0.227 1.207 0.0632 0.392 0.402 1.503 
Tumor 
size 
Tumor size 
High vs 
low 
0.0264 1.38 0.134 3.298 0.0172 2.743 1.197 6.284 
Grade Grade High 
vs low  
0.9364 0.969 0.446 2.107 0.8893 1.072 0.4 2.869 
Comedo 
Necrosis  
Comedo 
present vs 
absent  
0.0144 2.745 1.222 6.165 0.0177       
3.073 
1.215 7.770 
Radiother
apy 
Radiothera
py No 
0.7828 1.226 0.228 5.216 0.7509 1.279 0.280 5.845 
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4.4.7 Higher CAS is observed in the mixed DCIS cases when compared with the Pure DCIS  
In our mixed DCIS cohort, there were 87 patient samples with sufficient tissue for CA analysis. 
Out of these 87 samples 10 patients presented with ipsilateral recurrence. Patient cohort details are 
shown in Table 4.4.6. The median age of the 87 patients in the mixed group was 55 and the median 
follow up was 27.7 months. Comedo necrosis was present in 57 and no necrosis in 30. Out 
of 87 patients, 32 were nuclear grade 3, 39 were grade 2, and 16 were grade 1.  Given the presence 
of an invasive component in the mixed DCIS cohort the 40 patients were treated with adjuvant 
chemotherapy and 59 were treated with radiotherapy following surgery Table 4.4.6. We stained 
the mixed DCIS cases (n=87) for centrosomes using the same methodology as mentioned for 
discovery and validation cohorts. We observed that the mixed DCIS samples exhibited 
significantly higher CASi (p=0.0043), CASm (p=0.0006) and CAS total (p<0.0001) when 
compared to the pure DCIS cases (n=133) (Fig 4.4.11). This suggested that CA has a critical role 
in tumor progression.  
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Table 4.4.6 Descriptive statistics of clinicopathological characteristics for mixed DCIS 
patients (ICART5 cohort) based on the recurrence status. 
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Figure 4.4.11 Mixed DCIS exhibit higher CAS when compared with pure DCIS 
 Representative Box-whisker plots for the mixed DCIS (n=87) and pure DCIS (n=133) cases. A) 
CASi distribution, B) CASm distribution, C) CASt distribution. p<0.05 was considered significant. 
 
4.5 Discussion 
In the current management of DCIS patients, physicians are faced with the issue of whether to 
recommend adjuvant radiotherapy and/or chemotherapy treatment to their patients in addition to 
surgery. To aid in this decision, a number of factors are taken into account, including patient age, 
tumor margins, grade, and size, but the evidence to support these and other potential features as 
prognostic is variable. In the current study, we developed a novel methodology and algorithm to 
quantitate both numerical and structural centrosomal aberrations in tumor samples and generated 
a recurrence prediction score to help in the treatment decision. Our findings indicate that the 
patients with recurrence exhibit higher CAS total when compared with the recurrence free DCIS 
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patients. CAS was also associated with poor RFS in DCIS patients and this association was 
significant even in multivariable models. CAS total presented an HR of 7.5 in a univariate model 
and 8.5 in a multivariate model. These associations of CAS stayed significant in our validation 
cohort as well. We further compared the performance of CAS with a known predictive model 
VNPI. VNPI is based on clinical and histopathological markers like tumor size, margin width and 
pathologic classification (based on nuclear grade and presence/absence of comedo necrosis)[4, 17, 
18] incorporates age as the fourth contributing factor for the prediction. When both CAS and VNPI 
were factored into multivariable models, only CAS was significantly associated with RFS. This 
finding suggests that when CAS is accounted for VNPI no longer holds predictive value. 
CAS was further able to stratify the DCIS patients into high and low-risk groups of 
recurrence and was able to predict 5-year risk of local recurrence with higher concordance than 
what has been proposed by other models, independent of traditional clinical and pathological 
factors. These findings stayed significant for the validation cohort as well even though our 
discovery and validation cohort had patients with different clinical and pathological parameters 
thus indicating the applicability of CAS model is not limited to a specific cohort of patients. Most 
of the predictive models which have been used in clinics till now have been proven beneficial for 
specific cohort of patients such as Oncotype DCIS score. This test has limited applicability only 
to the cases with resection margins of at least 3 mm and low- or intermediate-grade DCIS 
measuring 2.5 cm or less, or if HG DCIS 1 cm or less in size, as this is the set of patients from 
ECOG 5194 study upon which the test was initially clinically validated[8]. Thus, the global 
applicability of this test is limited.  
Furthermore, when we further stratified the DCIS patients in the different subgroups based 
on the traditional clinical and histopathological parameters the recurrence rate (RR) of CAS high 
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group increased. In high age group regardless of CAS the recurrence rate was 44% (33% in overall 
patients) When we further stratified this (high age) group in high and low CAS groups we observed 
that the recurrence rates for the high CAS group increased to 73% suggesting that CAS was further 
able to stratify high and low age group in high and low-risk group. We observed similar trends for 
the other clinical and pathological markers such as tumor size and presence of comedo necrosis. 
Thus, we generated a combined score where we incorporated the prediction rate from these clinical 
and pathological factors. This new score, i.e., CAS plus score increased the concordance for 
recurrence prediction from 76.2 for CAS total alone to 82 with CAS plus score. These findings 
suggest that with the incorporation of these clinical and pathological parameters the recurrence 
prediction increased with a significant number for CAS.  
Another major challenge in the management of DCIS is the determination of the accurate 
margins. It is now documented that 10-50% of DCIS lumpectomies are followed by a re-surgery 
because of "close or positive margins"-in which some tumor is still found on postsurgical 
pathologic review in the margins of the removed breast tissue[19]. The positive margin suggests 
that some tumor was left behind in the body cavity, and frequently leads to a second surgery. These 
re-excisions cause considerable morbidity, as well as emotional, and financial burdens on the 
patients. Here in the current study we observed that high CAS was associated with positive margins 
and since CAS able to stratify the patients in high and low risk groups of recurrence we suspect 
that if CAS based risk profiling is done on the core biopsies it could significantly reduce re-
surgeries by better predicting who might need a mastectomy to begin with, and for whom re-
surgery might not be necessary even in the event of close/positive margins.  
CAS, as described earlier, is the linear expression of the extent and the frequency of 
numerical and structural CA. Centrosome clustering enables chromosomal missegregation 
123 
 
 
chromosomes and their unequal distribution to daughter cells resulting in chromosomal instability 
(CIN), thus contributing to neoplastic transformation. Given that CIN engenders karyotypic 
diversity within tumors, we assert that CAS may perhaps even serve as an indirect measure of ITH 
in DCIS. Moreover, our findings also indicate higher levels of CAS in the mixed DCIS cases. 
These findings are in line with the previous findings where we and others observed TNBCs the 
most aggressive subtype of breast cancer exhibit highest CA among all subtypes[20, 21]. These 
findings further substantiate the role of CA in tumor progression and given that CA translates to 
the greater risk of malignant transformation, it may help to determine the patient prognosis. An 
exciting avenue for future research would be to profile CA in all the stages of tumor progression 
starting from the atypical hyperplasia to invasive and metastatic disease to evaluate if CA can 
function as a biomarker for tumor evolution.  
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5 A CENTROSOME CLUSTERING PROTEIN, KIFC1, PREDICTS AGGRESSIVE 
DISEASE COURSE IN SEROUS OVARIAN ADENOCARCINOMA 
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Mar 18;9;17as “A centrosome clustering protein KIFC1, predicts aggressive disease course in 
serous ovarian adenocarcinomas.” 
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5.1 Abstract 
Amplified centrosomes are widely recognized as a hallmark of cancer. Although supernumerary 
centrosomes would be expected to compromise cell viability by yielding multipolar spindles that 
results in death-inducing aneuploidy, cancer cells suppress multipolarity by clustering their extra 
centrosomes. Thus, cancer cells, with the aid of clustering mechanisms, maintain pseudobipolar 
spindle phenotypes that are associated with low-grade aneuploidy, an edge to their survival. 
KIFC1, a nonessential minus end-directed motor of the kinesin-14 family, is a centrosome 
clustering molecule, essential for viability of extra centrosome-bearing cancer cells. Given that 
ovarian cancers robustly display amplified centrosomes, we examined the overexpression of 
KIFC1 in human ovarian tumors. We found that in clinical epithelial ovarian cancer (EOC) 
samples, an expression level of KIFC1 was significantly higher when compared to normal tissues. 
KIFC1 expression also increased with tumor grade. Our In silico analyses showed that higher 
KIFC1 expression was associated with poor overall survival (OS) in serous ovarian 
adenocarcinoma (SOC) patients suggesting that an aggressive disease course in ovarian 
adenocarcinoma patients can be attributed to high KIFC1 levels. Also, gene expression levels of 
KIFC1 in high-grade serous ovarian carcinoma (HGSOC) highly correlated with expression of 
genes driving centrosome amplification (CA), as examined in publically-available databases. The 
pathway analysis results indicated that the genes overexpressed in KIFC1 high group were 
associated with processes like regulation of the cell cycle and cell proliferation. In addition, when 
we performed gene set enrichment analysis (GSEA) for identifying the gene ontologies associated 
to KIFC1 high group, we found that the first 100 genes enriched in KIFC1 high group were from 
centrosome components, mitotic cell cycle, and microtubule-based processes. Results from in vitro 
experiments on well-established in vitro models of HGSOC (OVSAHO, KURAMOCHI), 
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OVCAR3 and SKOV3) revealed that they display robust centrosome amplification and expression 
levels of KIFC1 was directly associated (inversely correlated) to the status of multipolar mitosis. 
This association of KIFC1 and centrosome amplification with HGSOC might be able to explain 
the increased aggressiveness in this disease. These findings compellingly underscore that KIFC1 
can be a biomarker that predicts an aggressive disease course in ovarian adenocarcinomas. 
5.2  Introduction 
Ovarian cancer is the sixth most common cancer affecting women worldwide and is the fifth 
leading cause of deaths related to gynecological malignancies with less than 40% overall cure rate 
[1]. The overall mortality of ovarian cancer has remained largely unchanged over the past decades 
even though there is a great advancement in surgical and therapeutic approaches [2]. The standard 
treatment for ovarian cancer patients is debulking surgery followed by a platinum- based 
chemotherapy (cisplatin and carboplatin) [3, 4]. One of the primary causes of the high mortality 
and poor survival in ovarian cancer is the diagnosis at late stages [5]. Despite years of extensive 
research, there is still a dearth of reliable biomarkers for early detection, prognosis, and predicting 
disease aggressiveness. Since ovarian cancer is a heterogeneous disease with different 
histopathological features and clinical behavior, a better understanding of molecular subtypes and 
search for clinically-facile prognostic factors that can aid in histological subtyping is imperative. 
Greater than 90% of malignant ovarian tumors are epithelial ovarian carcinomas (EOC) 
comprising of various subtypes namely serous, endometrioid, clear cell, transitional cell, squamous 
cell and mucinous carcinomas [6, 7].  About 70-80% of all cases are serous ovarian cancer (SOC) 
among which high-grade serous ovarian cancer (HGSOC) is the most prevalent [8]. Intriguingly, 
HGSOC shares similar genomic features with triple negative breast cancer (TNBC) as per reports 
from Cancer Genome Atlas (TCGA) Network analysis; in particular, the deregulated pathways 
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characterizing HGSOC are very similar to those in TNBC [9].  Several independent studies have 
indicated that HGSOC is associated with very high genomic instability and chromosomal 
aberrations including intrachromosomal breaks and aneuploidy, which incidentally, also typify and 
drive intratumoral heterogeneity in TNBC [10, 11]. 
Specifically, the most common mutations present in both kinds of tumors (HGSOC and 
TNBC) are of p53 and BRCA1/2. It is well established that BRCA1 and BRCA2 tumor suppressor 
genes directly preserve genomic stability by regulating DNA repair, p53-mediated cell cycle 
checkpoint control as well as centrosome duplication cycle [12-14]. These findings establish the 
causative link between BRCA1 and BRCA2 mutations and extensive chromosomal instability 
found in HGSOC patients. Furthermore, HGSOC tumors frequently overexpress cyclin E and 
Aurora-A, resulting in aberrant activation of the centrosome duplication cycle that induces 
centrosome amplification (CA), and eventually genetic instability fueling ovarian cancer 
progression [15-17]. CA results in numerous and voluminous centrosomes [18]. Subjectively, the 
presence of supernumerary centrosomes sets the stage for the formation of multipolar spindles that 
may succumb to a mitotic catastrophe. However, cancer cells avoid this calamitous fate by 
clustering their extra centrosomes at the two spindle poles, which allows them to evade cell death 
but ultimately engenders low-grade aneuploidy and genetic instability [19-21]. 
KIFC1, a nonessential kinesin motor protein, also known as HSET, plays a critical role in 
clustering of extra centrosomes in cancer cells. Recently several studies have shown that 
knockdown of KIFC1 in cancer cell lines containing supernumerary centrosomes causes the excess 
centrosomes to be scattered by pole-separating forces that induce spindle multipolarity and cell 
death. However, KIFC1 is not required for bipolar spindle assembly in healthy somatic cells [22, 
23]. We recently demonstrated that EOC clinical samples harbor extra centrosomes and display 
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high levels of centrosome clustering in interphase as well as mitosis. In addition, the study 
highlighted that the gene expression levels of KIFC1 are higher in EOC when compared to normal 
ovarian tissues in silico and is associated with worse prognosis and survival [24]. To further 
understand and validate results of our previous study, we herein evaluated KIFC1 expression in 
clinical samples of ovarian cancer by utilizing immunohistochemical staining.  Our results 
indicated higher KIFC1 expression in EOC tumor samples when compared to normal tissues. 
Furthermore, KIFC1 expression levels in EOC increased with an increase in tumor grade. To 
understand better the association of KIFC1 with CA, we examined correlations between expression 
levels of KIFC1 and genes driving CA. Intriguingly, higher gene expression levels of KIFC1 was 
significantly correlated to expression of CA-driving genes. When GSEA was performed for the 
genes enriched in KIFC1-high group, they were also found to be related to centrosome components 
and microtubule-based processes. We further validated the correlation by doing quantitative 
analysis of CA and extent of clustering in cell lines derived from SOC patients. Our results 
indicated that KIFC1 was highly expressed in these in vitro models of SOC and was also associated 
to levels of centrosome clustering (mitotic), enabling cells to bypass mitotic catastrophe.  
Taken together our findings underscore that KIFC1 is a potential prognostic biomarker in 
ovarian adenocarcinomas wherein expression levels of KIFC1 may predict the course of disease 
aggressiveness. Work is underway in our laboratory to pin point molecular mechanism to explain 
the association of KIFC1 and CA with ovarian cancer aggressiveness and poor patient outcomes.  
5.3 Materials and Methods 
5.3.1 Cell Culture  
The four ovarian cancer cell lines primarily utilized in this study included OVCAR3, 
KURAMOCHI, SKOV3, and OVSAHO. The SKOV3 and OVCAR3 cell lines were obtained from 
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ATCC and KURAMOCHI, and OVSAHO were obtained from JCRB. All the cell lines were 
cultured according to the instructions given by the company.   
5.3.2 Immunohistochemistry and scoring 
Formalin-fixed paraffin-embedded tissue microarrays (TMAs) for ovarian cancer were obtained 
from US, Biomax, Inc. Company provided the ethical statement to confirm that, all the participants 
provided their written consents and patient privacy and anonymity was maintained. TMAs were 
deparaffinized in a 60°C oven for 20 minutes and placed in 3 consecutive xylene washes. 
Rehydration of the slides were carried out by putting them through a series of washes involving 
different concentrations of ethanol in water - 100%, 95%, 70%, and 50% - for 3 minutes each. The 
antigen retrieval process was done using a pressure cooker and 0.01M citrate buffer with a pH of 
6.1. The slides were heated at a temperature of 120°C for 30 minutes. After cooling in ice for 20 
minutes, the slides were first subjected to hydrogen peroxide blocking and then protein blocking 
(both obtained from ThermoScientific) for 20 minutes and 10 minutes, respectively. Tissues were 
incubated with anti-KIFC1 antibody (Abcam) for 1 hour, before incubating with MACH2 HRP-
conjugated secondary antibody (Biocare Medical) for 30 minutes. Enzymatic antibody detection 
using Betazoid DAB Chromogen Kit (Biocare Medical) was followed by nuclear staining with 
Myer’s hematoxylin (Dako). The staining intensity was scored as 0=none, 1=low, 2=moderate, or 
3=high, and the percentage of KIFC1-positive cells from 10 randomly selected fields (~500 cells) 
was determined. The product of the staining intensity and the percent of positive cells constituted 
the WI. Statistical analysis was performed using – Tukey’s post hoc test.  
5.3.3 Cell staining and imaging 
Cells were cultured on coverslips and, after the confluency reached approximately 80%, 
the cells were fixed with ice-cold methanol for 7 minutes. The cells were blocked with 5% 
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BSA/0.01% Triton X for 45 minutes at room temperature and then incubated at 37°C with 
antibodies directed against γ-tubulin and α-tubulin at a dilution of 1:2000 for 30 minutes. The cells 
underwent quick washes 5 times with 1xPBS before being incubated with Alexa Fluor 488 anti-
mouse and Alexa Fluor 555 anti-rabbit at a dilution of 1:2000 at 37°C for 30 minutes. After 
washing the cells 8 times with 1x PBS briefly, the cells were then incubated with Hoechst 33342 
(1:5000 dilution) at room temperature for 10 minutes. The cells were mounted with Prolong-Gold 
antifade reagent after being washed with 1x PBS 3 times and observed using Zeiss LSM 700 
Confocal microscope (Oberkochen, Germany) and the images were processed with ZEN software 
(Oberkochen, Germany). 
5.3.4 Immunoblotting 
Cell lysates were prepared from 80% confluent cells by scraping with 250ul of 1x lysis prepared 
from 10x cell lysis buffer (Cell Signaling). The 1x lysis buffer contained 1mM b-
glycerophosphate, 20mM Tris-HCl (pH 7.5), 1mM Na2EDTA, 1mM Na3VO4, 150mM NaCl, 
1mM EGTA, 2.5mM Na4P2O7, 1ug/ml leupeptin, and 1% Triton. Cell lysates were fractionated 
using 10% SDS-PAGE gel. The samples were allowed to run at 70V for 90 minutes. Protein 
transfer onto polyvinylidene difluoride (PVDF) membrane was done for 2 hours via the wet 
transfer method at 70V. The membrane was then blocked in 5% non-fat, dry milk in 1x TBST for 
1 hour at room temperature and probed with the relevant antibodies at a dilution of 1:1000 
overnight at 4°C. Primary antibody incubation was followed by incubation with the corresponding 
secondary antibody at a dilution of 1: 10,000 for 1 hour at room temperature. SuperSignal West 
Pico Chemiluminescent Substrate (ThermoScientific) was directly applied to the membrane for 
the subsequent analysis.  Cyclin E and Centrin-2 antobodies were obtained from Santa Cruz 
Biotech, γ-tubulin from Dako, and KIFC1 and Aurora A antibodies from Abcam. 
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5.3.5  In silico analysis  
One channel microarray data was downloaded from gene expression omnibus (GEO) database for 
primary ovarian cancer samples GSE 9899 [25]. Data was Mas5.0 normalized and was further 
taken for processing. Logarithm to the base 2-transformed KIFC1 expression levels from all 
ovarian cancer samples (n=284) regardless of histotypes were extracted from GEO database. 
Further analysis were carried only on the serous adenocarcinoma samples (n=200). Overall 
survival (OS) was calculated as the time interval (in months) from the date of histological diagnosis 
to date of death from any cause.  KIFC1 was categorized into high and low groups based on the 
optimal overall survival cut - points using the log-rank test.  
5.3.6 Public microarray data analysis 
Robust Multi-array Average normalized expression levels of KIFC1 and genes which drive CA 
(CCNA2, CDK1, NEK2, AURKA, MYCN, CCNE2, STIL, LMO4, PLK4, MDM2, CEP63, E2F1, 
E2F2, E2F3, CEP152, PIM1, PIN1, CCND1) from the primary serous ovarian carcinoma of 154 
patients were obtained from GEO series GSE 9899 To obtain Pearson’s correlation coefficients 
between genes whose dysregulation drives CA, SAS software (IBM) was used for the analyses, 
with p<0.05 indicating statistical significance. 
5.3.7 Gene set enrichment analysis of public microarray data 
Publicly available pre-processed gene expression profiles of primary ovarian tumors (n=154 from 
Tothill dataset [25], GSE9899; Patients were stratified into two groups by KIFC1 score. Patients 
with KIFC1 expressions below the optimal KIFC1 survival threshold where placed in the low-risk 
group whereas the above threshold patients where stratified to the high-risk group. GSEA was 
performed as indicated in studies by Tamayo, et al. (2005, PNAS 102, 15545-15550) and Mootha, 
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Lindgren, et al. (2003, Nat Genet 34, 267-273). False discovery rate q-values.25 were considered 
statistically significant.  
5.3.8 In silico analysis of KIFC1 gene expression and centrosomal amplification index 
(CAI) genes in cell lines 
One channel microarray data was downloaded from GEO database for four cell lines with GSM 
ids GSM133614, GSM133609, GSM887467 and GSM887488 namely, Ovcar-5, SKOV3, 
OVSAHO, and OVCAR3 respectively. Data was Mas5.0 normalized and was further taken for 
processing. Logarithm to the base 2 transformed KIFC1 and expression levels from ovarian cell 
lines were extracted from the GEO database. PLK4, Aur-A, Aur B, Cyclin E, Centrin, γ-tubulin 
and pericentrin genes expression values were added to make centrosomal amplification index.  
5.3.9 Statistical analysis 
Statistical analyses were performed using two-tailed Student’s t-tests, Anova and Tukey’s post hoc 
tests. The criterion for statistical significance for all analyses was p<0.05. Standard errors were 
calculated using the general Excel formula where we divided the standard deviation by the square 
root of the number of samples. Kaplan-Meier analysis and Cox regression were performed using 
SPSS (IBM). Optimal cut-points were identified with the stratification which gave the largest log-
rank χ2 value. 
 
5.4 Results 
5.4.1 KIFC1 is overexpressed in Epithelial Ovarian adenocarcinoma (EOC) clinical samples 
We first examined whether KIFC1 is upregulated in human ovarian cancers by analyzing KIFC1 
overexpression in EOC clinical samples. To this end, we immunostained paraffin-embedded 
formalin-fixed tissue microarrays of EOC (n=120) and normal ovarian epithelial tissue (n=13) for 
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KIFC1. The staining intensity was scored as 0=none, 1=low, 2=moderate, or 3=high, and 
percentage of positive cells (i.e., with 1+ staining intensity) from randomly selected fields (~500 
cells) was determined [18]. The product of the staining intensity and the percent of positive cells 
constituted the Weighted Index (WI). Descriptive statistics regarding patient and 
clinicopathological characteristics is given in Table 5.41A, B. In consonance with our previously 
published study [24], our immunohistochemical analysis showed overexpression of KIFC1 in EOC 
tissues with negligible expression in normal ovarian epithelial tissue (Figure 5.4.1A). We found 
that the number of positively-stained nuclei per field in high-grade ovarian cancers (Figure 
5.4.1A) was significantly higher compared to low-grade ones. We then compared the nuclear 
KIFC1 WI values for normal and tumor samples and also across grades for tumor samples. 
Interestingly, we observed that nuclear KIFC1 WI was significantly higher in EOC tissues when 
compared to normal tissues (p<0.01). Also, the nuclear KIFC1 WI increased with increasing tumor 
grade (Figure 5.4.1Bii) (p<0.05). Among subtypes, we noticed that the number of positively-
stained nuclei per field in high-grade serous ovarian cancers (Supplementary Figure. 5.7.1A3) 
was significantly higher compared to low-grade serous ovarian cancers (p<0.05). Collectively, 
these observations indicate robust KIFC1 overexpression in human ovarian adenocarcinoma and 
strong association of KIFC1 expression levels with clinical progression of the disease. These data 
suggest that KIFC1 might play an active role in driving the progression of tumors into more 
malignant and aggressive forms.  
                                                 
3 3 All supplemental data, tables, and figures appear in Appendix C for this chapter 
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Figure 5.4.1High grade epithelial ovarian carcinomas exhibit higher expression of KIFC1 
than low-grade adenocarcinomas and uninvolved, adjacent normal tissues.  
A. Low magnification (4x) and their corresponding higher magnification (20x) images depicting 
KIFC1 expression in normal, low-grade and high-grade EOC tissues. The tissues were stained for 
KIFC1 (brown) and nuclei (blue). Scale bar (red) 20 µm. Bi. Box-whisker plot depicting the 
weighted index (WI) of KIFC1 expression in normal and tumor tissue. Bii. Box-whisker plot 
representing the WI for KIFC1 expression in low and high-grade EOC samples. 
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Table 5.4.1 A: Descriptive statistics for patient and clinicopathologic characteristics in the 
analysis of KIFC1 levels in tumors and matched normal tissue. 
Variable  Level Number  Percentage 
Age   
20-40 23 19.2 
41-60 81 67.5 
61< 16 13.3 
Grade 
1 32 26.7 
2 36 30 
3 46 38.3 
Unknown 6 5 
Stage 
I 69 57.5 
II 31 25.8 
III 12 10 
IV 3 2.5 
  Unknown 5 4.2 
Primary Tumor (T) 
T1 72 60 
T2 31 25.8 
T3 12 10 
Unknown 5 4.2 
Regional Lymph 
Nodes(N) 
N0 103 85.8 
N1 12 10 
Unknown 5 4.2 
Distant Metastasis 
Yes 3 2.5 
No 112 93.3 
Unknown 5 4.2 
Tissue Type 
Malignant 115 95.8 
Metastasis 5 4.2 
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Table 5.4.1 B: Descriptive statistics for Pathological diagnosis in the analysis of KIFC1 levels 
in tumors and matched normal tissue. 
Variable  Level Number  Percentage 
Pathological 
Diagnosis  
Adenocarcinoma 2 1.7 
Serous 
Adenocarcinoma 
6 5 
Serous Papillary 
Adenocarcinoma 
3 2.5 
Endometrioid 
Adenocarcinoma 
10 8.3 
Metastatic 
Adenocarcinoma 
4 3.3 
Metastatic 
Mucinous Adenocarcinoma 
1 0.8 
Mucinous 
Adenocarcinoma 
11 9.2 
Clear Cell 
Carcinoma 
4 3.3 
Serous Papillary 
Carcinoma 
32 26.7 
Serous Papillary 
Cystadenocarcinoma 
47 39.2 
SD= standard deviation; 
 
5.4.2 Enhanced KIFC1 gene expression is associated with poor survival in HGSOC patients  
Having established a significant correlation between KIFC1 expression and tumor differentiation, 
we next wanted to determine if there is any association between KIFC1 gene expression and 
clinical outcomes (overall survival (OS)) for ovarian cancer patients. To this end, we examined 
single channel microarray data from GEO (GSE9899) [25] to compare the expression levels of 
KIFC1 among different subtypes. Interestingly, we found that the gene expression levels of KIFC1 
were significantly higher in serous ovarian adenocarcinoma (n=154) when compared to all other 
subtypes (Borderline serous adenocarcinoma, n=18 and Peritoneal serous adenocarcinoma, n=22) 
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(Figure 5.4.2A). Further, we examined grade-wise trends in KIFC1 expression in serous ovarian 
adenocarcinoma. We observed a significant increase in KIFC1 expression levels with increasing 
grade (Figure 5.4.2B). OS was calculated as the time interval (in months) from the date of 
histological diagnosis to date of death from any cause.  We then carried out a survival analysis 
wherein patients were stratified into high- and low-KIFC1 expressing subgroups using the optimal 
KIFC1 expression cut-point (based on the log-rank test). Irrespective of the histological subtypes 
(n = 284), those with higher KIFC1 expression had shorter OS (p<0.067) than patients with lower 
KIFC1 (Supplementary Figure 5.7.2A). To investigate in-depth, we performed a similar survival 
analysis by stratifying serous ovarian adenocarcinoma patients (n= 201) on the basis of site 
(primary, n= 154 and metastatic, n= 47) of sample collection. Univariate regression revealed high 
KIFC1 gene expression correlated significantly (HR= 2.14, p=0.024) with poor OS in primary 
tumors only (Figure 5.4.2C) but not in metastatic ones (data not shown). This association stayed 
significant (HR=2.6, p=0.006) during multivariate analysis when potentially confounding factors 
like grade and tumor stage were added (Supplementary Figure 5.7.2B). In sum, enhanced gene 
expression levels of KIFC1 in primary tumors is strongly associated with poor clinical outcome. 
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Figure 5.4.2 KIFC1 is highly expressed in High grade serous ovarian adenocarcinoma and 
is associated with poor overall survival.  
A. Box-whisker graphs depicting the expression levels of KIFC1 among different subtypes of 
ovarian cancer. B. Box- whisker graphs depicting the expression levels of KIFC1 in serous ovarian 
adenocarcinoma in different tumor grades. Ci. Kaplan-Meier plots showing overall survival of 
HGSOC patients based on low or high expression of KIFC1 gene. Cii. Summary of the number of 
censored and uncensored values for the Kaplan-Meier survival analysis. 
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Table 5.4.2. Descriptive statistics and clinicopathologic characteristics for patients included 
in in silico analysis of KIFC1 expression and overall survival. 
VARIABLE LEVEL NUMBER PERCENTAGE 
Age (Range) 20-29 1 0.5 
30-39 4 1.9 
40-49 23 11.1 
50-59 84 40.4 
60-69 54 26 
70-79 40 19.2 
80-89 1 0.5 
Unknown 1 0.5 
Cancer Site Primary 154 74 
Metastasis 50 24 
Unknown 4 1.9 
FIGO Stage I 9 4.3 
II 9 4.3 
III 126 60.6 
IV 10 4.8 
Unknown 54 26 
Grade 1 6 2.9 
2 80 38.5 
3 120 57.7 
Unknown 2 1 
Survival Status Alive 109 52.4 
Dead 98 47.1 
Unknown 1 0.5 
Recurrence Recurrence 154 74 
No Recurrence 53 25.5 
Unknown 1 0.5 
5.4.3 KIFC1 gene expression correlates with expression of genes related to centrosomal 
amplification in serous ovarian cancer 
Next, we sought to examine the correlation of KIFC1 and genes driving CA. We analyzed 
expression levels of genes including CCNA2, CDK1, NEK2, AURKA, MYCN, CCNE2, STIL, 
LMO4, PLK4, MDM2, CEP63, E2F1, E2F2, E2F3, CEP152, PIM1, PIN1 AND CCND1, whose 
deregulation is known to drive ca [18, 26-28]. Specifically, we tested the associations between 
robust multi-array average-normalized expression levels of these genes in primary soc from 154 
patients using gene expression omnibus (GEO) series GSE9899. Higher expression of KIFC1 was 
significantly correlated with high expression OF CCNA2, CDK1, NEK2, AURKA, E2F2, MYCN, 
STIL, CCNE2, E2F3, LMO4, PLK4, PIN1 AND E2F3 (Table. 5.4.3). These results suggest that 
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KIFC1 upregulation and enhanced centrosome clustering in the serous ovarian adenocarcinomas 
may enable tumor cells to manage their increased centrosomal load, avert mitotic catastrophe and 
promote survival.  
Next, we identified the biological processes which are deregulated in the KIFC1 high risk group. 
To this end, we probed the publicly-available microarray dataset (GSE9899) and stratified the 154 
serous ovarian adenocarcinoma patients from the dataset into KIFC1-high and KIFC1-low groups. 
We then identified the gene ontologies of significantly overexpressed genes associated with the 
KIFC1-high group utilizing the panther classification system. When pathway analysis was 
performed we found that majority of the genes overexpressed were associated to cellular processes 
like cell communication, cell cycling, cytokinesis and cell proliferation (Figure 5.4.3ai, ii). We 
then validated these results by performing the gene set enrichment analysis (26). We found that 
KIFC1 high group was significantly (FDR <0.25 and es p<0.05) enriched in centrosome and cell 
cycle gene sets (Figure 5.4.3bi, ii and Supplementary Figure 5.7.3a) (see supplementary table 
5.7.1, 2 and 3 for these and all other enriched gene ontologies). The results from GSEA showed 
that the top 100 gene sets enriched in KIFC1 high group were among the ones which plays key 
roles in, driving ca (NEK2, PLK1, CCNA2), clustering centrosomes (PRC1), microtubule spindle 
(KIF11, NUSAP1, NUMA1) etc. Altogether our data shows that the KIFC1-high group had a 
preponderance of genes representing all four important mitotic kinases –namely polo-like kinases 
(PLK1), aurora kinases (AURKA, AURK B), cyclin dependent kinases (CDK1) and nima related 
kinases (NEK1, NEK2). The coordination of progression through mitosis is mainly orchestrated by 
protein phosphorylation ensured by these kinases. Thus, it is reasonable to speculate that 
overexpression of these kinases results in deregulation of the cell cycle resulting in abnormal 
mitosis that generates cells with aberrant centrosomes and abnormal chromosomal content.  
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Figure 5.4.3 Gene set enrichment analyses for biological processes associated to KIFC1 
high group.  
Ai. Biological processes enriched in KIFC1 high group. Aii. Cell cycle processes enriched in 
KIFC1-high group. Bi Enrichment plots of centrosome-related genes. Bii. Enrichment plot of 
genes associated with cell cycle progression, with red indicating correlation with the KIFC1-high 
group and blue the KIFC1-low group. 
 
 
 
 
144 
 
 
 
Table 5.4. 3.  Correlation between KIFC1 expression and expression of genes whose 
dysregulation drives centrosome amplification.  
 
GENE PEARSON CORRELATION P-VALUE 
CCNA2 0.62527 <.0001 
NEK2 0.60066 <.0001 
E2F1 0.54218 <.0001 
CDK1 0.52124 <.0001 
E2F2 0.51764 <.0001 
AURKA 0.46987 <.0001 
STIL 0.397 <.0001 
CCNE2 0.36387 <.0001 
LMO4 0.36306 <.0001 
PLK4 0.34292 <.0001 
MYCN 0.31914 <.0001 
E2F3 0.31548 <.0001 
MDM2 0.24766 0.002 
PIN1 0.23016 0.0041 
CEP152 0.18128 0.0245 
PIM1 0.17826 0.027 
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5.4.4 HGSOC cell lines show higher incidence and severity of centrosome amplification 
Having confirmed the association between upregulation of KIFC1 gene and CA genes in HGSOC, 
we wanted to investigate the CA profile in well-established in vitro cell lines that mimic HGSOC. 
To this end, we first screened four well-established cancer cell lines (namely, KURAMOCHI, 
OVCAR3, OVSAHO and SKOV3 by immunostaining centrosomes (γ-tubulin, green) and 
microtubules (α-tubulin, red) and counterstaining nuclei with DAPI (blue) Figure 5.4.4A. 
Employing confocal microscopy we imaged 10 areas of interest (at least 500 cells were counted 
per cell type). Cells with abnormal number (more than two) of gamma tubulin spots were 
considered as cells with amplified centrosomes. We found that KURAMOCHI exhibited the 
highest percentage of cells with amplified centrosomes (~38%) followed by OVSAHO (~24%), 
OVCAR3 (~15%) and SKOV3 (~9%) (Figure 5.4.4B). In a recent molecular profiling study by 
Domcke et al., KURAMOCHI and OVSAHO were selected as the representative cell lines for 
HGSOC  [29]. Thus, our findings here parallel previous studies that recognize CA as a biomarker 
of aggressive tumors. Furthermore, we validated our results by evaluating the expression levels of 
centrosome-related proteins by performing immunoblotting assays. We found that the cell lines 
with high CA (KURAMOCHI and OVSAHO) expressed higher levels of centrosome structural 
proteins (densitometry values for centrin-2 relative to loading control β actin (KURAMOCHI - 
0.291445, OVSAHO - 0.432561) and proteins whose dysregulation is known to drive CA (for 
Cyclin-E and Aurora A, KURAMOCHI- 0.194213 and 0.256828, OVSAHO- 0.428814, 1.664283 
respectively) (Figure 5.4.4C). Our next step was to investigate if aberrations in centrosome 
numbers among the different cell lines had any bearing on the mitotic spindle geometry.  
Interestingly, we found that the percentage of multipolar mitotic cells in three cell lines 
(OVSAHO, SKOV3 and OVCAR3) was lower (by ̴ 2-fold) in comparison with the proportion of 
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cells with supernumerary centrosomes (Figure 5.4.4B). This difference in the proportion of cells 
with CA and multipolar spindles clearly supports the hypothesis that ovarian cancer cells cluster 
supernumerary centrosomes to form pseudobipolar poles. But as the results here indicate that 
KURAMOCHI showed significantly more multipolar mitoses when compared to the other ovarian 
cancer cell lines we tested, we evaluated if there existed variability in the level of clustering 
molecules that help cancer cells to deal with supernumerary centrosomes by corralling them to 
form pseudobipolar spindles [24]. To this end, we performed immunoblotting to evaluate 
expression level of centrosome clustering protein KIFC1 in cell lysates obtained from the ovarian 
adenocarcinoma cells (KURAMOCHI, OVCAR3, OVSAHO and SKOV3). We found that all the 
three cell lines with pronounced centrosomal clustering expressed higher levels of KIFC1 
(SKOV3- 0.342396, OVCAR3- 0.204796 and OVSAHO- 0.452534) whereas negligible KIFCI 
expression was noted in KURAMOCHI (0.145452). It is noteworthy to mention that a recent report 
shows that KURAMOCHI is the only cell line that did not induce tumorigenesis in vivo [11]. This 
finding resonates with our notion that centrosome clustering is essential for the viability of cancer 
cells with extra centrosomes and therefore determines their tumorigenicity.  
The in vitro findings were validated in silico by probing publically-available microarray 
dataset using Gene set. We interrogated publically-available microarray dataset of ovarian cancer 
cell lines (GSM133614, GSM133609, GSM887467 and GSM887488). We calculated a 
cumulative gene expression-based centrosome amplification index (CAI) by adding log-
transformed, normalized gene expression for both structural centrosomal proteins (CETN2 
(centrin-2), TUBG1 (γ-tubulin), PCNT2 (pericentrin)), and genes implicated in centrosome 
amplification (PLK4 (polo-like kinase 4) and CCNE1 (cyclin E) genes) (Supplementary Figure 
5.7.4 Ai). The analysis showed that CAI genes are expressed in all cell lines but is highest in 
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OVSAHO. In addition, we evaluated gene expression levels of KIFC1 and found that the gene 
expression levels of KIFC1 was higher in cancer cell lines in comparison to normal ovarian surface 
epithelial cells (Supplementary Figure 5.7.4 Aii). Taken together, our results indicated that CA 
and KIFC1 levels are associated with HGSOC cell lines. 
 
Figure 5.4.4 HGSOC cell lines show higher incidence and severity of Centrosome 
amplification.  
A. Confocal microscopic images showing the presence of centrosome amplification and clustering 
in ovarian cancer cell lines. Centrosomes and microtubules were visualized by immunostaining 
for γ-tubulin (green) and α-tubulin, respectively, and DNA was stained using DAPI (blue).  Scale 
bar (white) 5 µm. B. Bar graphical representation of percent cells showing centrosome 
amplification and multipolar mitosis in human ovarian cancer cell lines. 500 cells were counted in 
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each case. C. Immunoblots showing the levels of KIFC1 and centrosomal markers in ovarian 
cancer cells lines (KURAMOCHI, OVCAR3, OVSAHO, and SKOV3).  
 
5.5  Discussion 
Ovarian cancer in the advanced stage remains the deadliest gynecologic malignancy. One of the 
major causes of the low five-year survival is the diagnosis at later stages after it has already 
metastasized beyond the pelvis [30]. While extensive literature contains information on the 
different kinds of biomarkers for ovarian cancer, risk predictive or prognostic markers that are 
utilized in clinical settings are few and far between. Generally, most researchers focus on single 
prognostic markers which may be insufficient for complete prognostic information, and also most 
of them have very low clinical utility. A combination of multiple factors needs to be considered 
simultaneously to more accurately predict a patient’s prognosis. Presence of heterogeneity in 
ovarian cancer is another key factor to be considered in prognosis as many ovarian cancer studies 
have failed to take into account differences in the histological subtype which clearly pose 
prognostic and therapeutic challenges [30, 31]. Essentially, these unique attributes and challenges 
can be addressed by personalizing treatments based upon the unique biomarker profiles of 
individual patients. Thus, a comprehensive understanding of risk predictive or prognostic factors 
with regard to histological subtype is imperative to devise relevant treatment strategies specific for 
the particular group of patients or tumor subtypes.   
Chromosomal instability (CIN) is the main cause of complex genomic alterations in 
tumorigenesis. Since CA engenders CIN, the role of CA driven karyotypic diversity is well studied 
in several malignancies including pancreatic ductal adenocarcinoma, TNBC and colon cancer [18, 
20]. Several studies have highlighted the presence of supernumerary centrosomes in ovarian cancer 
suggesting that CA is a hallmark of ovarian cancer [32-34].  Recently, we also demonstrated the 
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presence of amplified centrosomes in EOC [24].  Supernumerary centrosomes in cancer cells tend 
to cluster to manage the centrosomal load and thus escape from the perils of mitotic catastrophe. 
KIFC1 is well studied for its role in clustering supernumerary centrosomes [22, 23]. In our 
previous study, we emphasized the role of KIFC1 in tumor progression of EOC at the gene 
expression level [24].  In the present  study we have validated those findings by immunostaining 
ovarian cancer tissue samples for KIFC1. Our findings show that  KIFC1 expression increases 
with the grade in EOC. Among the various subtypes that comprise EOC, we found that KIFC1 
expression was highest among high-grade SOC samples. This helped us to focus our study on 
HGSOC, which is a more prevalent and aggressive form of ovarian cancer. This strong relationship 
of KIFC1 with HGSOC suggests that KIFC1 may be directly involved in tumor development and 
in driving aggressiveness by allowing the cancer/poorly differentiated cells to escape mitotic 
catastrophe and thrive. Moreover, data from our GSEA analysis showed that BIRC5 gene, which 
codes for the protein Survivin, that performs dual roles in promoting cell proliferation and 
preventing apoptosis [35, 36], was among the first 20 enriched genes in KIFC1-high group. Thus, 
KIFC1 overexpression not only protects cancer cells from undergoing mitotic catastrope but also 
endows them with low-grade aneuploidy, as a form of genomic instability, and high levels of 
survival signaling that together facilitate tumor evolution and disease progression. This finding 
was bolstered by results obtained from in silico analysis wherein we found that primary tumors 
with higher gene expression of KIFC1 were associated with poor survival; by contrast, while 
samples collected from the metastatic sites showed similar expression levels of KIFC1 as in 
primary sites, high KIFC1 expression in metastatic sites was not significantly correlated to poor 
survival. This differential effect of high KIFC1 expression strongly suggests that elevated KIFC1 
in primary sites perhaps helps tumor cells present in the primary sites to acquire karyotypic 
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diversity (through CIN), which is more likely to lead to successful metastasis and poor survival. It 
is possible that once metastasis commences, high KIFC1 levels in the metastatic clones provides 
little further survival advantage for the cancer cells; alternatively, once metastasis occurs, the 
survival difference between KIFC1-high and KIFC1-low patients is no longer so marked. Further 
studies are required to gain more insights into these intriguing issues.  
Given the direct association of CA with KIFC1  in the present study, we examined the 
association of KIFC1 with CA-associated genes. Our in silico analysis indicated that in primary 
SOC samples KIFC1 expression was positively correlated to the expression of genes which drive 
CA. CCNA2, NEK2, and AURKA were among the top 10 genes which were highly correlated to 
KIFC1 expression. Role of NEK2, CCNA2, and AURKA as potential targets in ovarian cancer 
has been recently highlighted by a detailed systematic bioinformatic study [37].  Besides, this 
enrichment analysis showed that the KIFC1-high group was enriched in genes implicated in cell 
cycle regulatory processes, especially genes participating in G2-M transition and the spindle 
assembly checkpoint (MAD2, BUB1). Several studies in past have reported MAD1 and MAD2 
overexpression in different malignancies, and association of this overexpression with aneuploidy 
and poor overall survival [38-40]. Thus, our findings from the GSEA and Pathway analysis 
suggests that KIFC1 overexpression drives overexpression of genes that control mitotic 
checkpoints (Supplementary Table 5.7.2), which by generating aneuploidy, accelerate tumor 
progression and evolution of more aggressive phenotypes.  
 In line with these in silico findings, we found that cell line derived from  HGSOC displayed 
robust CA, and the proteins which are known to drive CA were also highly expressed. Some recent 
studies on molecular profiling of ovarian cell lines have demonstrated that OVSAHO represents 
most of the characteristics (KRAS, p53 and BRCA1 and 2 mutations) of HGSOC [29] and is 
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considered to be most aggressive cell line among all. From our study, we found that OVSAHO 
cells expressed the highest levels of KIFC1 and in spite of presence of interphase supernumerary 
centrosomes it showed significantly low level of multipolar mitosis. These findings clearly indicate 
that strong association of CA and clustering with KIFC1 overexpression, which leads to CIN, 
could be the underlying cause of aggressiveness in these cells. Testing effects of centrosome 
declustering drugs on these cells could prove to be advantageous.  
In conclusion,  our results indicate that HGSOC overexpresses KIFC1, which is associated with 
poor overall survival suggesting a causative link between KIFC1 and tumor aggressiveness. These 
findings highlight KIFC1 as a potential biomarker to predict disease aggressiveness KIFC1 may 
also serve as a cancer-selective therapeutic target for high-grade serous ovarian adenocarcinoma 
patients. 
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6.1 Abstract  
Loss or mutation of p53 gene is the most frequent genetic lesion in late-stage colon cancers. 
The optimal management of p53 mutant colorectal cancer (CRC) remains a significant therapeutic 
challenge owing to its resistance to 5-fluorouracil, the first-choice chemotherapy drug for CRC. 
Thus, the search for novel therapeutic targets for the treatment of p53 mutant CRC is highly 
warranted. We report here that p53 negatively regulates expression of KIFC1 (a centrosome 
clustering protein), which can serve as a potential therapeutic target for p53 mutant CRCs.  To test 
this hypothesis, we first immunohistochemically stained 203 CRC tissue samples for p53, KIFC1, 
and FOXM1 and calculated their weighted indices (WIs) for nuclear staining. Further, we 
quantitated the protein levels of KIFC1 and FOXM1 by immunoblotting. For determining the 
mechanistic relationship of KIFC1 and p53, overexpression (OE) of p53 and ChiP assays were 
performed. Finally, inhibited KIFC1 by pharmacological and genetic methods to elucidate the role 
of the KIFC1 inhibition on the vitality of p53-/- CRC cells. Our results indicated that p53-/- and 
p53 mutant CRC [p53 null n=82, p53mutant n=40, and WT n=81] exhibited significantly 
(p<0.001) higher expression of KIFC1 and FOXM1 when compared with the p53 WT CRC tissue 
samples and was associated with worse overall survival (HR=4.249, p=<0.001)). p53-/- cells 
showed increased expression of KIFC1 and FOXM1. OE of p53 in p53-/- cells decreased the 
expression of FOXM1 and KIFC1 indicating the negative regulation of KIFC1 via FOXM1 which 
was further strengthened by ChiP assay (FOXM1 interaction with KIFC1 promoter was 
significantly higher p=0.037 in p53-/- cells when compared with p53 WT cells). Inhibition of 
KIFC1 using shRNA, CW069 (a known KIFC1 inhibitor) and griseofulvin (a known centrosome 
declustering drug), led to increased multipolarity followed by cell death only in p53-/- CRC cells. 
Collectively our results indicate that p53 negatively regulates expression of KIFC1 via FOXM1 
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and contributes to poor outcomes in p53 mutant CRCs. Thus, KIFC1 may serve as a potential 
therapeutic target for p53 mutant CRCs.  
6.2  Introduction 
Colorectal cancer (CRC) is one of the leading causes of cancer morbidity and mortality in the 
United States. Studies indicate that the multistep progression from normal intestinal epithelial 
tissue to metastatic neoplasm in CRC results from impairment of multiple regulatory mechanisms 
involving major signaling pathways that regulate important cellular functions [1, 2]. Inactivation 
of tumor suppressor genes such as those encoding adenomatous polyposis coli (APC) [3, 4] and 
p53 [5]; and oncogenic activation of KRAS and BRAF have been shown to be crucial for the 
pathogenesis of CRC [6]. The mutations in p53 or its loss of function mainly occur at the transition 
from adenoma to cancer, and the frequency of alterations in the gene increases with the 
corresponding progression of the lesion [7]. p53 is a stress-inducible transcription factor, which 
regulates a large number of diverse downstream genes to exert regulative function in multiple 
signaling processes [8]. p53 mutation occurs in approximately 40%-50% of sporadic CRC, and 
the status of p53 mutation is closely related to the progression and outcome of sporadic CRC [8, 
9].  
Studies have shown that CRC cells carrying p53 mutation often develop resistance to the apoptotic 
effects of 5-fluorouracil (5-FU is the first-line adjuvant therapeutic agents used CRC therapy) [10], 
both in vitro [11, 12] and in vivo [13-18]. Resistance to chemotherapy represents the major 
obstacle for the improvement of survival of nearly 50% of CRC patients and the current therapies 
to target mutant p53 are not effective as different mutations affect p53 function differently and 
different agents may be required to target different mutations. Thus, identification of molecules or 
pathways that can be targeted in p53 mutant CRC might help in improving the patient outcome.  
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Studies have shown that p53, has been linked to the regulation of centrosome duplication 
and centrosome amplification (CA) is a consequence of mutation of p53 [19-21] in multiple 
cancers. In cancer cells, excess centrosomes cluster into two polar groups during mitosis, giving 
rise to pseudo-bipolar spindles. Merotelic attachment of individual kinetochores to more than one 
spindle pole is a frequent occurrence. Such inappropriate attachments can cause CIN in the 
resulting two, three, or more daughter cells via missegregation of whole chromosomes and/or the 
separation of parts of chromosomes via the stress placed on chromosomes by microtubule 
attachments and their misguided forces, rendering the chromosomes unstable and liable to break 
[22]. Further, clustered supernumerous centrosomes are inherited by progeny cells, leading to a 
perpetuation of CIN in progeny cells. Numerical and structural CA has been reported in CRCS 
and researchers have reported CA and chromosomal instability in several CRC cell lines 
suggesting a link between CA and CIN in CRCs. In another study, it was reported that inactivation 
of p53 in CRC cells HCT116 lead to a 3.5-fold increase in tetraploidization. Also, p53 is involved 
in centrosome clustering and thus preventing cells to undergo mitotic catastrophe. Therefore, loss 
of p53 leads to both induction of CA and generation of CIN in CRCs.  
KIFC1, also known as HSET, is a nonessential kinesin motor protein, that plays a crucial 
role in centrosome clustering in cancer cells [23, 24]. Knockdown of KIFC1 was shown to induce 
multipolar spindle defects and cell death in mitotic cancer cell lines containing extra centrosomes 
[24] whereas it had no effect on cell division in a variety of diploid control cell lines [24]. In cancer 
cells, the role of KIFC1 becomes indispensable due to the presence of supernumerary centrosomes. 
This differential dependence of cancer cells on KIFC1 for viability makes KIFC1 a cancer-cell 
selective therapeutic target. We and others have shown that KIFC1 is elevated in several cancer 
types [25-28], including colon cancer. To further understand the regulation and expression of 
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KIFC1 in CRCS herein this study we evaluated KIFC1 expression in clinical samples of p53 
mutant, WT and null CRCs and observed higher expression of KIFC1 with p53 mutation/loss and 
was associated with poor overall survival in patients. Furthermore, to understand better the 
association KIFC1 and p53 mutation/loss we performed invitro assays to disseminate role of 
upstream molecules of KIFC1 in indirect regulation through p53. We observed the FOXM1 
member of the Forkhead Box (Fox) family of transcription factors positively regulates expression 
of KIFC1 in p53 null CRC cells. Studies have also shown that p53 negatively regulates expression 
of FOXM1[29]. Thus, collectively suggesting that p53 negatively regulates expression of KIFC1 
in CRCs via FOXM1. Furthermore, we showed that suppression of KIFC1 via pharmacological 
(CW069 known inhibitor) genetic (siRNA) induces multipolarity in p53-/- CRC cells resulting in 
increased cell death. Lastly, we presented that CRC cells with p53 mutation show higher sensitivity 
to griseofulvin (GF), and treatment with GF causes extensive multipolarity followed by mitotic 
catastrophe in these cells suggesting GF might be triggering centrosome declustering by inhibiting 
KIFC1. Collectively our study shows that KIFC1 can serve as a novel therapeutic target in p53 
null/mutant CRCs. 
6.3 Material and Methods 
6.3.1 Clinical samples 
203 formalin-fixed paraffin-embedded (FFPE) CRC resection samples (full-face sections) with 
information on all clinicopathologic parameters and clinical outcomes were obtained from Emory 
University Hospital, Atlanta, USA. All aspects of the study including protocols, sample 
procurement, and study design were approved by IRBs of Emory University Hospital. 
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6.3.2 Cell culture 
All the cell lines used in the study were obtained from American Type Culture Collection (ATCC). 
The colon cell lines utilized in this study included HCT 116 wild type (WT) and HCT 116 p53 
null. were grown in McCoy’s 5A media supplemented with 10% Hyclone Fetal Bovine serum and 
1% penicillin/streptomycin. All cell lines were maintained in humidified 5% CO2 atmosphere at 
370 C. 
6.3.3 Lysate preparation and immunoblotting 
Whole cell protein lysates were prepared from ~80% confluent cells with 250ul of 1x RIPA cell 
lysis buffer (Cell Signaling). The 1x lysis buffer contained 1 mM b-glycerophosphate, 20 mM 
Tris–HCl (pH 7.5), 1 mM Na2EDTA, 1 mM Na3VO4, 150 mM NaCl, 1 mM EGTA, 2.5 mM 
Na4P2O7, 1 ug/ml leupeptin, and 1% Triton. Lysis buffer was supplemented with 10% protease 
inhibitor to prevent protein degradation. Equal amounts of protein (30ug) was loaded and 
fractionated using 10% SDS-PAGE gel. Pierce ECL kit (Thermo-Scientific) was used for detection 
of immune-reactive bands corresponding to the respective primary antibody. β-actin was used as 
loading control. 
 
6.3.4  Immunofluorescence staining, imaging, and scoring of clinical specimens 
Formalin-fixed paraffin-embedded tissue slides were deparaffinized in xylene (three changes) 
followed by serial rehydration in ethanol baths (100%, 95%, 70% and 50%). Antigen retrieval was 
done by heating slides in a pressure cooker in citrate buffer (pH 8.5) at psi 15 for 30 min. Blocking 
was performed by incubating the slides with the 100mM glycine for 30 min. Tissue samples were 
then incubated with primary mouse antibody against γ -tubulin at 1:1000 dilution at room 
temperature for 1 h, followed by washing 3X with PBS. The samples were then incubated with 
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secondary antibody (Alexa-555 anti-mouse) at 1:2000 dilution for 2 h, at 37 °C followed by 
washing 3X with PBS. Next, the tissue samples were incubated with Hoechst 33342 (1:5000) at 
room temperature for 10 minutes. Finally, coverslips were mounted with Prolong-Gold Antifade 
Reagent with DAPI (Invitrogen). Tissue samples were imaged using the LSM 700 Confocal 
microscope (Oberkochen, Germany) and the images were processed using the Zen software 
(Oberkochen, Germany). The percentage of cells with CA was quantitated from 10 randomly 
selected fields, with ~ 200 cells counted for each sample.  
6.3.5  Immunohistochemistry and scoring 
Samples were processed in the same way till antigen retrieval as mentioned above in 
Immunofluorescence section. Following antigen retrieval, slides were cooled down by keeping 
them in ice for 20 minutes. Slides were subjected to two blocks- firstly with hydrogen peroxide 
block for 20 minutes to quench endogenous peroxidase activity, secondly with protein block for 
10 minutes. Slides were incubated with primary antibodies for p53 (Santa Cruz) and KIFC1 
(Abcam) for 1 hour. MACH2 HRP-conjugated secondary antibody was applied for 30 minutes 
followed by chromogen visualization by DAB (Biocare Medical). Finally, slides were 
counterstained with Myer’s hematoxylin (Dako), dehydrated with serial washes in ethanol 
followed by xylene and mounted. A relative intensity score was represented as 0 = none, 1 = low, 
2 = moderate, or 3 = high. The product of intensity and frequency was measured as a weighted 
index (WI) for both the nucleus and cytoplasm. 
6.3.6 Immunocytofluorescence staining 
Cells were cultured on coverslips and, after the confluency reached approximately 80 %, cells were 
fixed with ice-cold methanol for 7 min. The cells were blocked with 5 % BSA/0.01 % Triton X 
for 45 min at room temperature and then incubated at 37 °C with antibodies directed against γ-
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tubulin and α-tubulin at a dilution of 1:2000 for 30 min. Cells were washed 5 times with 1x PBS, 
followed by incubation with anti-rabbit Alexa Fluor 488 and anti-mouse Alexa Fluor 555 at 370 C 
for 30 minutes. Next, cells were washed briefly for 8 times with 1x PBS, followed by staining with 
Hoechst 33342 used at a dilution of 1:5000 for 10 minutes at room temperature. Finally, cells were 
washed with 1x PBS for 3minutes and, mounted with Prolong Gold antifade reagent. 
Immunofluorescence imaging was carried out using the Zeiss LSM 700 confocal microscope 
(Oberkochen, Germany) and images were analyzed using the Zen software (Oberkochen, 
Germany).  
6.3.7 p53 overexpression and KIFC1 knockdown 
HCT 116 WT and null cells were grown to 70% confluency and transfected using Lipofactamine 
2000 according to manufacturer’s instructions. KIFC1 gene knockdown in HCT116 null cell was 
achieved using KIFC1 siRNA (Origene). The non-targeting universal scrambled siRNA was used 
as the negative control in both the cell lies. 24 hours post transfection, whole cell protein lysates 
were prepared for immunoblot assay. HCT 116 null cells were grown to 70% confluency and 
transfected using Lipofactamine 2000 according to manufacturer’s instructions. For this, 6 ul of 
lipofectamine was added to 4ug of p53 overexpression vector and the mixture was slowly added 
to the cells. GFP tagged p53 vector was a generous gift from Dr. Tylor Jacks (Addgene plasmid 
#12091). 24 hours post transfection, whole cell protein lysates were prepared for immunoblot 
assay.   
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6.4 Results  
6.4.1  p53-mutant CRCs show poorer overall survival (OS) compared to p53-wild-type CRCs 
203 formalin-fixed paraffin-embedded FFPE) CRC resection samples (full-face sections) were 
stained immunohistochemically (IHC) for p53 (Figure. 6.4.1A) and were scored by two 
independent pathologists without prior knowledge of the patients’ pathologic/outcome data. 
Samples wherein <80% but >1% of cells stained positive for p53 were considered p53 wild type 
(WT) (n=81), those wherein ≥80% of cells stained positive for p53 were considered p53-mutant 
(M) (n=40), and those where in <1% cells were stained for p53 were considered as p53-null (N) 
(n=81). Multiple studies have provided evidence where p53 IHC staining can be used as a 
surrogate for the mutational analysis in the diagnostic workup of the various carcinomas. Kaplan-
Meier survival analysis suggested that p53-null CRC patients have the worse prognosis than p53-
mutant and p53-WT. Also, p53 mutant CRCs were associated with worse OS than p53 WT CRCs. 
(HR=4.249, p=<0.001) (Figure. 6.4.1B). These findings were supported by our in silico findings 
GSE41258) where the p53-mutant (n=93) CRC was associated with poorer OS (HR=1.46, 
P=<0.05) (Figure. 6.4.1C) than p53-WT CRCs. 
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Figure 6.4.1 p53-mutant CRCs show poorer overall survival (OS) compared to p53-wild-
type CRCs 
A) Representative micrographs of p53 IHC staining in CRC tissue samples. (B)  Kaplan-Meier 
plots of OS based on p53 status in clinical tissue samples. (C) Kaplan-Meier plots of OS based 
on p53 status in in silico data.  
6.4.2  p53-mutant CRCs exhibit higher centrosome amplification than p53-WT CRCs 
Studies have shown that p53 mutations in various tumor types are associated with CA. To study 
this we visualized amplified centrosomes in 40 CRC samples (n=20 p53-WT and n=20 p53-
mutant) employing multicolor confocal immunofluorescence microscopy. Centrosomes were 
labeled by anti-γ-tubulin (green) antibody, and centrosomal aberrations were determined by 
quantifying percentage of cells bearing abnormal numbers of γ-tubulin foci (more than two). We 
found that the number of cells/500 cells harboring extra centrosomes was higher in p53-mutant 
CRCs when compared with to p53-WT CRCs (p=0.086) (Figure. 6.4.2.1 A, B). In line with this, 
we observed that p53-null colon cancer cell line (HCT116 p53-null CRC cells) exhibited notably 
higher CA (~40%) as compared to p53-WT (~10%) cells (Figure. 6.4.2. A, B). Furthermore, 
protein levels of proteins associated with CA were also elevated in p53-null cells when compared 
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with the p53-WT CRC cells (Figure. 6.4.3 C). Thus, these findings indicate that p53null/mutant 
CRCs exhibit higher CA when compared to the WT CRCs.  
 
Figure 6.4.2 p53-mutant CRCs exhibit higher centrosome amplification than p53-WT 
CRCs 
(A) Representative confocal images showing the presence of CA in p53-mutant and WT CRC 
tissue. (B) Box whisker graph representing the distribution of % numerical CA in p53-WT and 
p53-mutant CRC tissue sections  
 
Figure 6.4.3 HCT 116 p53-/- CRC cells exhibit higher centrosome amplification than WT 
cells 
(A) Confocal micrograph showing the presence of CA in HCT-116 p53-null CRC cells and 
HCT-116 p53-WT cells. Scale bar, 5 µm. (B) Degree of CA in p53-null and p53-WT CRC cells. 
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(C) Immunoblots showing expression of the CA associated proteins in p53-null and p53-WT 
CRC cells. 
6.4.3  p53-mutant CRCs exhibit higher expression of the centrosome clustering kinesin, 
KIFC1  
 In cancer cells that harbor supernumerary centrosomes, KIFC1 is required for proper spindle 
assembly [23], where it promotes centrosome clustering and suppresses multipolar spindle 
formation and cell death [24]. Thus, given the association of high CA with p53-mutant status in 
CRCs, we suspected that KIFC1 levels may perhaps be elevated in these samples in order to cope 
with the increased centrosomal load. Therefore, serial sections from the 203 CRC tissue samples 
that were stained for p53 (see 6.3.1.) were stained for KIFC1. Scoring was performed for both the 
intensity of staining (0 = none,1 = low, 2 = moderate, 3 = high) and the percentage of cells with 
any positivity (i.e., staining of 1+). KIFC1 WIs were calculated as the product of the nuclear 
staining intensity and percentage of positive cells. P53-null (p53-/-, n=82) and p53-mutant CRC 
(n=40) exhibited significantly (p<0.001) higher expression of KIFC1 when compared with the 
p53-WT CRC (n=81) tissue samples (Figure. 6.4.4 A, B). Similarly, we observed that the p53-
null CRC cells exhibited higher expression of KIFC1 (immunoblotting) when compared with the 
p53-WT CRC cells (Figure. 6.4.4 C). 
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Figure 6.4.4 p53-mutant CRCs exhibit higher expression of the centrosome clustering 
kinesin, KIFC1 
 A) Representative micrographs of p53 and KIFC1 IHC staining in p53 null/ mutant and p53-WT 
CRC tissue samples. B) Box whisker graph representing the KIFC1 expression in p53-null, p53-
mutant and p53-WT CRC tissue samples. C) Immunoblots showing expression of KIFC1 in p53-
null and p53-WT CRC cells. 
6.4.4 FOXM1 expression is correlated with KIFC1 and is higher in p53-mutant when 
compared with the WT 
Serial sections from 203 CRC tissue samples used in Section 6.3.1 were IHC- stained for FOXM1 
and WIs for nuclear staining was calculated. We observed that expression of FOXM1 was 
significantly higher in p53-mutant and p53-null group when compared with the p53-WT CRCs 
(Figure 6.4.5). In addition, expression of FOXM1 was strongly correlated with KIFC1 expression 
(r=1.3, p=<0.05). We also observed that p53-null CRC cells expressed higher levels of FOXM1 
when compared with p53-WT CRCs.  
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Figure 6.4.5 Box whisker graph representing the FOXM1 expression in p53-mutant and 
p53-WT CRC tissue samples. 
 
6.4.5  FOXM1 and KIFC1 expression was decreased by p53 overexpression (OE) in p53-null 
cells and FOXM1 binds to the promoter of KIFC1 with higher binding affinity 
Next, we transiently transfected the pEGFP-P53 construct into HCT116 p53-null CRC cells. Given 
a transfection efficiency of ~70%, we observed that FOXM1 and KIFC1 expression decreased in 
HCT 116 p53-null CRC cells with OE of p53, when compared with the control vector (Figure. 
6.4.6A). Literature has reported that KIFC1 promoter has binding sites for FOXM1. In line with 
this, our in silico analysis using publily-available TRANSFAC dataset showed that KIFC1 
promoter regions contain two FOXM1 binding motif sites suggesting that KIFC1 is a potential 
target gene of FOXM1 (data not shown). Additionally, our ChIP results indicated a significantly 
higher (p=0.037) binding of FOXM1 to the KIFC1 promoter in p53-null CRC cells when compared 
with the p53-WT CRC cells (Figure. 6.4.6B). Thus, collectively indicating that p53 negatively 
regulates expression of KIFC1 via FOXM1. 
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Figure 6.4.6 FOXM1 regulates expression of KIFC1 in p53-/- CRC cells 
A) Immunoblots showing decreased expression of KIFC1 and FOXM1 after overexpression of 
p53 in HCT116 p53-null cells. B) Bar graph representing FOXM1 interaction with KIFC1 
promoter in HCT 116 p53-null and p53-WT CRC cells. 
6.4.6  Inhibition of KIFC1 using siRNA led to increased multipolarity only in p53-/- colon 
cancer cells 
Given that KIFC1 was significantly upregulated in p53-mutant and p53-null CRC cells, we were 
prompted to examine the effects of depletion of cellular pools of KIFC1 in CRC cells. We 
performed transient siRNA transfections using pools of KIFC1 siRNA duplexes in p53-null and 
p53-WT CRC cells. KIFC1 depletion induced centrosome declustering and significant spindle 
multipolarity (Figure. 6.4.7A) in p53-null HCT116 cells. p53-WT HCT 116 cells, however, 
maintained bipolarity upon KIFC1 RNAi (Figure. 6.4.7B), indicating that KIFC1 is a potential 
cancer-selective therapeutic target for p53-null/mutant CRC. 
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Figure 6.4.7 Bar graph representing % bipolar and multipolar cells in KIFC1 KD and CV 
(A) p53-WT (B) p53-null CRC cells. 
6.4.7 Griseofulvin induces multipolarity and downregulates expression of KIFC1 
Griseofulvin (GF) is an antifungal drug which has recently been shown to inhibit proliferation of 
various types of cancer cells and to inhibit tumor growth in nude mice.  Studies have shown that 
Griseofulvin inhibits microtubule dynamics, which leads to spindle tension causing centrosome 
declustering, multipolar mitosis and cell death. Thus, we suspected that Griseofulvin might be 
leading to centrosome declustering via inhibition of KIFC1 activity in p53-mutant CRCs. To this 
end, we tested efficacy of Griseofulvin in CRC cells. We observed that Griseofulvin induced 
extensive centrosome declustering and mutlipolarity (~85% of mitotic cells were multipolar) in 
p53-null CRC cells when compared with the p53-WT CRC cells (~30% of mitotic cells were 
multipolar). Furthermore, the extent of multipolarity and cell death induced by Griseofulvin was 
far superior to that of a known KIFC1 inhibitor CW069 (Figure. 6.4.8A-C). Further, we performed 
intensive in silico modeling and observed that Griseofulvin (similar to CW069) docks onto a 
pocket within the motor-domain that houses the ATP-binding site of KIFC1 (Loop-5) with similar 
(-0.24 for CW069 and 0.25 for Griseofulvin) mean ligand efficiency. The predictive free energy 
(∆G) for this binding is -6.0 Kcal/mole (Figure. 6.4.8A, C).  
170 
 
 
 
Figure 6.4.8 Griseofulvin induces multipolarity and downregulates expression of KIFC1 
A) Confocal micrographs showing rampant multipolarity after treatment with CW069 and 
Griseofulvin (GF). B) Bar graphs representing % bipolar and multipolar cells in CW069- and 
GF-treated in p53-WT and p53-null CRC cells. 
6.4.8 Griseofulvin inhibits the ATPase activity of KIFC1 
Since KIFC1 is a kinesin-like microtubule motor protein, it contains a conserved motor domain 
that catalyzes ATP hydrolysis and generates a minus end-directed mechanical force along the 
microtubule. We, therefore, asked if Griseofulvin can inhibit the ATPase activity of KIFC1 in 
vitro. Employing the Kinesin ATPase ELIPA assay kit (Cytoskeleton Inc.) containing a kinesin 
heavy chain motor domain protein (KIF5B) (as a positive control) and microtubules as a substrate 
for kinesin activity, our results indicated that Griseofulvin inhibits KIFC1’s ATPase activity to a 
similar degree as CWO69 (Figure. 6.4.9B). Thus, Griseofulvin inhibits the motor activity of 
KIFC1 and induces centrosome declustering. 
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Figure 6.4.9 Griseofulvin inhibits the ATPase activity of KIFC1 
A) Distribution of binding energies of GF and CW069 from docking simulation. (B) Bar graph 
representing percentage inhibition of KIFC1 activity by GF and CW069 at 50 and 100µm. (C) 
Binding efficiency values of the CW069 and GF at loop 5 on KIFC1. 
 
6.5  Discussion  
In this study we showed that the expression of KIFC1 is significantly higher in p53 mutant/null 
CRCS when compared to the p53 WT CRCs and is associated with poor overall survival. Further, 
we evaluated the role of upstream regulators of KIFC1 to understand better the association KIFC1 
and p53 mutation/loss. We observed the FOXM1 member of the Forkhead Box (Fox) family of 
transcription factors positively regulates expression of KIFC1 in p53 null CRC cells. Studies have 
also shown that p53 negatively regulates expression of FOXM1[29]. Thus, collectively suggesting 
that p53 negatively regulates expression of KIFC1 in CRCs via FOXM1. Moreover, we showed 
that inhibition of KIFC1 via pharmacological (CW069 known inhibitor) and genetic (siRNA) 
methods induced multipolarity specifically in p53-/- CRC cells resulting in increased cell death. 
Finally, we observed that HCT116 p53-/- CRC cells were significantly higher sensitivity to GF 
when compared that of HCT116 p53WT CRC cells, and treatment with GF induced extensive 
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multipolarity followed by the mitotic catastrophe in the p53 null CRC cells. This suggests that GF 
might be triggering centrosome declustering by inhibiting KIFC1.  
In conclusion, our results indicate that p53 null/mutant CRCs overexpresses KIFC1 which is 
associated with poor overall survival suggesting a causative link between KIFC1 and tumor 
aggressiveness. Taken together our findings underscore that KIFC1 is a potential cancer selective 
therapeutic target for p533 null/mutant CRCs. 
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7.1 Abstract 
Docetaxel is the only FDA-approved first-line treatment for castration resistant prostate 
cancer (CRPC) patients. Docetaxel treatment inevitably leads to tumor recurrence after an initial 
therapeutic response with generation of multinucleated polyploid (MP) cells. Here we investigated 
role of MP cells in clinical relapse of CRPC. Herein, prostate cancer (PC-3) cells were treated with 
docetaxel (5 nM) for 3 days followed by a wash-out and samples were collected at close intervals 
over 35 days post drug-washout. The tumorigenic potential of the giant MP cells was studied by 
implanting MP cells subcutaneously as tumor xenografts in nude mice. Docetaxel-induced 
polyploid cells undergo mitotic slippage and eventually spawn mononucleated cells via 
asymmetric cell division or neosis.  Both MP and cells derived from polyploid cells (CDPCs) had 
increased survival signals, were positive for CD44 and were resistant to docetaxel chemotherapy. 
While MP cells were tumorigenic in nude mice, these cells took a significantly longer time to form 
tumors compared to parent PC-3 cells. Generation of MP cells upon docetaxel therapy is an 
adaptive response of apoptosis-reluctant cells. These giant cells ultimately contribute to the 
generation of mononucleated aneuploid cells via neosis and may play a fundamental role 
precipitating clinical relapse and chemoresistance in CRPC.         
7.2 Introduction 
Despite significant advances in research, diagnosis, and clinical practice, prostate cancer still 
remains the second most commonly diagnosed cancer and the sixth most common cause of cancer-
related death among men worldwide [1]. Androgen-deprivation remains the mainstay of the first 
line treatment for both primary and metastatic prostate cancer. Initially majority of the patients 
respond well to this treatment but eventually the tumor progresses to castration-resistant prostate 
cancer (CRPC) which is the major cause of mortality [2].  Docetaxel was approved by the 
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European Medicine Agency and the US Food and Drug Administration in 2004 for the first-line 
treatment of patients with CRPC and is now the only standard of care in this setting [3, 4]. While 
this clinical regimen prolongs overall survival in CRPC patients, the cancer unfortunately recurs 
(clinical relapse) inevitably after an initial illusionary therapeutic response. Currently, there is a 
lack of mechanistic knowledge underlying this tumor cell “replenishment” after docetaxel 
treatment which inevitably leads to tumor recurrence and translates to only a modest increase in 
overall survival. The present study explores this therapy-relapse paradox that inescapably results 
in tumor recurrence shortly after a therapy response. 
The formation of giant multinucleated polyploid (MP) cells after therapeutic 
intervention with either taxane-based chemotherapy including docetaxel or DNA damaging 
agents has been well described. Studies have reported that some tumor microenvironmental 
factors including hypoxia are also responsible for the generation of MP cells. Studies have also 
shown that hypoxia-mimicking CoCl2 treatment induces formation of polyploid cells that 
contributes to expansion of a cell subpopulation with stem cell characteristics [5, 6]. 
These polyploid cells can be a result of DNA over-replication [7], abrogated mitotic checkpoint 
[8] or failed cytokinesis [9]. It was long assumed that these giant polyploid cells do not survive 
and die due to “mitotic catastrophe” subsequent to multipolar cell division. But, recent evidence 
indicated that while most polyploid cells succumb to cell death, a small percentage of them 
survive and produce viable progeny [10, 11]. A study also found that colon cancer cells treated 
with DNA damaging agent cisplatin generated giant polyploid cells, a subset of which were able 
to engender viable clones via asymmetric cell division; furthermore, this phenomenon was 
recapitulated in an in vivo xenograft model of colon cancer treated with cisplatin [12] . Another 
study revealed that when PC-3 cells were treated with docetaxel, it led to growth arrest and 
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formation of multinucleated cells and the generation of docetaxel-resistant progeny [13]. A very 
recent study has reported the cabazitaxel, a second line chemotherapy in CRPC treatment, also 
leads to chemoresistance by inducing severe multinucleation in prostate cancer cells [14]. 
Altogether, these data suggest that polyploid cells that were once presumed to be either destined 
for terminal growth arrest or cell death may actually represent a “transition state” for generation 
of viable clones. 
The current study a imed to analyze the long-term effects of post  docetaxel exposure 
on prostate cancer cells. Our study shows that most of the prostate cancer cells exposed to 
docetaxel undergo cell death following mitotic arrest. However, a small percentage of the cells 
“slip out” of mitosis to form giant MP cells. Most of these MP cells succumbed to cell death, but 
a small fraction survived for several weeks, eventually giving rise to small mononucleated cells 
via an asymmetric cell division process called neosis. We further show that these MP cells 
have tumorigenic potential in nude mice and that both MP cells and cells derived from 
multinucleated polyploid cells (CDPC) are chemoresistant and were positive for cancer stem cell 
marker CD44. In conclusion, the formation of MP cells after docetaxel treatment suggests an 
escape process that is involved in tumor relapse and chemoresistance following an initial 
illusionary therapeutic response. 
7.3 Material and Methods 
7.3.1 Cell culture and treatment schedule 
PC-3 and DU145 cells were obtained from American Type Cell Culture (ATCC) and were grown 
in RPMI medium supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin. Cells were maintained in humidified 5% CO2. All experiments were 
performed using 5nM of docetaxel unless stated otherwise. 
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7.3.2 Flow cytometry 
Cells were harvested at different time intervals, washed twice with ice-cold PBS, and fixed in 
70% ethanol for at least 24 h. Cell pellets were then washed with PBS followed by RNase A (2 
mg/ml) addition and staining with anti-MPM-2 primary antibody and Alexa-488 conjugated 
secondary antibody. Propidium iodide (0.1% in 0.6% Triton X-100 in PBS) was added for 45 
min in dark followed by analysis on a FACS Canto flow-cytometer (BD Canto) using FlowJo 
software. 
7.3.3 Immunofluorescence 
Cells were grown on glass coverslips for immunofluorescence microscopy and were fixed and 
blocked as described previously [40] . Coverslips were incubated in primary antibodies (1:2000 
dilution) against γ-tubulin and α-tubulin at 1:2000 dilution for 1 h at 37°C, washed with 1XPBS 
for 10 min at room temperature, and then incubated in 1:2000 Alexa 488- or 555-conjugated 
secondary antibodies (Invitrogen; Carlsbad, CA). Cells were washed 5x with PBS and then 
mounted with Prolong-Gold antifade reagent that contained DAPI (Invitrogen). 
7.3.4 Microscopy 
Immunofluorescently stained cells were imaged utilizing the Zeiss LSC 700 confocal microscope 
(Oberkochen, Germany) and were processed with Zen software (Oberkochen). 
7.3.5 Time lapse imaging 
Giant MP cells were isolated and plated 12 days after docetaxel removal. Cells were imaged for 
7 days using time-lapse microscopy at 40x magnification on Zeiss Axio Observer 5A 
(Oberkochen, Germany). Differential Interface Contrast Images were captured at multiple points 
every 2 h for 7 days and were processed with Zen software (Oberkochen, Germany). 
Magnifications and details related to imaging are provided in individual sections. 
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7.3.6  Lysate preparation and immunoblotting 
Cells were cultured to ~80% confluence and after treatments as mentioned in individual sections 
protein lysates were prepared as described previously [41]. Polyacrylamide gel electrophoresis 
was used to resolve the proteins, which were transferred onto polyvinylidene fluoride membranes 
(Millipore). The immune reactive bands were visualized by using Pierce ECL 
chemiluminescence detection kit (Thermo Scientific).  Primary Antibodies, Phospho-Bcl2 (Thr 
56) human, Bcl-XL (54H6), Survivin (71G4B7), Beclin-2 and CD44 (156-3C11) were obtained 
from Cell Signaling. -actin (SC47778 from Santa Cruz Biotechnology) was used as loading 
control. All relative band intensities were quantitated by densitometry and were normalized 
against β-actin values using ImageJ.  
7.3.7  Cell migration assay using Boyden Chambers 
A total of 10,000 cells suspended in RPMI medium containing 0.5% FBS were added to the 
upper well of the Boyden chamber. The lower chamber was filled with RPMI medium 
containing 10% FBS. After 48 h, cells that had migrated to the bottom surface of the filter were 
fixed with 70% methanol, stained with crystal violet, and counted under a microscope in ten 
randomly selected fields at a magnification of 20x. 
7.3.8 MTT assay 
MTT assay was used to measure metabolic activity suitable for analysis of proliferation rates 
between PC-3, giant MP, and CDPC. Approximately 10,000 cells of each cell type were seeded 
into each well of a 96-well microplate. The assay was performed over a six-day period with 
incubation times at 24 h, 48 h, 72 h, 96 h, 120 h, and 144 h. At the end of each incubation period, 
10μl of MTT (Sigma-Aldrich, Germany) at 5mg/ml in PBS was added into each well after removal 
of the culture medium and incubated for 4 h under the same conditions. After the incubation, 
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100μl of DMSO was added to dissolve the formazan crystals. Absorbance was measured at 570nm 
using a 96-well microplate reader. 
7.3.9  In Vivo Tumor growth 
A total of 50,000 PC-3 cells or giant MP cells (cells that were treated with 5nM docetaxel and 
harvested one day after drug removal) were subcutaneously injected in the right flank of 6-week 
old male BALB/c nude mice (Harlan Laboratories, Indianapolis, IN). Tumors were measured 
every week using a digital Vernier Caliper. The two longest perpendicular axes in the x/y plane 
of each xenograft tumor were measured to the nearest 0.1 mm. The depth was assumed to be 
equivalent to the shortest of the perpendicular axes, defined as y. Tumor volume was calculated 
using the formulae xy2/2 as is standard practice. All animal experiments were performed in 
compliance with Georgia State University (GSU) Institutional Animal Care and Use 
Committee (IACUC) guidelines. All animal protocols (including description of experiments 
and experimenters) were approved by GSU IACUC.  
7.3.10 Statistical analyses 
Unless otherwise stated in the Methods and Results sections, statistical analyses were performed 
using two-tailed Student’s t-tests. The criterion for statistical significance for all analyses was 
p<0.05.  
 
7.4  Results 
7.4.1  Docetaxel induces formation of giant multinucleated polyploid (MP)cells 
To corroborate the fact that docetaxel treatment causes mitotic arrest prior to cell death, we 
examined the cell cycle events post docetaxel treatment. To this end, we treated PC-3 cells with 
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5nM docetaxel for 72 h and then stained them for MPM-2 antibody (mitotic cell marker) by flow 
cytometry. As shown in Figure7 . 4 . 1A, there was an induction of mitotic arrest 24 h post 
docetaxel treatment. Using immunofluorescence confocal microscopy, we noticed large number 
of mitotically-arrested cells (Figure.7.41B) displaying aberrant multipolar spindles 24 h after 
docetaxel treatment. On the other hand, DMSO treated control cells showed normal bipolar cell 
division (Figure 7.4.1B).  Following this, a disappearance of the M-phase population and an 
emergence of apoptotic cells (sub-G1 population) was observed at 48 h after docetaxel 
treatment (Figure 7.4.1D). 
We next investigated if docetaxel in addition to causing mitotic arrest and cell death 
induces other phenotypic changes. At 72 h post-treatment, there was an emergence of G1/G2-
interphase cells, which in addition to being much bigger in size were also multinucleated 
compared to parent PC-3 cells (Figure 7.4.1B). Also, we observed that there was a significant 
drop in the percentage of MPM-2 positive cells from ~11% at 48 h to 1% at 72 h and a 
simultaneous increase in MPM-2 negative population from ~26% at 24 h to 42% at 72 h 
(Figure.7.4.1A, D). Most likely, these large multinucleated cells resulted from a mitotic exit, that 
is, cells slipping out of mitosis without cell division. Since cells have failed to successfully 
progress through mitosis to execute cytokinesis, they have twice or more the amount of DNA as 
compared to parent PC-3 cell in the G1 phase of the cell cycle (Figure.7.41C). We termed these 
pseudo-G1 like cells as giant multinucleated polyploid (MP) cells.  Almost 95% of the surviving 
cells after 3 days of docetaxel treatment were giant MP cells. Taken together, these observations 
clearly suggest that, upon docetaxel treatment a small percentage of cells slip out of mitosis 
resulting in the formation of giant MP cells. The induction of giant MP cells was not limited 
to PC-3 cells but was also formed in two other cell lines: DU-145 (androgen dependent prostate 
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cancer cell line) and MDA-MB-231 (triple negative breast cancer cell line) (Supplementary. Figure 
7.7.14). 
 
Figure 7.4.1Docetaxel induces formation of giant multinucleated polyploid cells.  
                                                 
4 All supplemental data, tables, and figures appear in Appendix D for this chapter 
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A) Cell-cycle histograms of doubly-stained PC-3 cells treated with docetaxel at 5 nM 
concentration for different time points showing mitotic arrest and slippage at different time points. 
B) Representative immunofluorescent confocal micrographs of PC-3 cells treated with docetaxel 
for 24 h and 72 h indicating mitotic arrest and emergence of giant multinucleated polyploid cells 
respectively. Centrosomes and microtubules were immunolabeled for γ-tubulin (green) and α-
tubulin (red), respectively, and DNA was counterstained with DAPI (blue). Scale bar (white) 5 
µm.  C) Cell-cycle histogram of docetaxel treated PC-3 cells showing emergence of polyploid 
population. D) Bar-graphs showing the percentage of sub-G1 and mitotic population resulting from 
5nM docetaxel treatment. E) Bar-graphs showing the percentage of giant multinucleated polyploid 
cells 72 h after docetaxel treatment. 
7.4.2 Giant MP cells undergo asymmetric cell division via neosis 
Having established that docetaxel treatment induces the formation of giant MP cells we next 
followed the fate of these giant MP cells for the consequent 35 days after docetaxel removal. 
To accomplish this, we collected cells every 3rd day post drug removal and, employing confocal 
microscopy we visualized the morphology of PC-3 cells. Microtubules were immunolabeled for 
α-tubulin (red)and DNA was counterstained with DAPI (blue). For the first 15 days post drug 
removal we did not observe any remarkable changes in cell morphology.  After 15 days in culture 
we started observing the formation of small mononucleated cells in the vicinity of giant MP cells 
(Fig 2A). The number of mononucleated cells further increased by day 25 (Figure.7.42A and 
E). At later time points (day 35) following the removal of docetaxel, sparse colonies of small, 
tightly-packed, mononucleated cells were observed in the culture dish (Figure.7.42A and E). 
We next examined the origin of these mononucleated cells at day 15 after removal of docetaxel. 
To this end, starting at 12 days after docetaxel removal, we isolated and plated 3 giant MP cells 
per well by serial dilution and followed them for 7 days using time lapse imaging. We observed 
asymmetric cell division pattern in giant MP cells through a process known as neosis [15-17]. 
Small mononucleated daughter cells were seen budding from the giant MP cells from the 
branches of the giant MP cells (Figure.7.4.2B). To confirm the presence of DNA in the 
budding cells, we stained the giant MP cell along with the budding cells with Hoechst 33342 
185 
 
 
and used it in combination with differential interference contrast (DIC) microscopy. Using this 
method, we were able to detect the presence of DNA in the budding daughter cells (Supplementary 
Figure. 7.7.2). We named these budding cells as cells derived from multinucleated polyploid 
cells (CDPC). Furthermore, by using confocal microscopy, we demonstrated that the DNA was 
transported within the branches of the giant MP cells (Figure.7.4.2C). These results demonstrate 
that giant MP cells produce daughter cells through a process of budding also known as neosis 
where the branches of the giant MP cells can serve as vessels for DNA transport.   
 
  Figure 7.4.2 Giant MP cells undergo asymmetric cell division via neosis.  
A) Confocal micrographs of docetaxel treated PC-3 cells. Cells are stained with α-tubulin (red) 
and DNA (blue) and showed emergence of small mononucleated cells on different days (D) after 
drug removal. Scale bar (white) 5 µm. B) Time lapse images of giant MP cells generating small-
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sized daughter cells via budding (black arrows) over a 7-day period. Scale bar (black) 5 µm. C) 
Confocal immunographs of cells stained with α-tubulin (red) and DNA (blue) showing transport 
of DNA from the branches of the giant MP cells (white arrows). D) Line graph representing the 
total number of small sized nucleated cells and giant MP cells at different days after drug 
removal. 
7.4.3  Giant MP cells and CDPC are chemoresistant 
After establishing that giant MP cells can survive and can form small mononucleated cells via 
neosis, we next determined their response to docetaxel treatment. For this purpose, PC-3, CDPC 
and giant MP cells were treated with 5nM of docetaxel for 48h. Cell death was estimated by 
measuring the expression of cleaved caspase-3 and cleaved PARP. Interestingly, we observed 
increased levels of cleaved caspase-3 staining in PC-3 cells after 48 h of docetaxel treatment 
(Figure.7.43A). This was further substantiated by increased protein expression of cleaved PARP 
and cleaved caspase-3 by immunoblotting (Figure.7.43B and Supplementary Table 7.7.1). On the 
other hand, CDPC and giant MP cells showed lower expression of both cleaved caspase-3 and 
cleaved PARP after docetaxel exposure, suggesting that these cells were resistant to docetaxel 
treatment. 
Next, we evaluated the sensitivity of PC-3, CDPC and giant MP cells to various 
concentrations of docetaxel (5nM, 10nM and 20nM) using MTT assay. PC-3 cells exhibited 
a dose dependent increase in cell death 48 h after docetaxel treatment when compared with, both 
CDPC and giant MP cells (Figure 7.4.3C).  In  addit ion,  we assessed the expression of anti-
apoptotic and survival proteins in both CDPC and giant MP cells and compared them to the 
parental cells. The expression of anti-apoptotic proteins like Bcl-2, pBcl-2 and Bcl-XL were much 
higher in giant MP cells (day 1 to day 25 in figure 3D and Supplementary Table 2) and CDPC 
(day 35) as compared to parental PC-3 cells (Day0). Similarly, survival protein like survivin and 
beclin-2 were also higher in giant MP cells and CDPC compared to parent PC-3 cells. Taken 
together, these results suggested that both giant MP cells and CDPC exhibited a completely 
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different response to docetaxel treatment as compared to the parental cells owing to the increased 
expression of anti-apoptotic and survival proteins. We also observed that the giant MP and CDPC 
cells were positive for CD44 which a cancer stem cell marker is (Supplementary Fig 7.7.3E and 
Supplementary Table 7.7.4). 
 
  Figure 7.4.3Giant MP cells and CDPC are chemoresistant.  
A) Confocal images of cleaved caspase-3 staining (red) on docetaxel treated PC-3 cells. B) 
Representative Immunoblot images of cleaved caspase-3 and cleaved-PARP for docetaxel 
treated cells. Actin was used as the loading control. C) Graphical representation of cell survival 
using MTT assay. Cells were treated with 3 different concentrations of docetaxel and MTT 
assay was done 48h after docetaxel treatment. D) Western blots of anti-apoptotic and survival 
proteins in at different days after docetaxel removal. D0 are control PC-3 cells while cells on 
D35 are CDPCs. 
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7.4.4  Giant MP cells and CDPC show differential ability to migrate and proliferate as 
compared to parent PC-3 cells 
We next examined the ability of the giant MP cells and CDPC to migrate and proliferate and 
compared it to the parent PC-3 cells. Transwell migration assay was used to compare the 
migratory ability of CDPC and giant MP cells with that of the parent PC-3 cells. At 48 hours, 
the mean number of parent PC-3 cells that had migrated across the membrane was 9-fold higher 
than the giant MP cells and 2-fold higher than the CDPC cells (Figure 7.4.4A and B). The MTT 
assay showed the giant MP cells showed no signs of proliferation over a six-day period. On the 
other hand, the proliferation rate of CDPC was similar to that of the parent PC-3 cells over the 
six-day period (Figure.7.4.4C). Surprisingly, the mesenchymal marker vimentin was much higher 
in CDPC and giant MP as compared to the parent PC-3 cells (Figure.7.4.4D and Supplementary 
Table 7.7.3). We speculate that the giant MP cells use this mesenchymal phenotype to transport 
DNA through the branches in order to produce small mononucleated cells via neosis 
(Figure.7.4.2D). These results suggest that giant MP cells have slow proliferation and low rates 
of invasion and tumor formation compared to the parent PC-3 cells, suggesting that giant MP 
cells are less aggressive or malignant than that of parental cells. 
We next wanted to see if the CDPCs have a different genetic profile as compared to the 
parent PC-3 cells. We measured the degree of aneuploidy in the CDPC and parent PC-3 cells 
using fluorescent in situ hybridization (FISH) (Figure.7.4.4E). The average number chromosomes 
in the parent PC-3 cells were 83 as compared to 82 in the CDPC (Figure.7.4.4F). We next 
calculated the percent aneuploidy in parent PC-3 and CDPCs by counting the number of cells that 
had either < 80 or > 86 chromosomes. Using this method, the percent aneuploidy in parent PC-3 
cells was 12% compared to 18% in CDPC. Taken together the degree of aneuploidy in CDPC 
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was comparable to that of the parent PC-3 cells (eg: chromosomal translocation). Since there was 
a high number of translocations/duplications/etc. in the parent PC-3 cells, making many of the 
chromosomes unidentifiable, we were not able to measure the degree of structural 
chromosomal abnormalities in the PC-3 and CDPC cells. These results suggested that the 
degree of aneuploidy in the parent PC-3 and CDPC was not very different. 
 
 
Figure 7.4 .4 Phenotypic changes in CDPC and giant MP cells.  
A) Bright-field microscopic images of cells stained with crystal violet showing invasion capacity 
of PC-3, CDPC and giant MP cells. B) Bar graph representing the number of migrated cells in a 
Boyden chamber. C) Cell proliferation assay over a 7-day period using MTT assay. D) 
Representative immunoblots of Vimentin in PC-3, giant MP and CDPC’s. E, F) Graphical 
representation of the percent aneuploidy and number chromosomes respectively using FISH 
analysis. A total of 50 cells were counted. 
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7.4.5  Giant MP cells have tumorigenic potential 
To test the tumorigenicity of giant MP cells, we collected the giant MP cells 3 days after 
docetaxel treatment. A total of 50,000 PC-3 or giant MP cells were injected into the right flank 
of the nude mice (n=6).  As shown in Figure.7.4.5A, 6/6 mice (100%) injected with PC-3 cells 
formed tumors while only 2/6 mice (33%) injected with giant MP cells formed tumors in the nude 
mice. We also measured the kinetics of the tumor growth over a period of 60 days.  Measurable 
tumors started to form as early as 15 days post inoculation in mice injected with parent PC-3 
cells. On the other hand, measurable tumors were started to form only after 28 days’ post 
inoculation in mice injected with giant MP cells. The rate of tumor growth was also much higher 
in mice injected with PC-3 cells compared to mice that were injected with giant MP cells 
(Figure.7.4.5C). At the end of 60 days, the tumor weight of mice injected with PC-3 cells was 3 
times higher than the tumors formed by giant MP cells (Figure.7.4.5B, C)). These results 
suggested that even though the giant MP cells have tumorigenic capacity the rate of tumor 
formation is much slower than the parent PC-3 cells. 
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Figure 7.4.5Giant MP cells have tumorigenic potential.  
A) Bar graph representing the number of animals forming tumors after injecting either PC-3 or 
giant MP cells. B) Bar graph representing the tumor weight. C) Tumor growth monitored (by 
Vernier calipers) and presented as tumor volume in cubic millimeter over a period of 60 days.  
 
7.5  Discussion 
Docetaxel, a member of the taxane class of antimicrotubule agents is the only FDA-approved 
chemotherapeutic agent for CRPC. In many clinical situations, tumors will initially respond 
successfully to docetaxel but subsequently relapse and become progressively more malignant. 
This is mainly because of the intermittent dosing schedule followed for docetaxel administration. 
This intermittent dosing regimen allows tumor regrowth between treatment schedules resulting 
in only a partial regression of the prostate tumor mass. Our current study very elegantly 
demonstrates that the formation of giant MP cells due to docetaxel treatment is the culprit cell 
population responsible for cancer relapse. We describe here that the formation of giant MP cells 
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is mainly a result of mitotic slippage. It is well known that the mitotically slipped cells can 
undergo a second round of DNA replication without undergoing mitosis leading to formation of 
giant MP cells [18] . This phenomenon is known as endoduplication [19, 20].  Several reports 
suggest that p53 is an important component of ploidy checkpoint and its overexpression can lead 
to endoduplication of cell [21]. Also, generation of resistant giant multinucleated cells has 
been reported in p53 mutated tumor cells [22]. Since PC-3 cells lack p53 [23],  endoduplication  
and subsequent formation of giant MP cells may be attributed to the loss of p53 gene.  
 
These giant MP cells can not only survive for a long period of time but could give rise to small 
mononucleated, actively proliferating cells that can later cause the tumor to relapse. Here, the 
giant MP cells undergo a novel type of cell division that involves nuclear budding followed by 
intracellular cytokinesis to produce mononucleated daughter cells that “bud off” from the giant 
MP cell, a phenomenon known as neosis or reductive cell division. Previous studies have also 
shown that giant MP cells can form small daughter cells through this process of neosis [10, 12, 
16, 17, 24, 25]. These mononucleated daughter cells have previously been reported to be highly 
error -prone which increases the rates of genomic instability and contributes to tumor regrowth 
[26].  
We further show that giant MP cells and cells generated from them (CDPC) are 
chemoresistant. The fact the giant MP cells are chemoresistant was not surprising. It is well 
known that tumor cells in patients’ bodies are present in different phases of the cell cycle (G1, 
S, G2 and M) and conventional chemotherapy kills only the most vulnerable phase of the cell 
cycle but spares the others [ 2 7 ] . In other words, the cell death upon administration of the 
chemotherapeutic agent depends upon the “cytotoxicity window” of the drug [27].  In 
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particular, extensive literature reports that the high “cytotoxicity window” of docetaxel 
corresponds to late S and G2 phase of the cell cycle [28, 29]. Studies have convincingly 
demonstrated that cells are variably sensitive to docetaxel when treatment is applied to cells 
synchronized in different phases of the cell cycle It is now well established that docetaxel is 
almost totally lethal against S -phase cells but is only partially toxic against cells in G1 phase 
of the cell cycle. Since these giant MP cells are pseudo-G1 like cells, these cells are very 
unlikely to die upon docetaxel treatment. We also speculate that the chemoresistance of CDPC 
cells could be attributed in part to high expression of antiapoptotic (cIAP-1, cIAP-2, XIAP and 
survivin, clusterin) [30] proteins and survival proteins (Bcl-2, Bcl-XL) [31, 32]. It is also likely 
that CDPCs have altered expression of drug transporter proteins thus making them less 
susceptible to docetaxel toxicity.[33-36] 
 
These cells also express cancer stem cell (CSC) marker CD44. This CSC marker plays a 
critical role in regulating the properties of CSCs like, tumor initiation, self-renewal and 
chemoradioresistance [37]. Our findings are in line with a previous study which reported that 
docetaxel resistant prostate cancer cells exhibit increased stemness compared to their parental 
counterpart [38]. Thus, targeting CSCs seems to be potential mechanism to combat the resistance 
and relapse developed after docetaxel treatment. In line with this a recent study showed that 
Napabucasin (BBI608) a cancer cell stemness inhibitor suppresses the prostate cancer growth and 
makes the prostate cancer cells sensitive to docetaxel by killing the prostate cancer stem cells that 
were resistant to docetaxel [39]. Thus, we speculate that the docetaxel treatment leads to clonal 
selection of highly aggressive phenotype with stem cell like phenotype and this in part is 
responsible for the chemotherapy failure. 
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Finally, we show evidence that giant MP cells have tumorigenic potential in nude mice. 
The giant MP cells take a significantly longer time to form the tumor as compared to the parent 
PC-3 cells. This is because the giant MP cells first need to produce the mononucleated daughter 
cells which then subsequently proliferate to form the tumor. This result is in concordance to the 
fact that tumor relapse always occurs after a significant delay usually ranging from a couple of 
months to sometimes years. 
Taken together, our studies show that generation of giant MP cells that were once 
presumed to be either destined for terminal growth arrest or cell death may actually represent 
a “transition state” for generation of viable clones. These cells may play an integral part in tumor 
relapse and generation of chemoresistance. Strategies preventing the formation of giant MP cells 
and understanding the molecular mechanism of neosis will help us identify key targets to prevent 
tumor relapse. 
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8 CONCLUSIONS  
In the collection of the studies described in this dissertation we have presented centrosome 
amplification and clustering as important risk predictors of tumor aggressiveness and progression 
that can serve as a surrogate of intra tumor heterogeneity (ITH). Since there are no cost-effective 
readily quantifiable markers available for ITH these studies presented here highlight the role of 
CA as a more comprehensive biomarker which can work as a clinically adaptable readout of ITH.   
 High CA is associated with increased tumor grade and has been shown to impart 
aggressive phenotypes, such as invasive behavior and enhanced cell migration in pancreatic ductal 
adenocarcinoma (PDAC) and the genes that drive CA are associated with worse overall survival 
in this cancer type. Thus it is reasonable to suspect that CA is associated with worse 
clinicopathology and survival rates in PDAC and can serve as an independent prognostic marker 
for which there are no prognostic and predictive biomarkers available. In addition we also observed 
that the African American (AA) PDACs exhibited higher CA when compared to the European 
Americans (EA), AA PDACs have ~30% higher incidence and more aggressive disease course 
than EA PDAC patients[1], perhaps in part because their tumors display elevated mutations in 
genes whose dysregulation is known to drive CA that are common in PDAC (e.g., TP53 [2, 3], 
SMAD4 [4], CDKN2A [5], CHEK2 [6],). The relationship between ethnicity and mutations in these 
genes needs to be further investigated.  
Moreover, in DCIS where high levels of ITH is present and in order to predict the 
recurrence, there is a pressing clinical need for prognostic indices that can take into account the 
heterogeneous nature of DCIS lesions. Current recurrence predictors based on commonly used 
histopathological parameters such as histologic grade, tumor margins, and age lack consistency, 
reproducibility fails to integrate the molecular predictors, underestimating the heterogeneity of 
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DCIS lesions[7]. Deregulation of numerous pathways have been shown to result in CA; this 
phenotypes thus integratively captures information about deregulation of multiple pathways and 
the ITH-generating potential inherent in a tumor thus, the extent of CA can be used a predictor in 
recurrence in DCIS. The major challenge of using CA as a biomarker is that there are no clinically-
facile methods to quantify CA in tumor cells. In order to quantify CA and investigate its utility as 
a predictive biomarker for recurrence in DCIS, we have pioneered a novel semi-automated 
platform that integrates immunofluorescent confocal microscopy with digital image analysis 
algorithms and yields a quantitative centrosomal amplification score (CAS) by evaluating the 
severity and extent of numerical and structural centrosomal aberrations in a clinical sample. We 
observed that the clinical samples with the higher risk of recurrence exhibited high CAS values 
thus indicating a great extent of CA and consequently higher degree of ITH compared to samples 
with a lower CAS value. Also, CAS was able to stratify the DCIS patients in high risk and low 
risk of recurrence in a multivariable model. Not only this when the performance of CAS was 
compared to another known predictor tool Van Nuys index, the performance of CAS was 
significantly better in prediction than the other model. Thus, CAS offers a comprehensive and a 
quantitatively precise measure of aberrant centrosomal status in DCIS lesions and with its ability 
to predict recurrence in these lesions provides us a new tool to help tailor the treatment according 
to individuals risk of recurrence in DCIS patients and avoid the over and under treatment of these 
patients. Furthermore, we observed that mixed DCIS cases which have the invasive component in 
them exhibited higher CAS compared to pure DCIS thus indicating that CA is associated with the 
greater risk of malignant transformation and thus its quantitation may help to determine which 
tumor will metastasize or become chemoresistant. Further studies are required to gain more 
insights into these intriguing issues.  
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Since centrosome amplification and clustering are cancer cell-specific phenomena, 
centrosome-clustering proteins may also serve as attractive prognostic markers and theranostic 
targets. The presence of higher KIFC1 in HGSOC and its association with poor overall survival 
and aggressive phenotype predict that the patients with high KIFC1 levels experience high 
mortality. In this study, we observed that primary tumors exhibited higher expression of KIFC1 
gene expression and was associated with poor overall survival by contrast, while samples collected 
from the metastatic sites showed similar expression levels of KIFC1 as in primary sites, high 
KIFC1 expression in metastatic sites was not significantly correlated to poor survival. This 
differential effect of high KIFC1 expression strongly suggests that elevated KIFC1 in primary sites 
perhaps helps tumor cells present in the primary sites to acquire karyotypic diversity (through 
CIN), which is more likely to lead to successful metastasis and poor survival. It is possible that 
once metastasis commences, high KIFC1 levels in the metastatic clones provides little further 
survival advantage for the cancer cells; alternatively, once metastasis occurs, the survival 
difference between KIFC1-high and KIFC1-low patients is no longer so marked, an interesting 
question for future studies. Another intriguing avenue for future research would be to test whether  
HGSOC patients would benefit from the centrosome declustering drugs.  
The non essential role of the KIFC1 in normal somatic cells and its crucial requirement for 
the viability of cancer cells, together makes KIFC1 an ideal cancer selective drug target. This 
proposition is bolstered by the observation that KIFC1 expression was significantly higher in the 
mutant p53 CRCs and that the depletion by pharmacological and genetic methods in CRC cells 
induced robust spindle multipolarity and subsequent apoptosis specifically in p53 null colorectal 
cancer cells without minimal toxicity to the WT cells, a mechanistic insight that can guide rational 
drug design as resistance to chemotherapy represents the major obstacle for the improvement of 
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survival of nearly 50% of CRC patients. Since, the current therapies to target mutant p53 are not 
effective as different mutations affect p53 function differently and different agents may be required 
to target different mutations.[8] The identification of molecules or pathways that can be targeted 
in p53 mutant CRC might help in improving the patient outcome. A major challenge faced in 
development of the targeted therapies for cancer is the fundamental disconnect between preclinical 
data and clinical results. Although the number of drugs entering in clinical trials is very high when 
compared to other diseases as in a span of 10 years ~30% (~3000)drugs which entered in clinical 
trials are for cancer but only 13.8% (~200) made it from the phase I to the testing approval [9]. 
This high rates of failure of therapies in the clinics is due to the lack of appropriate preclinical 
models which can recapitulate all the features of individuals tumor and show accurate efficacy 
rates. The preclinical models (both established tumor cell lines and tumor cell line xenografts) are 
far from ideal, they have been widely used given that the rapid doubling times in such models 
permit a fast-tracked drug-development timeline. Nonetheless, this perceived advantage rather 
puts us at a loss when the doubling time itself is in the spotlight and the drug’s activity relies on 
the preponderance of the mitotic population, which hinges on doubling rate. The brisk doubling 
times of the preclinical models explain why drugs targeting mitosis proved active in these models 
but were ineffective against patient tumors.[10-12] Our study highlights the importance of low-
passage patient-derived cell line systems as being most representative of the clinical scenario and 
thus constituting an invaluable experimental model that could better guide drug development and 
clinical trial design . We performed a rigorous, systematic analysis of the relationship between a 
universal prognostic factor (mitotic index) and a well-known cancer-cell-specific trait and a 
potential prognosticator (CA) in a spectrum of model systems ranging from cultured cells, 
preclinical tumor xenografts, patient-derived primary cultures and patient tumors. Our data 
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reconfirm that rapid cell division is not as predominant a trait of human tumors as it is of 
immortalized cell lines and tumor cell line xenografts which explains  the lack of response of 
patient tumors to antimitotic drugs. Thus, to discern meaningful activity of drugs before they are 
tested in clinical trials, it is imperative that we consider the shortcomings of our existent cell line 
models and rather develop robust and relevant preclinical models that mimic cellular traits 
observed in patient tumors. As highlighted by our study the role of centrosome declustering drugs 
in tumor suppression and progression the study of these drugs in the early-passage patient-derived 
tumor cell lines, which exhibit similar CA to patient tumors remains a uncharted territory and thus 
can be an intriguing question for future studies.  
A new era of precision medicine has dawned in oncology with the recent advances in 
cancer genomics—an era in which a patient’s tumor can be characterized extensively for mutations 
and other molecular abnormalities, and treatment can be based mainly on the identified molecular 
changes (not just the type of cancer)[13, 14]. As defined by the National Cancer Institute precision 
or personalized medicine is “A form of medicine that uses information about a person’s genes, 
proteins, and environment to prevent, diagnose, and treat disease”[15]. It further elaborates that 
“In cancer, personalized medicine uses specific information about a person’s tumor to help 
diagnose, plan treatment, find out how well treatment is working, or make a prognosis.” Thus, the 
biomarkers described herein constitute precision medicine because they can assist oncologists in 
prognostication and planning treatment. Collectively all the findings presented in this dissertation 
highlight the role of CA as a surrogate of ITH. Where it was presented that majority of the tumors 
exhibit CA and centrosome clustering and that clustering of supernumerary centrosomes during 
mitosis causes chromosome missegregation; thus, CA and centrosome clustering collectively fuel 
karyotypic diversification and, thus, ITH. Therefore, I envision that CA and centrosome clustering 
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these two factors may yield a reliable and comprehensive “ITH index” which can identify patients 
which are likely to exhibit heterogeneity and associated aggressive disease features with the 
increased need for aggressive treatment. Furthermore, the inclusion of the histopathological 
features and features associated with tumor microenvironment in the developed CAS score might 
help to develop models which can predict metastasis, which is the next question I intend to address 
in my post-doctoral research. I am also interested in investigating the process by which CA leads 
to the malignant transformation as the disease progresses which may help in limiting the extent of 
ITH at an early stage, thus rendering it relatively manageable. 
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APPENDICES 
Appendix A: Supplementary Data for chapter 2 
Detailed Description of Centrosome Amplification Quantitation 
To evaluate the number of centrosomes in tumor samples per cell, we immunostained centrosomes 
in tissues (normal and tumor for respective cancer types) with anti-γ-tubulin antibody and 
counterstained nuclei with DAPI. We imaged these tissue slides at low magnification (20x) 
employing LSM 700 confocal microscope to capture images of 10 fields of view that encompass 
several nuclei and centrosomes (Supplementary Figure. 2.7.1). For each field we selected a region 
with 30-35 clearly distinguishable nuclei and defined it as region of interest (ROI) by drawing a 
boundary around the outer edges of outermost nuclei in the ROI. Next, we quantified the number 
and volume of γ-tubulin foci in each ROI at higher magnification (63X objective). In our study, 
nuclei associated with more than two centrosomes were deemed to have “numerically” amplified 
centrosomes and nuclei associated with structurally abnormal centrosomes were accounted to have 
“structurally” amplified centrosomes. Centrosome amplification (CA) was calculated as a 
percentage by adding percent cells harboring more than two γ-tubulin foci and percent cells 
harboring γ-tubulin foci with volume greater than upper range of mean centrosomal volumes found 
in respective normal tissues (Supplementary Figure. 2.7.1). Since centrosomes pass through a 
duplication cycle that involves large volume changes, we needed to define a “normal range” for 
centrosomal volumes using both adjacent uninvolved tissue from cancer patients and normal tissue 
for disease-free individuals for each cancer type. To determine the normal range, we analyzed 
volumes of centrosomes (500 centrosomes for each sample) in adjacent uninvolved tissue from 
cancer patients (20 samples for each cancer type) and in normal tissues (20 normal tissue samples 
for breast, pancreas and bladder). Normal tissue samples were obtained from Biomax Inc. in the 
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form of commercial tissue microarrays. We evaluated the volume of centrosomes by using the 
three-dimensional measurement module in the Zeiss imaging software. Mean volumes of 
centrosomes in normal breast, pancreatic and bladder epithelial cells ranged between 0.22-0.76 
µm3, 0.20-0.56 µm3, and 0.20-0.74 µm3, respectively. The various centrosomal phenotypes 
observed in hypoxic conditions are represented in Supplementary Figure. 2.7.2 and 2.7.3. The 
presence of CA was confirmed via immunoblotting for CA-associated proteins as shown in 
Supplementary Figure.2.7. 4. 
 
Figure 2.7.1 Schematic showing the steps followed for quantitation of CA in the cancer 
tissues, normal tissues and their corresponding cultured cell lines. 
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Figure 2.7.2 Different configurations of Centrosome amplification observed in MDA-MB 
468 after hypoxia induction by treating them with CoCl2.  
Representative confocal micrographs of cells with centrosome amplification (dispersed 
represents cells with widely distributed centrosomes in the interphase, clustered represents cells 
with supernumerary centrosomes assembled together in the interphase but distinguishable, and 
PCM represents abnormally large centrosomes due to PCM accumulation). 
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Figure 2.7.3  Different configurations of centrosome amplification observed in MDA-MB 
231 cells immunolabeled for centrin-2 (green) and γ-tubulin (red) after treatment with 
CoCl2.  
Representative confocal micrographs of cells with centrosome amplification (dispersed 
represents cells with widely distributed centrosomes in the interphase, clustered represents cells 
with supernumerary centrosomes assembled together in the interphase but distinguishable, and 
PCM represents abnormally large centrosomes due to PCM accumulation). 200 cells were 
counted in each condition. 
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Figure 2.7.4  Representative immunographs of MDA-MB 231 immunolabeled for centrin-2 
(green) and γ-tubulin (red) after treatment with CoCl2 in split form.  
B: Split confocal images of dispersed centrosome amplification. C: Split confocal images of the 
clustered CA. D: Split confocal images of structural amplification with PCM accumulation. 
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Figure 2.7.5 Immunoblots showing the levels of hypoxia and centrosomal markers in cells 
treated with CoCl2 and cultured under hypoxia. 
A : Immunoblots showing the levels of hypoxia and centrosomal markers in MDA-MB-231 and 
MDA-MB-468 cells treated with 100µM of CoCl2 for 24 h. B. Immunoblots showing the levels 
of hypoxia and centrosomal markers in MDA-MB-231 and MDA-MB-468 cells exposed to 
hypoxia for 48 h. 
 
 
Figure 2.7.6 Immunoblots showing the levels of hypoxia and centrosomal markers in HIF-
1α KO and OE cells.  
A. Immunoblots of HIF-1α and centrosomal proteins in MDA-MB-231 and MDA-MB-468 
transfected with empty vector or degradation-resistant HIF-1α. B. Immunoblots of HIF-1α and 
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centrosomal proteins in MDA-MB-231 and MDA-MB-468 transfected with Cas9-sgRNA (HIF-
1α) construct or control vector (pSpCas9-2A-GFP). 
 
 
Figure 2.7.7 Quantitation of CA in cells treated with DMOG and MG132  
A. Representative confocal micrographs of centrosome amplification in MDA-MB-231 cells 
treated with DMOG and MG132. Representative confocal micrographs of centrosome 
amplification in MDA-MB-231 transfected with empty vector or degradation-resistant HIF-1α 
and with HIF-1α gene KO. B. Immunoblots showing the levels of hypoxia and centrosomal 
markers in cells treated with 1mM DMOG for 24 h.  Immunoblots showing the levels of hypoxia 
and centrosomal markers in cells treated with 5µM of MG132 for 5 h. C. Quantitation of 
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centrosome amplification per microscopic examination for DMOG and MG132 treated and 
untreated MDA-MB-231 and MDA-MB-468 cells. 
 
 Enrichment of centrosomal gene expression in tumors with a hypoxia-high gene expression 
signature 
We validated our in vitro findings of a correlation between CA and hypoxia in silico by 
probing the publicly-available Kao[1] and Jonsdottir[2] microarray datasets using Gene Set 
Enrichment Analysis (GSEA).[3] Essentially, our goal was to determine whether breast tumors 
that are enriched in hypoxia-associated transcripts also show a correlational enrichment in 
centrosomal transcripts. Publicly available pre-processed gene expression profiles of primary 
breast tumors (n=327 for the Kao dataset, GSE20685; n=94 for the Jonsdottir dataset, GSE46563) 
were used for GSEA. Within each dataset, patients were stratified into two groups by a hypoxia 
score, the reduced hypoxia metagene previously shown to have prognostic ability in multiple 
cancers.[4, 5] As previously defined, hypoxia scores were calculated as the median expression of 
26 genes that are upregulated in response to hypoxia. Scores  median were categorized as 
“hypoxia low” and scores > median were categorized as “hypoxia high.” For the Kao dataset, 
Affymetrix probes with the “x_at” extension was removed unless no other probe was available 
(e.g., as with ALDOA). For the Jonsdottir dataset, Illumina probes with the “A” designator were 
preferentially used. When multiple probes were present, their median expression was used in score 
calculation. GSEA was performed with 1000 permutations, and false discovery rate q-values<0.05 
were considered statistically significant. 
  Using the kao dataset, we collapsed features into gene symbols, resulting in 20,606 genes 
being available for gsea using curated gene sets from molecular signatures database[6] v5.0, 
including those from the gene ontology (go) consortium (for analysis of cellular components and 
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biological processes) and reactome [7] v53 (for pathway analysis), along with gene sets that we 
defined based on empirical evidence from the literature. We validated that the hypoxia-high group 
was differentially enriched in hypoxia-associated genes by performing gsea with the full hypoxia 
metagene as shown in supplementary Figure. 2.7.7 (also see supplementary table 2.7.1 for study 
details and supplementary table 2.7.2 for the ranked gene list; n=44 after filtering). We then 
performed GSEA to identify gene ontologies associated with the hypoxia-high group, which we 
found was significantly enriched in microtubule-organizing center and centrosome components, 
which were among the top-20 enriched cellular components (see supplementary table 1 for these 
and all other enriched gene ontologies). The hypoxia-high group was also enriched in cell cycle-
related processes, which constituted the top-ranked gene ontology among biological processes. 
Cellular pathway analysis using reactome terms identified mitosis as the third-most enriched 
pathway, with various other cell cycle-related pathways also significantly enriched. Cellular 
pathway analysis revealed an enrichment in genes associated with the recruitment of centrosome 
proteins and complexes. Intriguingly, the hypoxia-high group was also enriched in genes involved 
in the cellular pathway associated with loss of ninein-like protein (nlp), a γ-tubulin-binding protein, 
from mitotic centrosomes. It is known that plk1 and nek2 phosphorylate nlp at the onset of mitosis, 
resulting displacement of nlp from the centrosome, which is associated with centrosome 
maturation (involving the recruitment of γ-tubulin ring complexes and other pericentriolar material 
components) and a concomitant increase in microtubule-nucleating capacity. Plk1 or nek2 
overexpression results in premature nlp dissociation from centrosomes and also induces ca.[8]   
Although hypoxia-high breast tumors were clearly found to be enriched in centrosomal 
components and pathways, we wanted to more specifically test the hypothesis that they are 
enriched in gene ontologies related to CA per se. No high-throughput screen of CA-associated 
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genes has been performed to inform construction of a CA gene set; nevertheless, the literature 
reports that CA is associated with hormone receptor-negative and node-positive breast cancer.[9] 
Thus, we analyzed enrichment of centrosome-associated genes (namely, experimentally 
identified human centrosomal proteins in the MiCroKiTS[10] database; n=540 genes) in hormone 
receptor-positive node-negative patients, rationalizing that this gene set has a high likelihood of 
representing CA. We found that 77 of these genes were enriched in hormone receptor-negative 
node-positive breast carcinomas. Next, we performed GSEA using these 77 genes as a gene set, 
which we found was significantly enriched in the hypoxia-high group, as shown in Supplementary 
Figure. 2.7.7B (also see Supplementary Table 2.7.3 for the ranked gene list). Many genes 
implicated in CA (such as AURKA, CCNA2, CCNE2, CEP152, NEK2, PLK4, and STIL) or 
amplified centrosome clustering (such as KIFC1, the top-ranked hit, along with BIRC5 and 
TACC3) from the literature are among the enriched genes from this set. Because CA drives 
chromosomal instability (CIN), we wondered whether hypoxia-high cases were also enriched in 
CIN-associated genes. To this end, we performed GSEA with genes from the CIN25 signature, net 
overexpression of which has prognostic significance in various types of cancer.[11] We found this 
set was highly enriched in the hypoxia-high group (Supplementary Table 2.7.1). Collectively, 
these results suggest that hypoxic breast tumors are enriched in CA- and CIN-associated genes. 
Enrichment of centrosomal gene expression in tumors with a hypoxia-high gene expression 
signature regardless of mitotic activity 
Many CA-associated proteins do not exclusively localize to the centrosome; some also 
localize to the mitotic spindle. Thus, it could be argued that, rather than having a greater extent of 
CA, the hypoxia-high group merely has more mitotic cells than the hypoxia-low group. To test 
this hypothesis, we analyzed the Jonsdottir dataset, which contains gene expression profiles and 
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mitotic activity indices for 94 breast tumor specimens from lymph node-negative patients. To 
begin, we validated that the hypoxia-high group was enriched in hypoxia-associated genes. We 
performed GSEA with the full hypoxia metagene and found significant enrichment 
(Supplementary Table 2.7.1), which also underscores the robustness of this 26-gene hypoxia 
signature across platforms and breast cancer datasets. We then performed GSEA using the 77 
potentially CA-associated genes (that is, those that were enriched in the hormone receptor-negative 
node-positive breast carcinomas from the Kao dataset) and found significant enrichment in the 
Jonsdottir dataset as well (Supplementary Table 2.7.4). This is especially interesting because the 
Jonsdottir patients are also all node-negative, indicating this gene set captures a phenotype that is 
not wholly dependent on nodal status. There was substantial overlap in the potentially CA-
associated genes enriched in the Jonsdottir and Kao hypoxia-high groups. Next, we did find that 
the hypoxia-high group was associated with a high mitotic activity index (MAI; >10 mitotic figures 
per 10 fields of vision) based on the Mann-Whitney test (p=0.01). Nonetheless, when we 
performed GSEA on the MAI-low group (n=60) using hypoxia scores as the phenotype, we still 
found that the hypoxia-high group was enriched in potentially CA-associated genes 
(Supplementary Table 2.7.5). Thus, even among tumors with relatively low mitotic activity, 
hypoxia-high tumors show enrichment in potentially CA-associated genes, minimizing the 
probability that we are merely capturing proliferation-associated genes with our gene set. 
Combined with our in vitro data, these in silico data substantiate the hypothesis that hypoxia is 
associated with CA in patient breast tumors. 
Finally, we were interested to determine whether hypoxia-associated CA, as determined 
by gene expression levels, predicts worse outcomes and, if so, whether its predictive ability 
depends on mitotic activity. To this end, we created a score based on the top ten CA-associated 
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genes enriched in the hypoxia-high samples of the Jonsdottir dataset (from Supplementary Table 
2.7.4). Specifically, we defined the hypoxia-associated CA score as the median expression of those 
top 10 genes. Kaplan-Meier analysis and Cox regression were performed using SPSS Statistics 
version 21 (IBM). For multivariate Cox regression analysis, all potential predictors were entered 
into the full model and then eliminated stepwise based on an α=0.10 elimination criterion. Optimal 
cut points based on distant-metastasis-free survival (DMFS) were found using X-tile[12] per the 
highest Χ2 value following dichotomization. We found that stratifying patients based on a cutpoint 
of 317 resulted in the CA score having the best predictive ability using the 94 node-negative breast 
cancer patients of the Jonsdottir dataset (p=0.020; Supplementary Figure. 2.7.6C). Univariate Cox 
regression revealed that a high hypoxia-associated CA score (i.e., >317) was associated with worse 
DMFS (HR=2.87; p=0.026), which was upheld in multivariate regression adjusting for all 
available potentially confounding covariates (including tumor size, Nottingham grade, estrogen 
and human epidermal growth factor receptor 2 statuses, and mitotic activity index). In fact, only 
this score remained in the final model. When hypoxia score was added to the Cox regression 
analysis, the effect of CA score on DMFS was more pronounced (HR=3.39, p=0.011). Only the 
CA score and hypoxia score remained in the final model, though the hypoxia score was no longer 
significant (HR=2.22, p=0.066). When the analysis was repeated without the CA score in the full 
model, however, the hypoxia score was a significant predictor of DMFS (HR=2.45, p=0.047), as 
was mitotic activity (HR=2.88, p=0.0.17), with no other variables in the final model. These results 
raise the tantalizing possibility that the ability of the hypoxia score to predict DMFS results from 
its association with CA. Even more intriguing is the idea that hypoxia might upregulate CA to 
drive metastatic dissemination, an exciting avenue of future research. 
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Figure 2.7.8 Gene-set enrichment and Kaplan-Meier analyses based on hypoxia- and 
centrosome amplification-associated genes.  
A. Enrichment plots of hypoxia metagene components available in the Kao dataset and B. genes 
potentially associated with centrosome amplification (CA), with red indicating correlation with 
the hypoxia-low group and blue the hypoxia-high group. C. Plots of Kaplan-Meier product limit 
estimates of distant metastasis-free survival of patients in the Jonsdottir dataset stratified by 
hypoxia-associated CA score (low vs. high), p=0.020 by the log-rank tesst. TTDM=time to distant 
metastasis. Di. Number of distant metastases and censored cases by centrosome amplification 
score. Dii. Mean distant metastasis-free survival time by centrosome amplification score. 
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Figure 2.7.9 Representative immunoblots  
A. Immunoblots of HIF-1α in MDA-MB-231 and MDA-MB-468 transfected with empty vector 
or degradation-resistant HIF-1α. B. Immunoblots of VEGF in MDA-MB-231 and MDA-MB-468 
cells treated with 100µM of CoCl2 for 24 hrs.  
 
 
Figure 2.7.10 Representative immunoblots showing the levels of HIF-1α in nuclear and 
cytoplasmic lysates of MDA-MB-231 and MDA-MB-468 cells treated with 100µM of CoCl2 
for 24 hrs.  
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Table 2.6.1 Gene Set Enrichment Analyses for specified Gene Ontologies. 
Reactome pathways, literature-based gene sets, and self-defined gene sets. GO and Reactome 
IDs (for curated gene sets) and publication details (for literature-based gene sets) are given in 
parentheses. ES=Enrichment Score; NES=Normalized Enrichment Score; NOM=nominal; 
FDR=False Discovery Rate; FWER=Family-Wise Error Rate 
 
Gene Set Size 
after 
Filterin
g 
ES ES NOM p-
value 
FDR q-
value 
FWER p-
value 
Ran
k at 
Max 
Kao- Entire 
Dataset 
       
Hypoxia 
Metagene (Buffa 
et al., 2010) 
44 -0.77 -2.04 <0.001 <0.001 <0.001 3686 
Microtubule 
Organizing 
Center 
(GO:0005815) 
57 -0.54 -2.06 <0.001 4.5E-03 0.03 1531 
Centrosome 
(GO:0005813) 
49 -0.54 -2.01 <0.001 0.01 0.05 1531 
   Cell cycle 
(GO:0007049) 
285 -0.61 -2.33 <0.001 3.1E-03 0.02 2632 
Cell Cycle - 
Mitotic 
(Pathway:6927) 
271 -0.67 -2.29 <0.001 4.2E-03 0.01 2316 
Recruitment of 
Mitotic 
Centrosome 
Proteins and 
Complexes 
(Pathway:380270) 
54 -0.46 -1.89 0.02 0.02 0.01 2313 
Loss of NLP from 
Mitotic 
Centrosomes 
(Pathway:380259) 
47 -0.46 -1.85 0.02 0.02 0.40 2313 
Centrosomal 
Genes 
Upregulated in 
ER/PR+ Node- 
Tumors 
77 -0.82 -1.88 <0.001 <0.001 <0.001 2630 
CIN25 Genes                   
(Carter et al., 
2006) 
23 -0.89 1.69 <0.001 <0.001 <0.001 1297 
Jonsdottir - 
Entire Dataset 
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Hypoxia 
Metagene (Buffa 
et al., 2010) 
47 -0.81 -1.55 0.01 0.01 0.003 5057 
Centrosomal 
Genes 
Upregulated in 
ER/PR+ Node- 
Tumors 
77 -0.81 -1.56 4.0E-03 4.0E-03 2.0E-03 4008 
Jonsdottir - MAI-
Low Only 
       
Hypoxia 
Metagene (Buffa 
et al., 2010) 
47 -0.75 -1.49 0.04 0.04 0.02 5163 
Centrosomal 
Genes 
Upregulated in 
ER/PR+ Node- 
Tumors 
77 -0.85 -1.72 <0.001 <0.001 <0.001 1813 
 
 
Table 2.6.2 Rank-ordered list of filtered hypoxia metagene components with associated rank 
metric scores, enrichment scores (ES), and whether each gene is part of the core enriched genes 
(i.e., the leading-edge subset) in the hypoxia-high group of the Kao dataset 
GENE SYMBOL RANK IN 
GENE LIST 
RANK METRIC SCORE RUNNING ES CORE 
ENRICHME
NT 
ALDOA 10185 -0.001037822 -0.4951352 No 
ANKRD37 12004 -0.013171702 -0.5810628 No 
LRRC42 13846 -0.026962586 -0.6655041 No 
MCTS1 15337 -0.04007807 -0.73039776 No 
MIF 15612 -0.042822175 -0.7356349 No 
CHCHD2 15748 -0.044233657 -0.7338455 No 
LDHA 16016 -0.047092326 -0.7379356 No 
GAPDH 16182 -0.049089462 -0.73668796 No 
GPI 16921 -0.058381788 -0.76155204 Yes 
SEC61G 17016 -0.059670471 -0.75485283 Yes 
UTP11L 17344 -0.064875908 -0.75850195 Yes 
HK2 17604 -0.069081984 -0.75804955 Yes 
TUBB6 17812 -0.072616458 -0.7544006 Yes 
PSMA7 17838 -0.073151112 -0.7417994 Yes 
          SLC25A32 17903 -0.074541941 -0.7308322 Yes 
PGK1 18012 -0.076205611 -0.72169065 Yes 
BNIP3 18017 -0.076291725 -0.70747495 Yes 
P4HA1 18145 -0.07900098 -0.69872946 Yes 
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MAD2L2 18230 -0.080925092 -0.68752927 Yes 
CORO1C 18285 -0.082037203 -0.67465997 Yes 
ENO1 18319 -0.082770482 -0.6606309 Yes 
TPI1 18340 -0.083269544 -0.64587533 Yes 
SLC16A1 18401 -0.084655896 -0.63280326 Yes 
YKT6 18405 -0.084711224 -0.6169486 Yes 
DDIT4 18565 -0.088841394 -0.6079007 Yes 
MRPL15 18878 -0.098103359 -0.60454416 Yes 
MRPL13 19107 -0.106322989 -0.59554994 Yes 
AK3L1 19315 -0.114598989 -0.5839712 Yes 
NDRG1 19351 -0.11648801 -0.56367075 Yes 
NP 19458 -0.121711895 -0.5458365 Yes 
SLC2A1 19484 -0.12285845 -0.52384645 Yes 
MRPS17 19534 -0.126033917 -0.50242376 Yes 
ACOT7 19727 -0.138207912 -0.48565617 Yes 
PFKP 19803 -0.144859448 -0.46194214 Yes 
HIG2 19898 -0.152798504 -0.4376526 Yes 
PSRC1 19910 -0.154252052 -0.4090519 Yes 
ADM 20066 -0.17373921 -0.38377362 Yes 
CA9 20175 -0.192664087 -0.35263497 Yes 
CTSL2 20338 -0.228577107 -0.31733918 Yes 
SHCBP1 20490 -0.299957722 -0.2680258 Yes 
CDKN3 20524 -0.333389521 -0.20665893 Yes 
KIF20A 20528 -0.337646633 -0.14302899 Yes 
KIF4A 20545 -0.356419325 -0.07648543 Yes 
ANLN 20585 -0.420125276 9.73E-04 Yes 
 
Table 2.6.4  Rank-ordered list of potential centrosome amplification-associated genes with 
associated rank metric scores, enrichment scores (ES), and whether each gene is part of the core 
enriched genes (i.e., the leading-edge subset) in the hypoxia-high group of the Kao dataset. 
GENE SYMBOL RANK IN GENE 
LIST 
RANK METRIC 
SCORE 
RUNNING ES CORE 
ENRICHMENT 
TRIM22 9257 0.005535 -0.45051 No 
PRKAA1 10390 -0.0025 -0.50547 No 
MAP1B 11819 -0.01194 -0.57415 No 
GIMAP5 12039 -0.01341 -0.58383 No 
FYN 12842 -0.01913 -0.62148 No 
ODF2L 13067 -0.02089 -0.63085 No 
RASSF5 14099 -0.02883 -0.67894 No 
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PRKD3 14243 -0.02992 -0.6837 No 
MARCKS 14472 -0.03196 -0.69244 No 
LIMK1 14658 -0.03361 -0.69897 No 
SYK 14810 -0.0351 -0.70373 No 
HAP1 15154 -0.03818 -0.71762 No 
PIM1 16282 -0.05017 -0.76881 No 
FIGN 16589 -0.05401 -0.77973 No 
LIMK2 16953 -0.05886 -0.79306 No 
BRSK1 17048 -0.06002 -0.79321 No 
PRKCQ 17094 -0.06075 -0.79091 No 
SMURF2 17543 -0.06803 -0.80771 No 
SOCS1 17796 -0.07242 -0.81464 No 
NEK6 17977 -0.07552 -0.81783 Yes 
CRYAB 18091 -0.07784 -0.81758 Yes 
RUNX3 18196 -0.08005 -0.81673 Yes 
SPHK1 18224 -0.0808 -0.81208 Yes 
SASS6 18240 -0.08116 -0.80682 Yes 
SLC16A1 18401 -0.08466 -0.80836 Yes 
GNAI1 18457 -0.08613 -0.80467 Yes 
TSKS 18806 -0.09576 -0.81455 Yes 
WASF1 18833 -0.0967 -0.80867 Yes 
PLEKHG6 19038 -0.10343 -0.81097 Yes 
PDE7A 19279 -0.11301 -0.81431 Yes 
LCK 19344 -0.11619 -0.80885 Yes 
NDRG1 19351 -0.11649 -0.80054 Yes 
CCNA1 19406 -0.1191 -0.79437 Yes 
CENPJ 19444 -0.12114 -0.78722 Yes 
LMO4 19518 -0.12512 -0.78154 Yes 
PSMD3 19615 -0.13063 -0.77656 Yes 
VAC14 19642 -0.13237 -0.76805 Yes 
CDC25B 19705 -0.13691 -0.76096 Yes 
CHEK2 19769 -0.14153 -0.75357 Yes 
RANBP1 19788 -0.14291 -0.74389 Yes 
GPSM2 19923 -0.15544 -0.73894 Yes 
CKAP2 19951 -0.15892 -0.72852 Yes 
CEP152 19990 -0.16318 -0.71831 Yes 
MCM5 19996 -0.16407 -0.70644 Yes 
GMNN 20040 -0.16928 -0.69603 Yes 
EIF4EBP1 20052 -0.17204 -0.68385 Yes 
TACC3 20230 -0.20252 -0.67752 Yes 
FANCA 20250 -0.20734 -0.66313 Yes 
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BRCA2 20291 -0.21723 -0.64903 Yes 
SGOL1 20325 -0.22475 -0.63403 Yes 
STIL 20384 -0.24633 -0.61866 Yes 
ESPL1 20406 -0.25368 -0.60095 Yes 
CHEK1 20417 -0.2561 -0.58252 Yes 
TROAP 20421 -0.25745 -0.56365 Yes 
CCNB1 20430 -0.26098 -0.54476 Yes 
PTTG1 20441 -0.26845 -0.52542 Yes 
CRABP1 20449 -0.27154 -0.5057 Yes 
CCNA2 20464 -0.28031 -0.48567 Yes 
KIF15 20467 -0.28398 -0.4648 Yes 
MAD2L1 20468 -0.28479 -0.44376 Yes 
CENPF 20471 -0.28903 -0.42251 Yes 
AURKA 20480 -0.29411 -0.40117 Yes 
KIF11 20487 -0.29864 -0.3794 Yes 
HMMR 20503 -0.31248 -0.35705 Yes 
CDC25C 20510 -0.32075 -0.33365 Yes 
CCNE2 20511 -0.32077 -0.30996 Yes 
NEK2 20517 -0.32682 -0.28606 Yes 
CDKN3 20524 -0.33339 -0.26172 Yes 
KIF14 20548 -0.35903 -0.23632 Yes 
PLK1 20550 -0.35933 -0.20983 Yes 
KIF18A 20556 -0.37178 -0.18261 Yes 
ASPM 20557 -0.37248 -0.1551 Yes 
TTK 20560 -0.37723 -0.12733 Yes 
CEP55 20561 -0.37875 -0.09935 Yes 
BIRC5 20577 -0.40346 -0.07028 Yes 
CDC20 20586 -0.42014 -0.03964 Yes 
KIFC1 20603 -0.54844 9.75E-05 Yes 
 
 
 
Table 2.6.5 Rank-ordered list of potential centrosome amplification-associated genes with 
associated rank metric scores, enrichment scores (ES), and whether each gene is part of the core 
enriched genes (i.e., the leading-edge subset) in the hypoxia-high group of the entire Jonsdottir 
dataset. 
GENE 
SYMBOL 
RANK IN 
GENE 
LIST 
RANK 
METRIC 
SCORE 
RUNNING 
ES 
CORE 
ENRICHME
NT 
MAP1B 9927 0.027879 -0.2694731 No 
GIMAP5 11620 0.018845 -0.3146127 No 
NEK6 14304 0.006694 -0.3874912 No 
TSKS 20675 -0.02045 -0.5602645 No 
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LCK 21643 -0.0252 -0.585253 No 
GNAI1 21692 -0.02545 -0.5851359 No 
MARCKS 25609 -0.04594 -0.6894773 No 
SYK 25673 -0.04634 -0.6885981 No 
WASF1 25818 -0.04722 -0.689881 No 
FIGN 26288 -0.05058 -0.6998489 No 
SMURF2 26579 -0.05269 -0.704811 No 
CCNB1 26876 -0.05483 -0.7098172 No 
TRIM22 28230 -0.06621 -0.7430442 No 
SLC16A1 28325 -0.06714 -0.7418446 No 
BRCA2 29320 -0.07824 -0.764595 No 
RASSF5 29744 -0.08353 -0.7714585 No 
PRKAA1 30331 -0.0924 -0.7822752 No 
HAP1 30451 -0.09399 -0.780252 No 
ODF2L 30904 -0.10177 -0.7868843 No 
FYN 31621 -0.1156 -0.7999487 No 
PRKD3 31760 -0.11896 -0.7970437 No 
PSMD3 32154 -0.12857 -0.8005617 Yes 
SOCS1 32256 -0.13107 -0.7959673 Yes 
CRABP1 32696 -0.14402 -0.7998746 Yes 
CCNA1 32921 -0.15105 -0.7975177 Yes 
SASS6 33107 -0.15692 -0.7937663 Yes 
BRSK1 33320 -0.16365 -0.7903748 Yes 
CHEK2 33524 -0.17026 -0.7863668 Yes 
RUNX3 34028 -0.19051 -0.7894138 Yes 
LIMK1 34450 -0.20953 -0.789155 Yes 
KIF14 34790 -0.22531 -0.7857721 Yes 
SPHK1 34813 -0.22655 -0.7736645 Yes 
TACC3 34830 -0.22751 -0.7613397 Yes 
PRKCQ 34832 -0.22752 -0.7486046 Yes 
ESPL1 34847 -0.22799 -0.7361981 Yes 
FANCA 34935 -0.23268 -0.7255213 Yes 
CDC25C 34988 -0.23525 -0.7137451 Yes 
VAC14 35284 -0.25222 -0.7076517 Yes 
HMMR 35293 -0.25279 -0.6936903 Yes 
PLEKHG6 35543 -0.27288 -0.6851819 Yes 
CDC25B 35587 -0.27725 -0.6708041 Yes 
PLK1 35601 -0.27839 -0.655543 Yes 
EIF4EBP1 35641 -0.28117 -0.6408358 Yes 
CRYAB 35712 -0.28594 -0.6267073 Yes 
MCM5 35760 -0.29006 -0.61172 Yes 
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CKAP2 35792 -0.29443 -0.5960506 Yes 
ASPM 35799 -0.29504 -0.5796646 Yes 
KIF11 35823 -0.29804 -0.5635741 Yes 
CCNE2 35873 -0.30251 -0.5479429 Yes 
GMNN 35987 -0.31268 -0.5334887 Yes 
CENPJ 35995 -0.31324 -0.5161092 Yes 
NEK2 36018 -0.31532 -0.4990226 Yes 
CEP55 36028 -0.31635 -0.4815231 Yes 
CDKN3 36053 -0.31868 -0.4643022 Yes 
PIM1 36092 -0.32313 -0.4472143 Yes 
BIRC5 36106 -0.32495 -0.4293416 Yes 
KIF18A 36150 -0.3296 -0.4120271 Yes 
MAD2L1 36155 -0.33 -0.3936251 Yes 
CENPF 36214 -0.33744 -0.3762802 Yes 
PTTG1 36249 -0.34282 -0.3579785 Yes 
TROAP 36260 -0.3446 -0.3389218 Yes 
KIF15 36303 -0.35197 -0.3203251 Yes 
CEP152 36317 -0.35415 -0.3008146 Yes 
SGOL1 36319 -0.35452 -0.2809555 Yes 
TTK 36354 -0.3624 -0.2615553 Yes 
CDC20 36396 -0.36887 -0.2419837 Yes 
CCNA2 36406 -0.37126 -0.221404 Yes 
KIFC1 36418 -0.37251 -0.2008091 Yes 
LIMK2 36451 -0.37996 -0.1803693 Yes 
AURKA 36460 -0.38249 -0.1591323 Yes 
PDE7A 36488 -0.38882 -0.1380591 Yes 
GPSM2 36559 -0.4058 -0.1172072 Yes 
NDRG1 36567 -0.40833 -0.0944937 Yes 
RANBP1 36571 -0.40905 -0.0716305 Yes 
LMO4 36595 -0.41683 -0.0488768 Yes 
STIL 36597 -0.41794 -0.02546 Yes 
CHEK1 36684 -0.50451 4.92E-04 Yes 
 
Table 2.6.6 Rank-ordered list of potential centrosome amplification-associated genes with 
associated rank metric scores, enrichment scores (ES), and whether each gene is part of the core 
enriched genes (i.e., the leading-edge subset) in the hypoxia-high group of the mitosis-activity-
index-low cases of the Jonsdottir dataset 
GENE 
SYMBOL 
RANK IN 
GENE 
LIST 
RANK 
METRIC 
SCORE 
RUNNING 
ES 
CORE 
ENRICHM
ENT 
CRABP1 1247 0.196209 -0.022491 No 
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SYK 4586 0.083097 -0.108734 No 
MAP1B 4941 0.077617 -0.113828 No 
GNAI1 6693 0.05668 -0.158298 No 
PRKCQ 7260 0.051505 -0.170718 No 
CCNA1 11454 0.025851 -0.283677 No 
GIMAP5 12204 0.022238 -0.302817 No 
LIMK1 13681 0.015818 -0.342184 No 
TSKS 14283 0.013139 -0.35782 No 
HAP1 14837 0.010819 -0.372281 No 
NEK6 15431 0.008267 -0.387985 No 
LCK 16809 0.002983 -0.425406 No 
RUNX3 18761 -0.004223 -0.478425 No 
WASF1 19448 -0.006835 -0.496752 No 
SMURF2 20802 -0.012268 -0.532971 No 
SOCS1 21207 -0.014023 -0.543175 No 
CRYAB 23902 -0.025877 -0.615206 No 
PRKD3 24183 -0.027193 -0.621249 No 
SLC16A1 24424 -0.028282 -0.626136 No 
FANCA 24474 -0.028508 -0.625795 No 
TRIM22 26151 -0.036923 -0.66938 No 
ODF2L 26970 -0.041393 -0.689276 No 
LMO4 27255 -0.042918 -0.694502 No 
VAC14 28281 -0.049818 -0.719554 No 
FIGN 28767 -0.053333 -0.729655 No 
MARCKS 28812 -0.053722 -0.727692 No 
EIF4EBP1 30948 -0.074622 -0.781589 No 
CHEK2 31454 -0.081308 -0.790588 No 
RASSF5 32122 -0.091782 -0.803394 No 
FYN 32229 -0.093444 -0.800785 No 
PRKAA1 33495 -0.122161 -0.828128 No 
SPHK1 33904 -0.13265 -0.831455 No 
BRCA2 34464 -0.152763 -0.837721 No 
PIM1 34891 -0.169697 -0.839357 Yes 
BRSK1 35120 -0.181113 -0.834915 Yes 
LIMK2 35200 -0.184675 -0.826196 Yes 
PDE7A 35419 -0.198272 -0.82047 Yes 
PLEKHG
6 
35542 -0.20546 -0.811701 Yes 
PSMD3 35718 -0.219175 -0.80357 Yes 
GMNN 35762 -0.222346 -0.791649 Yes 
NDRG1 35901 -0.235135 -0.781568 Yes 
RANBP1 35918 -0.236222 -0.768093 Yes 
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MCM5 35984 -0.242655 -0.755576 Yes 
PLK1 36105 -0.258397 -0.743634 Yes 
SASS6 36241 -0.277588 -0.730971 Yes 
CEP152 36386 -0.312943 -0.716472 Yes 
CENPF 36392 -0.313983 -0.698116 Yes 
CDC25B 36411 -0.319583 -0.679785 Yes 
STIL 36430 -0.324553 -0.661162 Yes 
ASPM 36438 -0.326208 -0.642141 Yes 
AURKA 36476 -0.341741 -0.623024 Yes 
KIF14 36482 -0.342514 -0.602988 Yes 
BIRC5 36494 -0.345894 -0.582916 Yes 
CCNB1 36500 -0.348213 -0.562544 Yes 
KIF18A 36520 -0.356315 -0.542078 Yes 
TACC3 36528 -0.35818 -0.521174 Yes 
HMMR 36541 -0.363636 -0.500085 Yes 
CKAP2 36568 -0.374923 -0.478713 Yes 
MAD2L1 36570 -0.37601 -0.456595 Yes 
SGOL1 36580 -0.38294 -0.434287 Yes 
CCNE2 36581 -0.383755 -0.411685 Yes 
KIFC1 36583 -0.383929 -0.389101 Yes 
CCNA2 36587 -0.38714 -0.366382 Yes 
GPSM2 36588 -0.388246 -0.343516 Yes 
CDKN3 36616 -0.40076 -0.32065 Yes 
CDC20 36621 -0.406762 -0.296802 Yes 
ESPL1 36626 -0.410511 -0.272734 Yes 
CHEK1 36627 -0.412625 -0.248432 Yes 
TTK 36633 -0.414843 -0.224136 Yes 
CEP55 36647 -0.434241 -0.198916 Yes 
TROAP 36665 -0.460532 -0.172257 Yes 
KIF11 36671 -0.467194 -0.144878 Yes 
CDC25C 36678 -0.47623 -0.116993 Yes 
KIF15 36679 -0.477443 -0.088874 Yes 
NEK2 36683 -0.486579 -0.060298 Yes 
PTTG1 36691 -0.501135 -0.030975 Yes 
CENPJ 36699 -0.530558 8.18E-05 Yes 
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Appendix B: Supplementary Data for Chapter 3 
 
Supplementary Figure 3.7.1 Heat maps of genes whose dysregulation drives centrosome 
amplification and clustering. 
Heat maps of genes whose dysregulation drives centrosome amplification and clustering are 
upregulated in pancreastic ductal adenocarcinoma (N=36) relative to normal pancreas (N=16). 
Heat map generated with Oncomine Gene Browser. 
 
 
 
 
Supplementary Figure 3.7.2 The proportion of gene-level non-silent somatic mutations in 
The Cancer Genome Atlas pancreatic adenocarcinoma dataset (N=144). 
 
229 
 
 
 
Supplementary Figure 3.7.3 Risk factors for the development of PDAC that are associated 
with African American ethnicity 
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Appendix C: Supplementary Data for Chapter 5  
 
Supplementary Figure 5.7.1 High grade serous ovarian carcinomas exhibit higher 
expression of KIFC1. A. Box-whisker plot representing the weighted index for KIFC1 
expression in low and high-grade SOC tissues. 
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Supplementary Figure 5.7.2 Kaplan-Meier plots of overall survival based on low or high 
expression of KIFC1 gene in ovarian cancer patients regardless of histotypes. 
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Supplementary Figure 5.7.3 Gene set enrichment analyses for biological processes 
associated to KIFC1 high group.  A. Enrichment plot of genes associated to microtubule-based 
processes, with red indicating correlation with the KIFC1-high group and blue the KIFC1-low 
group. 
 
 
Supplementary Figure 5.7.4 HGSOC cell lines show higher expression of genes, driving 
Centrosome amplification, and KIFC1 in silico. Ai. Bar graph representing Log Base 2 
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KIFC1expression in ovarian cell lines (Ovcar5, OVCAR3, OVSAHO, and SKOV3). Aii Bar 
graph representing Log Base 2 Centrosome amplification index expression in ovarian cell lines 
(OVCAR5, OVCAR3, OVSAHO, and SKOV3).  
 
 
Table 5.7.1 Descriptive table for univariate and multivariate analysis. 
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Table 5.7.2 Rank-ordered list of filtered genes comprising centrosome components with 
associated rank metric scores, enrichment scores (ES), and whether each gene is part of the 
core enriched genes (i.e., the leading-edge subset) in the KIFC1-high group.  
GENE 
SYMBOL 
RANK IN 
GENE LIST 
RANK 
METRIC SCORE 
RUNNIN
G ES 
CORE 
ENRICHMENT 
TOP2A 25 0.334119827 0.0778286 Yes 
KIF15 31 0.329936087 
0.1556403
8 
Yes 
BIRC5 33 0.328538954 
0.2333162
1 
Yes 
NEK2 49 0.306233615 
0.3050340
7 
Yes 
PLK1 69 0.277375519 0.3697302 Yes 
CTAG2 133 0.232606009 
0.4216944
6 
Yes 
ESPL1 163 0.211262807 
0.4702634
2 
Yes 
SAC3D
1 
317 0.161001891 
0.5009095
7 
Yes 
NDE1 394 0.147750571 0.5321666 Yes 
BRCA2 470 0.137022048 0.5609342 Yes 
CROCC 841 0.106630601 
0.5681608
3 
Yes 
AZI1 1055 0.095914356 
0.5804899
3 
Yes 
CKAP5 1293 0.087143637 
0.5895765
4 
Yes 
 
Table 5.7.3 Rank-ordered list of filtered genes associated to mitotic cycle components with 
associated rank metric scores, enrichment scores (ES), and whether each gene is part of the 
core enriched genes (i.e., the leading-edge subset) in the KIFC1-high group. 
GENE 
SYMBOL 
RANK 
IN GENE LIST 
RANK 
METRIC SCORE 
RUNNING 
ES 
CORE 
ENRICHMENT 
KIF23 7 
0.38020667
4 
0.02617827
8 
Yes 
KIF2C 16 0.34368071 0.04975993 Yes 
NCAPH 19 
0.34149092
4 
0.07348197 Yes 
KIF15 31 
0.32993608
7 
0.09595834
5 
Yes 
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BIRC5 33 
0.32853895
4 
0.11882581
6 
Yes 
TPX2 43 
0.31242573
3 
0.14017852 Yes 
BUB1 45 
0.31174606
1 
0.16187464 Yes 
ANLN 47 
0.30931574
1 
0.18340124 Yes 
PRC1 48 
0.30758470
3 
0.20485595 Yes 
NEK2 49 
0.30623361
5 
0.22621644 Yes 
CDKN3 52 
0.30384364
7 
0.24731249 Yes 
CDC6 54 
0.30182740
1 
0.26831678 Yes 
UBE2C 58 
0.29473295
8 
0.28872848 Yes 
TTK 59 
0.29472723
6 
0.30928636 Yes 
NUSAP
1 
65 
0.28140944
2 
0.328671 Yes 
CENPF 68 
0.27754867
1 
0.34793293 Yes 
PLK1 69 
0.27737551
9 
0.3672805 Yes 
CDC7 72 0.27584514 0.3864236 Yes 
CENPE 76 
0.27514043
5 
0.4054687 Yes 
AURKA 77 
0.27472376
8 
0.4246313 Yes 
FBXO5 86 
0.27031439
5 
0.44309548 Yes 
CDC25
C 
93 
0.26497542
9 
0.46128497 Yes 
BUB1B 106 
0.25538018
3 
0.47851205 Yes 
KIF11 126 
0.23612600
6 
0.49405414 Yes 
CCNA2 128 
0.23533037
3 
0.5104201 Yes 
CDCA5 131 
0.23478570
6 
0.5266992 Yes 
RCC1 157 0.2154641 0.54050696 Yes 
ESPL1 163 
0.21126280
7 
0.55499876 Yes 
ZWINT 185 
0.20219287
3 
0.5680762 Yes 
CDK2 201 0.19581379 0.5810018 Yes 
CDKN2
A 
207 
0.19183807
1 
0.5941387 Yes 
STMN1 238 
0.18024593
6 
0.6052456 Yes 
CIT 255 
0.17556032
5 
0.61670965 Yes 
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KNTC1 264 
0.17323194
4 
0.6284021 Yes 
MAD2L
1 
305 0.16407761 0.6378927 Yes 
CDKN2
D 
327 
0.15915641
2 
0.6479683 Yes 
KIF22 343 
0.15704949
2 
0.65819 Yes 
E2F1 390 
0.14784903
8 
0.66625553 Yes 
SKP2 420 
0.14482110
7 
0.67494035 Yes 
MAD2L
2 
450 
0.14039075
4 
0.6833162 Yes 
DBF4 488 
0.13522075
1 
0.6909405 Yes 
CDKN2
C 
553 
0.12865872
7 
0.696788 Yes 
POLD1 564 
0.12719699
7 
0.70517176 Yes 
POLE 710 0.11385873 0.7060298 Yes 
DDX11 726 
0.11322832
9 
0.7131949 Yes 
PKMYT
1 
774 
0.10988337
5 
0.7185633 Yes 
SMC4 852 
0.10574237
3 
0.7221773 Yes 
PIN1 1119 
0.09343647
2 
0.71569943 Yes 
TBRG4 1304 
0.08683542
9 
0.71276724 Yes 
ASNS 1397 
0.08419103
2 
0.7141451 Yes 
SMC1A 1575 
0.07948930
6 
0.71104246 Yes 
PPP5C 1741 
0.07608585
8 
0.70828867 Yes 
CDC25
B 
1758 
0.07569229
6 
0.7127867 Yes 
CDC27 1859 
0.07366871
8 
0.7130398 Yes 
POLA1 1913 
0.07242853
9 
0.71550256 Yes 
BTG3 1918 
0.07231188
6 
0.72035104 Yes 
GSPT1 1927 
0.07214269
8 
0.72499233 Yes 
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Table 5.7.4 Rank-ordered list of filtered genes associated microtubule-based processes with 
associated rank metric scores, enrichment scores (ES), and whether each gene is part of the 
core enriched genes (i.e., the leading-edge subset) in the KIFC1-high group. 
GENE 
SYMBOL 
RANK 
IN GENE LIST 
RANK 
METRIC SCORE 
RUNNING 
ES 
CORE 
ENRICHMENT 
KIF23 7 0.380206674 
0.06844783
6 
Yes 
KIF2C 16 0.34368071 0.13023852 Yes 
KIF4A 32 0.329859108 0.18918754 Yes 
PRC1 48 0.307584703 0.24410658 Yes 
TTK 59 0.294727236 0.29694292 Yes 
NUSAP
1 
65 0.281409442 0.34761333 Yes 
KIF11 126 0.236126006 0.38741168 Yes 
RCC1 157 0.2154641 0.42493314 Yes 
STMN1 238 0.180245936 0.45364717 Yes 
TUBG1 542 0.129438803 0.46230626 Yes 
KIF1A 577 0.125762284 0.4834036 Yes 
KIF1B 729 0.112902582 0.496475 Yes 
NLGN1 846 0.106165938 0.51003253 Yes 
YKT6 972 0.098996036 0.5218544 Yes 
MAP1S 976 0.098900363 0.5396018 Yes 
CKAP5 1293 0.087143637 0.5399754 Yes 
SNAP29 1408 0.083875522 0.54959744 Yes 
SMC1A 1575 0.079489306 0.5558929 Yes 
CENPJ 1691 0.076832272 0.56419194 Yes 
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Appendix D: Supplementary Data for Chapter 7  
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Supplementary Figure 7.7.1: MDA-MB-231 and DU-145 cells showing formation of giant MP 
cells 72 h after treatment with 5nM docetaxel (DTX). 
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Supplementary Figure 7.7.2: DIC and Hoechst 33342 images showing presence of DNA 
(black arrows) in cells budding from the giant MP cells. 
 
 
Supplementary Figure 7.7.3:  Immunoblots of CD44 at different days after docetaxel 
removal.  C are control PC-3 cells while cells on D0 are cells collected 72 h post docetaxel 
treatment. 
 
Supplementary Figure 7.7.4: Representative immunofluorescent confocal micrographs of 
PC-3 cells treated with docetaxel (5nM) for 24 h and 72 h indicating mitotic arrest and 
emergence of giant multinucleated polyploid cells respectively. 
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 Centrosomes and microtubules were immunolabeled for γ-tubulin (green) and α-tubulin (red), 
respectively, and DNA was counterstained with DAPI (blue). Scale bar (white) 5 µm 
 
 
 
 
 
 
 
Supplementary Table 1: The quantification of Western Blot densitometry values in relation 
to loading control β-actin for Fig 3B (calculated using Image-J software).  
Cell type  Cleaved PARP Cleaved Caspase 
Giant MP - 0.027111272 0.02259534 
Giant MP + 0.440467057 0.57760081 
PC-3 - 0.070632216 0.054661554 
PC-3 + 1.035792334 1.586356511 
CDPC -  0.027747402 0.049495095 
CDPC + 0.746083581 0.827335698 
 
Supplementary Table 2: The quantification of Western Blot densitometry values in relation to 
loading control β-actin for Fig 3D (calculated using Image-J software).  
 Days after 
drug removal  Beclin-2  Survivin Bcl-XL P-Bcl2 Bcl2 
0 0.941251727 0.803824128 0.941123482 0.065360381 0.055159161 
1 2.822945541 0.981694271 0.803645446 1.195198385 0.804328047 
5 3.713716836 0.781451901 0.972501709 1.130220819 1.209606137 
10 0.433636748 1.074286244 0.434295141 0.461309892 0.34912065 
15 0.138397195 0.697108731 1.073126657 0.585133676 0.916490447 
25 0.074917074 1.469521135 1.339419773 1.17057988 0.517625674 
35 0.072369018 1.383199964 1.237650405 1.10612344 0.26394166 
 
Supplementary Table 3: The quantification of Western Blot densitometry values in relation to 
loading control β-actin for Fig 4D (calculated using Image-J software).  
  Vimentin 
PC-3  0.194946108 
Giant MP 1.683074943 
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Supplementary Table 4: The quantification of Western Blot densitometry values in relation to 
loading control β-actin for Supplementary Fig 3 (calculated using Image-J software).  
 
 
 
 
 
 
 
CDPC 1.480074389 
 Days after Drug 
Removal  CD44 
C 0.209981839 
0 0.895492234 
5 0.804897313 
10 0.260869891 
15 0.601404075 
20 0.149114788 
25 1.697150291 
30 0.682945733 
35 0.696615458 
